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Barnard, Alle N. M.S., Purdue University, August 2014. 1,25-dihydroxyvitamin D 
alters lipid metabolism and epithelial-to-mesenchymal transition in metastatic 
epithelial breast cancer cells. Major Professor: Dorothy Teegarden. 
 
 
 Evidence suggests that high vitamin D status (marked by serum 25-
hydroxyvitamin D, 25(OH)2D) is associated with a decreased risk of breast 
cancer.  It has been established that 1,25-dihydroxyvitamin D (1,25(OH)2D) can 
alter glycolysis and the Krebs cycle of breast cancer cells (Jiang et al., 2010; 
Zheng et al., 2013) but little information is available on 1,25(OH)2D's alterations 
of lipid metabolism in breast cancer cells.  Thus, the current research 
investigates if there was an effect of  1,25(OH)2D on proteins that regulate lipid 
metabolism in MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a epithelial 
breast cancer cells.  While no significant effects were seen at 24 hours of 
treatment with 10 nM of 1,25(OH)2D, several changes were see at 48 hours with 
the most significant effects in the MCF10CA1a line.  With 48 hour treatment of 
1,25(OH)2D there was a significant increase of fatty acid synthase (FAS), acyl-
CoA cholesterol acyltransferase 1 (ACAT1), insulin-inducing gene 2 (Insig2), 
perilipin 2 (PLIN2), and a non-significant trend towards an increase in stearoyl-
CoA desaturase 1 (SCD1) in the MCF10CA1a line.  Additionally, there was a 




(CPT1a), adipose triglyceride lipase (ATGL), and hormone sensitive lipase (HSL).  
Lipid accumulation was greater in the MCF10CA1a compared to the other 
MCF10A cell lines as shown by oil red O staining.  1,25(OH)2D treatment caused 
a non-significant trend towards a decrease in total triglyceride concentration in 
the MCF10CA1a cells.  Additionally, a multitude of alterations upon 1,25(OH)2D 
treatment were noted in specific phosphotidylcholines (PCs), sphingomyelins, 
and ceramides using MS-MS. Together, these results suggest that 1,25(OH)2D 
may alter lipid metabolism by increasing lipid storage and decreasing lipid 
degradation in epithelial breast cancer cells.  
 Additionally, while it is known that 1,25(OH)2D exerts anti-cancer effect on 
primary breast tumors (Welsh, 2004),the role of 1,25(OH)2D in metastasis has 
yet to be determined.  Thus, the current research also investigates if there was 
an effect of 1,25(OH)2D on epithelial-to-mesenchymal transition (EMT) protein 
markers and cell viability in MCF10CA1a metastatic epithelial breast cancer cells.  
To identify the impact of 1,25(OH)2D regulation of EMT and metastasis of breast 
epithelial cells to bone we employed a reconstructed metastasis (rMET) model.  
Upon 1,25(OH)2D treatment in the 3D matrix which recapitulates the mammary 
environment, mammospheres were visually smaller compared to vehicle treated 
cells though 3-(4,5-dimythylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) 
assays did not show a significant difference in the amount of live cells between 
treatments in 3D.  Additionally, the total number of cells to metastasize and 
survive in the reconstructed bone matrix (rBM) was significantly reduced in the 




regulation of  EMT, the mRNA abundance of markers of EMT in the upper well 
was determined.  Treatment with 1,25(OH)2D induced a significant increase in 
vimentin and fibronectin mRNA abundance, both markers of EMT, following 48 
hours of 10 nM of 1,25(OH)2D treatment compared to vehicle in 2D cell culture.  
Additionally, mRNA abundance of epithelial-cadherin (E-cadherin), which is 
decreased during EMT, had a trend towards an increase while neuronal-cadherin 
(N-cadherin) was unchanged.  Immunofluorescent staining of the upper well 
mammospheres for E-cadherin, vimentin, perilipin 2 (PLIN2), co-stained with 
neutral lipid stain, Bodipy, and the nuclear stain, DAPI, were completed.  
Although a visual difference employing Zeiss microscope, showed little difference 
between treatments, confocal images are being obtained and analyzed by our 
laboratory to more carefully assess the differences in protein expression.  
Together, these results suggest that 1,25(OH)2D decreases breast to bone 
metastasis by altering viability in the rBM and alterations in characteristic EMT 
protein expression in metastatic epithelial breast cancer cells, therefore 
decreasing cancer aggressiveness.  Overall, our findings contribute to the 
knowledge of vitamin D biology and its function in mammary cancer and 





CHAPTER 1 INTRODUCTION 
 
1.1. Vitamin D 
 The two major physiological forms of vitamin D are ergocalciferol (vitamin 
D2) from plants and cholecalciferol (vitamin D3) from animal sources.  While both 
forms can be obtained from the diet, there are only a few foods with naturally 
occurring vitamin D.  These include fatty saltwater fish, beef, liver, egg yolks, 
yeast, and mushrooms (Hill et al., 2012).  More often, vitamin D is fortified in 
foods such as dairy products, juices, and ready-to-eat breakfast cereals (Hill et 
al., 2012; National Institutes of Health).  The major source of cholecalciferol is 
through generation in the skin from 7-dehydrocholesterol upon exposure to 
ultraviolet B (UVB) radiation.  The current recommended dietary allowances 
(RDAs) for vitamin D are 600 International Units (IU)/day (15 micrograms (mcg)) 
(1 mcg = 40 IU) for both males and females ages one to 70 years old, as well as 
for women during pregnancy and lactation (Office of Dietary Supplements).  The 
RDA increases to 800 IU/day (20 mcg) for both men and women for those over 
70 years old (Office of Dietary Supplements).  Research suggests that vitamin D 
has a plethora of roles involving bone homeostasis, cancer prevention, immune 
function, insulin resistance in muscle, cardiovascular disease, and more(Rosen 




1.1.1. Vitamin D Action 
 Due to the multiple functions proposed for vitamin D, a wide range of 
research has been completed and is still ongoing to study vitamin D biology and 
its' effects in homeostatic and diseased states.  In this section, vitamin D 
metabolism, mechanism of action, and specific actions will be discussed. 
 
 
1.1.1.1. Vitamin D Metabolism 
 
 When UV form sunlight is absorbed in the skin, it converts 7-
dehydrocholesterol, the vitamin D precursor, to previtamin D3, which is rapidly 
isomerized into vitamin D3 (cholecalciferol) in the dermis and epidermis. 
Cholecalciferol, or vitamin D, from both sunlight and foodstuffs, is transported in 
the bloodstream to the liver where it is metabolized to 25-hydroxyvitamin D 
(25(OH)D) by 25-hydroxylase (DeLuca, 2004; Jiang et al., 2010). Because this 
conversion is uncontrolled, serum 25(OH)D  is a valid biomarker of vitamin D 
status. However, this metabolite does not readily bind to the nuclear vitamin D 
receptor (VDR) and so it is not biologically active. The 1α-hydroxylase, coded 
from the CYP27B1 gene, in the kidney further hydroxylates 25(OH)D to its 
bioactive form, 1,25-dihydroxyvitamin D (1,25(OH)2D) ,  which has a high affinity 
for VDR.  More recently, it has been found that extra-renal tissues also contain 
the 1α-hydroxylase enzyme for localized conversion (see section 1.1.1.3.).  The 
expression of 1α-hydroxylase is stimulated by parathyroid hormone (PTH) in 
response to a low serum calcium level. Additionally, this active metabolite 




and reduces the risk of many diseases (DeLuca, 2004).  Both the 25(OH)D 
serum marker and the 1,25(OH)2D active form can be hydroxylated again by 24-
hydroxylase, coded from the CYP24A1 gene, to generate 24,25-dihydroxyvitamin 
D and 1,24,25-trihydroxyvitamin D, respectively.  This additional hydroxylation 
marks both metabolites for degradation and then excretion (Inouye and Sakaki, 
2001; Sakaki et al., 2005). 
 
1.1.1.2. Vitamin D Signaling 
 The most well-researched and understood mechanism of vitamin D action 
is binding of the 1,25(OH)2D form to the VDR to initiate the transcription of 
several specific target genes.  In order for this process to occur, 1,25(OH)2D 
must bind to the VDR, which heterodimerizes with the retinoid X receptor (RXR) 
creating a VDR-RXR dimer.  Liganded VDR-RXR binds to vitamin D response 
elements (VDREs) in the promoter regions of target genes (Sutton and 
MacDonald, 2003).  Co-activators, along with basal transcriptional machinery, 
and histone modifiers complex together around the VDR-RXR on the VDRE to 
stimulate expression of 1,25(OH)2D regulated genes such as those involved in 
cell proliferation, differentiation, and apoptosis (Sutton and MacDonald, 2003). 
  
1.1.1.2.1. Classic VDR and Target Genes 
 Traditionally, 1,25(OH)2D works through VDR to regulate the serum 
calcium and phosphate levels (see section 1.1.2.) (Haussler et al., 1997).  It is 




proteins involved in cell proliferation, apoptosis, differentiation, immune functions, 
and more, through liganded-1,25(OH)2D.  For example, 1,25(OH)2D regulation 
through VDR acts on cell cycle regulators p21 and p27 to inhibit cell proliferation 
in multiple cancers (Welsh, 2007).  The same mechanism dephosphorylates the 
retinoblastoma-protein (Rb-protein) and increases thioredoxin reductase-1, 
thereby preventing entrance into the S-phase of the cell cycle (Swami et al., 2003; 
Welsh, 2007).  Similarly, liganded VDR-RXR induces cancer cell apoptosis by 
increased generation of reactive oxygen species (ROS), disruption of the 
mitochondrial membrane, and release of cytochrome C (Welsh, 2007).  Further, 
VDR-regulated 1,25(OH)2D down regulation of matrix metalloproteinases (MMPs) 
leads to increased invasive potential and eventual metastasis if left unchecked 
(Swami et al., 2003).  Thus, 1,25(OH)2D action through transcriptional regulation 
of the VDR is broad and has the capability to regulate cellular invasion, and 
proliferation. 
 
1.1.1.2.2. Non-genomic Response of Vitamin D 
 In addition to the classic genomic signaling of 1,25(OH)2D, research 
indicates that 1,25(OH)2D can rapidly stimulate ion fluxes and activate protein 
kinases, independent of the genomic mechanisms (Fleet, 2004). There are three 
proposed explanations for these events: 1) there is a membrane-bound receptor 
which functions as a vitamin D receptor; 2) these are new roles by the classical 
VDR that mediates membrane associated non-genomic effects; and 3), 




 (Fleet, 1999).  The first explanation is supported by Nemere et al. (1998) who 
identified a unique membrane-receptor for 1,25(OH)2D through its regulation of 
protein kinase C in cartilage cells (Nemere et al., 1998).  The second explanation 
is supported by the discovery of a VDR-alternative pocket, so a new ligand 
binding site within the VDR, suggesting new roles (Menegaz et al., 2011).  The 
third explanation has not yet been investigated at this time.  While it is possible 
both genomic and non-genomic 1,25(OH)2D signaling participates in cancer cell 
regulation, their contributions have yet to be clearly elucidated. 
 
1.1.1.3. Extra-renal 1α-hydroxylase  
 As mentioned in section 1.1.1.1., the main location for 1α-hydroxylase, the 
enzyme which converts circulating form of vitamin D, 25(OH)D to the active form, 
1,25(OH)2D, is in the kidney.  However, multiple extra-renal tissues such as, 
adipose (Li et al., 2008), bone (van Driel et al., 2006), breast (Friedrich et al., 
2006; Townsend et al., 2005), brain (Eyles et al., 2005), colon (Bises et al., 2004), 
macrophages (Hewison et al., 2007), endothelial cells (Zehnder et al., 2002), 
keratinocytes (Bikle et al., 2004), the pancreas (Bland et al., 2004), the 
parathyroid (Segersten et al., 2002), the placenta (Evans et al., 2004), and the 
prostate (Blomberg Jensen et al., 2010; Henry, 2011) have shown the presence 
of 1α-hydroxylase.  These discoveries have spurred the suggestion that local 
conversion may affect diseases such as cancer as 1,25(OH)2D can affect the cell 





1.1.2. Calcium Homeostasis 
 Vitamin D, along with parathyroid hormone (PTH), is traditionally known 
for its role as a key regulator in maintaining calcium homeostasis, thus 
preserving the skeletal system mineralization (Sutton and MacDonald, 2003).  
Conversion of 25(OH)D to 1,25(OH)2D is stimulated by increased PTH when low 
serum calcium levels are sensed.  1,25(OH)2D acts on the intestine to increase 
calbindin D9k (CaBPD9k), transient receptor vanelloid family member 6 (TRPV6) 
(Christakos et al., 2007), and basolateral calcium pump Ca2+-ATPase (PMCA1b) 
(Khuituan et al., 2013) synthesis to increase calcium absorption.  1,25(OH)2D 
additionally acts to increase alkaline phosphatase activity subsequently 
increasing phosphate absorption (Khuituan et al., 2013).  Within the kidney, PTH 
simulates activation of 1α-hydroxylase (Sutton and MacDonald, 2003), increasing 
synthesis of 1,25(OH)2D, and subsequently calbindin D28k (CaBPD28k) 
(Hemmingsen et al., 2002) synthesis, thus increasing resorption or calcium from 
the filtrate while simultaneously increasing phosphate excretion in the kidney.  
Additionally, when serum calcium levels are low, 1,25(OH)2D causes resorption 
of calcium and phosphate from the skeletal system through increased receptor 
activator of nuclear factor kappa B ligand (RANK-L) (Kitazawa et al., 2003).  
Conversely, if serum calcium levels exceed the normal range, calcitonin is 
released from the thyroid, causing mineralization of calcium and phosphate in the 
bone.  Together these actions serve to restore the serum calcium levels to 
normal range of 4.5-5.1 mg/dL in order to maintain normal cellular function 




1.1.3. Hypovitaminosis D and Toxicity 
 The current recommendation for vitamin D is 600 IU/day but, epidermal 
synthesis of vitamin D varies greatly depending on sunscreen use, age, ethnicity, 
gender, skin pigmentation, season, latitude, subcutaneous adipose deposition, 
and more (Binkley et al., 2007).  Therefore, these variations can lead to 
insufficiencies or toxicities in some populations.  
 
1.1.3.1. Vitamin D Insufficiency 
 Despite endogenous synthesis, fortified foods, and natural vitamin D 
containing foods, vitamin D insufficiency, defined as <50 nmol/L (Office of Dietary 
Supplements), is common in several populations.  Most often these include the 
elderly (Mateo-Pascual et al., 2014), institutionalized individuals (Nwosu et al., 
2014), and populations living in northern climates (Janssen et al., 2013).  In 
children, vitamin D insufficiency causes rickets, a disease characterized by soft 
bones and skeletal malformation (Wharton and Bishop, 2003).  In adolescents 
and adults, vitamin D insufficiency can lead to osteomalacia (Sunyecz, 2008), 
weakening of the bones, and eventually osteoporosis, which is structural 
deterioration of the skeletal mass.  As a result, there is an increase in fractures, 
breaks, and kyphosis in vitamin D insufficient individuals (Basit, 2013; Heaney, 
2003).  In a study with healthy ambulatory women, median age 84 years old, 
women consumed either a double placebo or a pill with 1.2 g of calcium and 800 
IU of vitamin D3/day for 18-months showed the number of fractures significantly 




25(OH)D increased 162% and proximal femur bone density increased 2.7% in 
the supplemented group (Chapuy et al., 1992).  Therefore, the results of this 
study demonstrate the importance of adequate vitamin D and calcium in reducing 
the risk of fractures. Another study showed that 200 IU/day of vitamin D was not 
adequate to inhibit bone loss in post-menopausal women residing in northern 
regions (latitude 42N) during a 2-year randomized, double-blind, trial (Dawson-
Hughes et al., 1995).  Together, these studies conclude that adequate vitamin D 
(>200 IU) is necessary for preventing osteomalacia, osteoporosis, and 
decreasing the risk of fractures. 
 
1.1.3.2. Vitamin D Safety 
 All micronutrients have an established tolerable upper limit to prevent 
toxicity.  Upper limits for vitamin D range from 1000-3000 IU/day for children 0-8 
years old and is set at 4000 IU/day for all people 9 years of age or older, 
including those pregnant or lactating (Office of Dietary Supplements). It is 
important to note that hypervitaminosis D is only possible through excessive 
dietary intakes and not through endogenous production.  Symptoms of 
hypervitaminosis D include hypercalcemia, anorexia, weight loss, heart 
arrhythmias, cardiovascular system damage, polyuria, kidney damage, and 
calcification of soft tissues (Jones, 2008; Sunyecz, 2008).  However, there is 
evidence that a higher daily intake may have additional therapeutic effects (Grant 
and Holick, 2005; Holick, 2013; Vieth, 2004; Vieth et al., 2001, 2004), such as 




current recommendations and the upper limit.  A risk assessment by Hathcock et 
al. (2007) reported several human trials that used vitamin D doses greater than 
or equal to 10,000 IU/day without indications of toxicity (Hathcock et al., 2007).  
Therefore, recommendations and the upper limit may need to be increased in 
order to receive the full spectrum of benefits from vitamin D.  
 
 
1.2. Breast Cancer 
          In 2013, it is estimated that 232,340 people will be diagnosed and 39,620 
will die of breast cancer in the United States alone (PDQ Screening and 
Prevention Editorial Board, 2014).  Breast cancer is also the most common 
cancer of any race or ethnicity within the United States (Centers for Disease 
Control and Prevention).  Of those diagnosed with breast cancer, 32% of will 
have spread to lymph nodes and another 5% to distant sites with 84.4% and 24.3% 
survival rates, respectively.  Compared to a 98.6% survival rate of patients with 
breast tumors only at diagnosis, it is clear metastasis of the tumor is correlated 
with increased mortality (Centers for Disease Control and Prevention).  While 
there are several non-modifiable breast cancer risk factors such as age, gender, 
and genetics; it may be possible to prevent breast cancer progression and/or 
metastasis by altering other modifiable factors.  Thus, additional research is 
needed to determine alternative strategies for breast cancer progression and/or 





1.2.1. Mammary Gland Biology 
 Female mammary gland development occurs throughout the lifecycle with 
its first changes beginning at puberty.  During puberty, hormones such as 
estrogen induce mammary gland growth via the epithelium branching into ducts.  
Additional changes occur if a female becomes pregnant and the ducts prepare 
for milk secretion by expanding. Upon weaning, the mammary gland regresses 
back to its pre-pregnancy state (Hansen and Bissell, 2000). 
 
 1.2.1.1. Mammary Tissue Development 
  Human mammary gland development begins as early as the tenth day 
after conception (Macias and Hinck, 2012).  The gland remains unchanged from 
birth until puberty when it responds to the ovarian steroid hormone, estrogen, as 
well as growth hormone (Hansen and Bissell, 2000; Macias and Hinck, 2012).  
Mammary gland estrogen response includes epithelial branching into ducts with 
alveolar-likes structures on the terminal ends, called acini. While breast 
development can vary between breasts and individuals, all contain adipocyte 
filled fat pads that help maintain the acini structures (Harvey and Bovbjerg, 2004; 
Macias and Hinck, 2012).   
 A second growth stage for mammary epithelial cells occurs during 
pregnancy.  Steroid hormones, progesterone and estrogen, significantly increase 
causing acini to expand and differentiate into lobules, preparing the mammary 
gland for milk synthesis and secretion (Hansen and Bissell, 2000).  After weaning 




and return to the pre-pregnancy gland state.  Hence, the human female 
mammary gland cycles through growth, differentiation, apoptosis, regression, 
and remodeling over its lifetime (Bissell et al., 2003). 
 
1.2.1.2. Mammary Tissue Structure 
 Regardless of the mammary gland developmental stage, there is a 
polarized epithelium bilayer consisting of a luminal layer of the acini and ducts, 
and a basal myoepithelial layer near the basement membrane (Sopel, 2010).  At 
least 80% of the breast volume consists of mammary stroma which includes 
adipose tissues, loose and dense connective tissues, and blood vessels (Hansen 
and Bissell, 2000; Rønnov-Jessen et al., 1996).  Normal mammary epithelial 
cells bud into three dimensional, hollow lumen, acini,  post-puberty (O’Brien et al., 
2002).   
 The epithelial layers are most susceptible to tumors.  Human studies by 
Rudman et al. showed that benign breast tumors contained both epithelial and 
myoepithelial cells, whereas malignant tumors contained only epithelial cells, 
indicating a potential tumor suppressive role of the myoepithelial cells (Rudland, 
1987, 1993; Rudland et al., 1995).  
 
1.2.2. Breast Cancer Development 
 The most common type of breast cancer is ductal carcinoma (70% breast 
cancer cases), followed by lobular carcinoma (10% breast cancer cases) which 




Editorial Board, 2014).  Other breast cancers are either a rare type or a mix of 
the two (PDQ Screening and Prevention Editorial Board, 2014).   
 
1.2.2.1. Breast Cancer Risk Factors 
 While many factors are non-modifiable, such as age, gender, and genetics, 
some can be controlled, thus reducing breast cancer risk. 
Increased risk is associated with 
 obesity (>180.84 lbs; RR=2.85); combination hormone therapy (estrogen 
 and progesterone; +26%) ; ionizing radiation exposure (6-fold); alcohol 
 intake(RR +7%/drink/day); genetic mutations (ex: BRCA1&2) (+80%; 
 mutation dependent), increasing age, female (100x vs. men), and family 
 history (20-30% with breast cancer have a family history of it)(PDQ 
 Screening and Prevention Editorial Board, 2014). 
Decreased risk is associated with 
 early pregnancy (<20yo, -50%); breast-feeding (-4.3%/year; -7%/birth); 
 exercise (>4hrs/week, premenopausal, normal weight; -30-40%);estrogen-
 replacement  post-hysterectomy (-23%) (PDQ Screening and Prevention 
 Editorial Board, 2014). 
 
1.2.2.2. Multistage Carcinogenesis 
 Cancer incidence is not a single initiating event; rather it is a multistage 
pathway that often takes decades, therefore explaining why incidence increases 




in three generally defined phases: initiation, promotion, and progression (Fearon 
and Vogelstein, 1990; Lopez-Garcia et al., 2010; Weinstein, 1988).  During 
initiation, a normal cell experiences an initiating event such as radiation exposure, 
infection, or a variety of other incidents, allowing for one or more mutations, 
possibly leading to abnormal growth and differentiation (Weinstein, 1988).  In the 
promotion phase, the initiated cells continue to expand and grow, forming a 
population of abnormal cells.  When one or more of these initiated cells attains 
additional genetic changes via a second event, the population continues to 
evolve toward a cancerous cell.  Continuous replication and growth of these 
mutated cells can lead to a benign tumor.  Progression occurs when the benign 
tumor or cells become malignant (Weinstein, 1988).   
 Continuous survival of the tumor requires oxygen, nutrients, and disposal 
of cellular wastes which is accomplished via angiogenesis (detailed explanation 
later, section 1.3.1.2.1.1.).  If the tumor is able to survive and grow unchecked, it 
may spread to secondary sites through a process called metastasis, which will be 
discussed in detail later (see section 1.4.).  This general, simplified, three step 
model helps explain the development of breast cancer though it is important to 
note that the initiations and secondary mutations vary case to case, thus 
individual cases often have distinct morphology and histology.  
 
1.2.2.3. Tumor Receptor Status 
 Aggressiveness and treatment of breast cancer is often determined by the 




subtypes: estrogen receptor (positive/negative) (ER+/-), progesterone receptor 
(positive/negative) (PR+/-), and human epidermal growth factor receptor 
(positive/negative) (+/-).  There are four groups of receptor expression 
combinations called luminal A, luminal B, basal-like, and HER2 enriched which 
represent 40%, 10-20%, 10-20%, and about 10% of tumors, respectively 
(American Cancer Society, 2014). 
 Luminal A breast cancers are HER2- and are ER+ and/or PR+ and are 
classified by their slow growth and lower aggressiveness compared to the other 
receptor combinations.  Since this type of cancer has at least one, and often two, 
receptors present, it is easier to therapeutically target and treat.  Thus, luminal A 
breast cancers have the best prognosis in the short-term, though long-term 
survival is surprisingly the same or even lower compared to the other receptor 
combinations (American Cancer Society, 2014).  Luminal B breast cancers have 
similar receptor expression, being ER+ and/or PR+ but may also be HER2+ 
and/or have a high growth rate (Cheang et al., 2009). 
 Basal-like breast tumors are more commonly referred to as triple-negative 
as they are ER-, PR-, and HER2- (Perou and Børresen-Dale, 2011).  
Subsequently, these tumors have the poorest patient prognosis as there are no 
treatment targets.  Women most likely to have a basal-like tumor include those 
with the Breast Cancer 1 (BRCA1) gene mutation, premenopausal women, and 
African American women (American Cancer Society, 2014).   
 Lastly, HER2 enriched breast cancers are ER- and PR- but have excess 




consequently leading to a lower prognosis compared to ER+ tumors (Blows et al., 
2010).   Fortunately, due to the high expression of HER2, treatments have an 
easy target, allowing for easier treatment than the basal-like tumors.   
 
1.2.2.4. ras Oncogene 
 Genetic alterations, or gene mutations, are usually involved in cancer 
development, including that of the breast.  Upon gene mutation, numerous 
proteins are altered consequently being under- or over-expressed within the 
tumor cell population.  One common mutation in tumors is that of proto-
oncogenes and once altered, cause changes in cell survival, growth, and 
differentiation (ICRP(1998). There are nine main classes of oncogenes: growth 
factors (i.e. GDGF-beta chain sis), receptor/non-receptor protein tyrosine kinases 
(erbB), receptors lacking protein kinase activity (angiotensin receptor), 
membrane associated G-proteins (Ras), cytoplasmic protein-serine kinases (raf-
1), cytoplasmic regulators (crk), nuclear transcription factors (myc, jun), cell 
survival factors (bcl-2), and cell cycle genes (cyclin D1) (ICRP(1998).   
 The ras oncogene was first discovered in 1964 (Malumbres and Barbacid, 
2003).  Three types of ras oncogenes exist: Neuroblastoma-ras (N-ras), Harvey-
ras (H-ras), and Kirsten-ras (K-ras) and all code for GTPases, allowing signal 
transduction across the cell membrane (Malumbres and Barbacid, 2003).  Ras 
signaling occurs through multiple pathways, though the most studied pathway is 
that of Ras to Raf to MEK to mitogen-activated protein kinase (MAPK) 




Raf is subsequently activated. Raf then activates MEK, a dual specificity 
serine/threonine and tyrosine kinase, via phosphorylation (Stamatakos et al., 
2010).  In turn, MEK activates the extracellular signal-regulated (Erk) family of 
MAPK.  Erk proteins effect and regulate growth survival and angiogenesis 
pathways as well as invasiveness through phosphorylation (Stamatakos et al., 
2010).  Alternatively, ras activation can also lead to phosphatidylinositol-3-OH 
kinase (PI3K) activation, leading to stimulation of the serine/threonine kinase, 
protein kinase B (Akt/PKB).  Akt/PKB stimulation often leads to apoptosis 
protection and cytoskeleton reorganization (Stamatakos et al., 2010).  The third 
most recognized downstream effector pathway is that of Ral guanine exchange 
factors (RalGEFs). Upon ras activation, RalGEFs stimulates smaller downstream 
GTPases (e.g. RalA, RalB) and have the ability to transform both rodent and 
human cells (Mishra et al., 2010).  Additionally, genetic knockdown of Ral 
function in vivo resulted in a reduced malignant phenotype (Mishra et al., 2010).  
Ras induces several other downstream effectors including Ras association family 
member (RASSF), and phospholipase C, epsilon, which induce apoptosis, and 
regulate cell growth, differentiation, and gene expression, respectively (Smith 
and Ikura, 2014).  Thus, GTP-bound Ras can effect numerous proteins that 
control cell growth, survival, differentiation, movement, and adhesion (Marshall, 
1996).   
 Despite the low frequency of ras mutations seen in breast cancers (<5%), 
uncontrolled or activated Ras can still effect breast cancer promotion and 




signaling from proteins and genes such as HER2, which is commonly over-
expressed in breast cancers.  In fact, cancer promotion by HER2 signaling is 
partially activated via Ras protein (Eckert et al., 2004).  Due to this intricate 
overlap, the mechanisms by which HER2 and Ras act independent of each other 
has not been clearly determined.  Despite this, it is important to understand the 




1.3. Chemoprevention of Breast Cancer by Vitamin D 
 Due to the prevalence of breast cancer in the world, it is important to 
identify methods of prevention.  There are three levels of breast cancer 
prevention: primary, secondary, and tertiary.  Primary prevention is defined as 
inhibiting the development of abnormal breast tissue growth and mutations 
(Teegarden et al., 2012).  Secondary prevention is defined as inhibiting 
progression of breast tumors, and tertiary prevention is defined as inhibiting 
metastasis and metastatic growth of breast tumors to new sites.  Many 
compounds have been proposed to play a role in breast cancer prevention; one 
of these is 1,25(OH)2D.   
 1,25(OH)2D is thought to exert many of its anti-cancer effects via the VDR, 
which is consistent with levels of VDR found in different stage breast tumors 
(Christakos et al., 2003).  Results demonstrate that the VDR is abundant in 




breast tumors (Lopes et al., 2010, 2012; Satish Rao et al., 2006). These results 
suggest decreased 1,25(OH)2D signaling capability, with decreased VDR, as 
cancer aggressiveness increases, and thus their ability to be affected by 
1,25(OH)2D is reduced as breast cancer progression continues to advance 
(Yagmurdur et al., 2009). 
 
1.3.1. Evidence for Anti-cancer Effects of Vitamin D 
 Epidemiological studies link increased UV exposure, thus vitamin D levels, 
to a decreased prevalence of breast cancer.  In a retrospective study of NHANES 
I, it was found that within a cohort of 5009 women, non-Caucasian ethnicity and a 
low sun exposure index were associated with increased breast cancer risk (John 
et al., 1999).  Similarly, in the same study increased sun exposure index and 
dietary vitamin D levels were associated with decreased breast cancer risk (John 
et al., 1999).  Confirming the results of this study, Anderson et al. (2011) linked 
an increased solar vitamin D score (measurement including all cutaneous vitamin 
D effectors such as sun screen use, outdoor exposure, latitude, etc) with 
decreased breast cancer risk in a population-based case-control study of 6,572 
women (Anderson et al., 2011).  Enhancing the link between vitamin D and 
breast cancer disease, a study by Kermani et al. (2011) suggests an association 
between breast cancer prognosis and serum 25(OH)2D in 119 newly diagnosed 
women with breast cancer disease (Kermani et al., 2011).  Taken together, there 




and breast cancer risk; however, the mechanisms involved were not defined by 
these studies. 
 
1.3.1.2. Anti-cancer Effects of Vitamin D: Mechanisms of Action 
 Given the epidemiological evidence for the potential anti-cancer functions 
of vitamin D, it was necessary to utilize in vitro and in vivo studies to define the 
mechanisms of action and effects. 
 
1.3.1.2.1. Molecular Targets of Vitamin D in Cancer 
 1,25(OH)2D is involved in secondary prevention by acting on the breast 
tumor to reduce tumor growth and progression through decreasing angiogenesis 
and proliferation, and increasing apoptosis (Hanahan and Weinberg, 2011).  A 
fundamental aspect of breast cancer disease is the formation of a solid tumor in 
the mammary gland.  A tumor requires oxygen and nutrients which are delivered 
to the tumor via new blood vessels driven by increased angiogenesis.  In addition, 
a tumor has unregulated cell proliferation contributing to the increase in size of 
tumor.  Finally, cells within tumors also have the ability to evade apoptosis.  All of 
these characteristics are targets of 1,25(OH)2D to prevent tumor survival, growth, 
and progression. 
 
1.3.1.2.1.1. Cancer Characteristics: Tumor Angiogenesis  
 Angiogenesis is the growth and differentiation of blood vessels to provide 




where angiogenesis is quiescent and only transiently activated, tumor 
angiogenesis is almost always activated (Hanahan and Weinberg, 2011).  
Identification of factors that regulate angiogenesis are thus important for the 
prevention of tumor growth and progression.  The most well known angiogenic 
inducer is vascular endothelial growth factor (VEGF) (Hanahan and Weinberg, 
2011).  VEGF is a glycosylated protein that stimulates endothelial cell growth, 
causing new blood vessel formation and mediating vascular permeability.  
Endothelial cells line the interior of arteries and lymph vessels and act as a semi-
selective barrier between blood and interstitial space.  In breast tumor cells, 
expression of VEGF is increased in cell culture, animal models, and human 
tumor samples (Syed Khaja et al., 2013).  The same study showed increased 
VEGF tumor cell expression caused increased angiogenesis to the tumor site, 
allowing blood to bring the necessary nutrients for the tumors growth in the 
xenograft mouse model (Syed Khaja et al., 2013).  A preliminary study induced 
over-expression of VEGF in endothelial cells via recombinant human VEGF and 
in breast carcinoma-xenografted mice via VEGF transfected MCF-7 cells and 
showed that both cellular and mouse models had increased endothelial cell 
proliferation and angiogenesis upon VEGF over-expression (Mantell et al., 2000). 
  The most recognized angiogenic inhibitor is thrombospondin-1 (TSP-1) 
(Hanahan and Weinberg, 2011).  TSP-1 is an adhesive glycoprotein that is 
involved in cell to cell interactions and inhibits angiogenesis. TSP-1 up regulation 
inhibited in vitro cell migration of MCF-7 breast cancer and PC3 prostate cancer 




significant increases in cellular migration (Kim et al., 2013).  Additionally, high 
TSP-1 levels in breast tissue from breast cancer patients was associated with 
reduced breast cancer reoccurrence as analyzed in 124 patients (Ioachim et al., 
2012).  Other factors that regulate angiogenesis have been reviewed in a paper 
by Rice and Quinn (Rice and Quinn, 2002).  The therapeutic potential for these 
factors was first recognized in 1971 and have remained of interest as 
preventative and therapeutic targets (Folkman, 1971).   
 
1.3.1.2.1.1. Vitamin D Induced-Decrease of Angiogenesis in Breast Cancer 
 VEGF has a well established role in breast cancer angiogenesis and has 
been shown to be inhibited by 1,25(OH)2D.  Treatment of 1,25(OH)2D  inhibited 
the VEGF-induced endothelial cell proliferation and angiogenesis in vitro and 
decreased tumor vascularization in vivo (Mantell et al., 2000).  1,25(OH)2D's 
ability to reduce VEGF is a mechanism of action for prevention of angiogenesis 
and thus secondary prevention of breast cancer.  Unfortunately, there is no 
current literature on breast tumor TSP-1 levels after treatment with 1,25(OH)2D in 
breast cancer, but future studies may be able to link 1,25(OH)2D's effects to 
increased TSP-1 as part of secondary prevention. 
 
1.3.1.2.1.3. Cancer Characteristics: Increased Proliferation 
 Cell proliferation is the carefully controlled replication of cells which is 
necessary for normal tissue growth and remodeling.   In cancer, cell proliferation 




uninhibited cycle progression, thus allowing a tumor to grow unchecked.  Tumor 
suppressor genes also have a role in cell proliferation by controlling the cell 
replication cycle, but these genes are frequently inactivated in many cancers 
(Sherr, 2004). Continuous cell proliferation that promotes the development of a 
tumor also has multiple pathways including autocrine signaling with growth 
factors (da Costa et al., 2014), stimulation of neighboring normal stroma cells to 
enhance growth factor release (Cheng et al., 2008), hyper-responsive growth 
receptors (Hanahan and Weinberg, 2011) and/or constant activation of 
downstream proliferation pathways (i.e. growth factor independent) (Davies and 
Samuels, 2010).  Three well established factors that promote cell proliferation in 
breast cancer are PI3K, the mammalian target of rapamycin (mTOR), and 
phosphatase and tensin homolog (PTEN) (Hanahan and Weinberg, 2011). 
 PI3K has both regulatory and catalytic functions in a wide range of cellular 
processes, such as cell growth and proliferation, and is known for its role in 
development of several different cancers, including breast (Fernandis and Wenk, 
2009).  In breast cancer, PI3K is both a marker of progression as well as a 
marker of metastatic transition.  Breast cancer patients with circulating tumor 
cells (CTCs) have increased PI3K expression compared to breast cancer 
patients without CTCs, indicating increased PI3K is associated with progression 
of breast cancer (Kasimir-Bauer et al., 2012).  Inhibition of these signaling 
pathways within the breast tumor cells may be a prevention or treatment target.  
mTOR is both an up- and down-stream factor of the PI3K pathway.  In normal 




However, in breast cancer tumor biopsies, up-regulation of the mTOR pathway 
was shown to be associated with poor prognosis in breast cancer patients 
(Creighton, 2007). 
 The PTEN gene in normal tissue is a tumor suppressor gene and codes 
for lipid metabolism enzymes.  PTEN is often mutated in breast cancer, leading 
to high levels of phosphorylated lipids which then act as growth-stimulating 
factors and, thus causing cancer cell proliferation.  Specific to its tumor 
suppressor function, mutated PTEN also increases tumor cell viability by 
inhibiting PI3K-dependent activation of the Akt pathway, leading to dysregulated 
cell cycle control (Cantley and Neel, 1999; Fernandis and Wenk, 2009). 
 
1.3.1.2.1.4. Vitamin D Induced-Decrease in Proliferation in Breast Cancer 
 Animal studies have shown that 1,25(OH)2D can prevent tumor growth 
and stunt tumor size by inhibiting breast cancer cell proliferation. 1,25(OH)2D 
significantly decreased tumor growth in athymic female mice xenografted with 
human breast cancer cells, T-47D, compared to the control group (García-Quiroz 
et al., 2013).  Furthermore, malignant mastectomy patient tissue samples treated 
with 1,25(OH)2D for 24 hours dose dependently (0, 10, and 100 nM) decreased 
the number of proliferating cells as determined by ki-67 staining (Suetani et al., 
2012).  1,25(OH)2D has been hypothesized to effect several specific pathways 
related to cell proliferation including PI3K (Vivanco and Sawyers, 2002), mTOR 
(O’Kelly et al., 2006), and PTEN (Stefanska et al., 2012), which will be briefly 




 The PI3K pathway may be altered by 1,25(OH)2D (Vivanco and Sawyers, 
2002).  1,25(OH)2D treatment caused PI3K activation and allowed for cancer cell 
survival in squamous cell carcinoma cells (Ma et al., 2006).  However, there is 
also evidence that vitamin D analogs, such as BXL628, may inhibit the PI3K 
pathway, as seen with inhibition of cancer cell survival in prostate cancer cell 
lines (Bonaccorsi et al., 2006).  Therefore, the role of 1,25(OH)2D in regulating 
PI3K in breast cancer remains elusive but needs urgent review as PI3K is an 
established marker in many cancers and is known to be mutated in breast cancer.  
 mTOR has been shown to be regulated by the vitamin D analog, Gemini.    
Treatment with the Gemini analog caused a decrease in mRNA 
translation/protein synthesis, an action of mTOR, in MCF-7 breast cancer cells, 
thus decreasing proliferation (O’Kelly et al., 2006).  The same study also noted 
downstream mTOR effectors were inhibited by the Gemini analog (O’Kelly et al., 
2006).  More studies on 1,25(OH)2D 's inhibitory role of mTOR effectors, thus 
decreased cancer cell proliferation, are needed. 
 Additionally, PTEN is up regulated by cholecalciferol.  Cholecalciferol 
treatment led to decreased methylation of PTEN and therefore increased PTEN 
activity and suppression of oncogene signaling transduction pathways in MDA-
MB-231 breast cancer cells (Stefanska et al., 2012).  Additional studies repeating 
this outcome would further solidify vitamin D's role as an inhibitor of breast 






1.3.1.2.1.5. Cancer Characteristics: Evasion of Apoptosis 
 Apoptosis is the process of programmed cell death.  The B-cell lymphoma 
2 (Bcl-2) regulatory protein family controls the balance of pro- and anti-apoptotic 
effectors, largely by either suppressing or allowing expression of pro-apoptotic 
proteins, Bax and Bak, among other mechanisms (Hanahan and Weinberg, 
2011).  The mechanism of action for Bax and Bak involves altering the potential 
of the mitochondrial membrane and allowing cytochrome c release, which causes 
a caspase activation cascade resulting in cell death.  Bcl-2 expression shifts the 
balance towards inhibition of apoptosis.  An increase in Bcl-2 expression is 
correlated with tumor size and grade, lymph node invasion and status, estrogen 
receptor levels, progesterone receptor levels, and epidermal growth factor 
receptor levels, histological tumor type, HER2, p53, and overall patient survival in 
582 breast cancer biopsies (Tawfik et al., 2012).  Therefore, evaluation of Bcl-2 
expression in cancer tissue may be beneficial to predict patient outcomes. 
 Evasion of apoptosis allows for cancer cells to survive longer by 
increasing cell number and thus tumor growth, which adds to the progression of 
a tumor as a whole.  Cancer cells elude apoptosis through several pathways, 
most commonly via loss of p53 tumor suppressor function (Muller et al., 2011).  
Additional pathways include increases in survival signals (Liu et al., 2013), 
decreased or down-regulated pro-apoptotic proteins (Gogada et al., 2013) 
increased anti-apoptotic regulators (Yadav and Chandra, 2014), and/or 




A thorough understanding of the pathways can be utilized to target breast tumor 
gene expression for prevention or treatment. 
 
1.3.1.2.1.6. Vitamin D Induced Apoptosis in Breast Cancer 
 Several studies have examined the role of 1,25(OH)2D in inducing 
apoptosis of breast cancer cells.  A dose dependent decrease in MCF-7 cell 
numbers were seen upon 1,25(OH)2D treatment.  Treatments of 10, 100, and 
1000 nM significantly lowered cell number compared to vehicle, 0.1, and 1 nM 
treatments of 1,25(OH)2D (Simboli-Campbell et al., 1996).  Furthermore, human 
mammary epithelial cells and MCF-7 cells treated with 100 nM of 1,25(OH)2D for 
one, three, or six days, significantly increased the number of apoptotic cells as 
measured by DNA fragmentation and caspase activity (Sergeev, 2004). 
 One mechanism by which, 1,25(OH)2D has been shown to regulate 
apoptosis is through tumor necrosis factor-α (TNF-α) and Bcl-2.  TNF-α, a gene 
that codes for a multifaceted cytokine involved in cell survival, progression, and 
death, is regulated by 1,25(OH)2D.  Specific to apoptosis, Pileczki et al. (2012) 
created a TNF-α knockdown triple negative breast cancer cell (Hs578T) resulting 
in a significant increase of apoptosis via increased mRNA abundance of 12 pro-
apoptotic genes (Pileczki et al., 2012).  Studies show 1,25(OH)2D treatment 
increases apoptosis in vitro  in breast cancer cells by altering TNF-α.  
1,25(OH)2D and TNF-α synergistically increased cytotoxicity in breast cancer 
MCF-7 cells when treated between one to 24 hours.  The authors suggest 




pathway, whose predominant action is to inhibit apoptosis in cancer (Weitsman 
et al., 2004).  Similarly, 1,25(OH)2D treatment increased apoptosis via an 
upstream regulator of TNF-α, Nuclear factor kappa B (NFκB), in breast cancer 
lines MCF-7 and MDA-MB-231 (Tse et al., 2010).  In breast cancer, NFκB 
promotes cell survival but 1,25(OH)2D treatment reversed this effect by 
repressing transcription of the NFkB activator component, p65 (Tse et al., 2010).  
Much remains to be investigated regarding the role of TNF-α in 1,25(OH)2D 
regulation of breast cancer, as both knockdown and up-regulation of TNF-α 
caused apoptotic effects in breast cancer.  It is possible that 1,25(OH)2D 
treatment acts on multiple upstream and downstream regulators of TNF-α, such 
as NFκB and p38/MAPK to enhance pro-apoptotic effects.  Given TNF-α's control 
of cancer cell apoptosis, further investigation of 1,25(OH)2D's mechanism of 
action on TNF-α's pro-apoptotic pathways is necessary.   
 As mentioned prior, the Bcl-2 regulatory protein family controls the 
balance of pro- and anti-apoptotic effectors, largely by either suppressing or 
allowing expression of pro-apoptotic proteins, Bax and Bak, among other 
mechanisms (Hanahan and Weinberg, 2011).  Some studies show 1,25(OH)2D 
treatment in vitro is pro-apoptotic via Bcl-2 down regulation (Hanahan and 
Weinberg, 2011).  Similarly, vitamin D analog treatments induced apoptosis in 
both MCF-7 and T47D breast cancer lines (Mathiasen et al., 1999). This effect 
was eliminated with over expression of Bcl-2, suggesting that anti-apoptotic 
1,25(OH)2D action must occur prior to Bcl-2 over-expression (Mathiasen et al., 




caused a decrease in Bcl-2 expression which led to increased pro-apoptotic 
proteins (i.e. p53, p21, claspin, etc) in the MDA-MB-231 breast cancer cell line 
(Brosseau et al., 2012).  It is possible that 1,25(OH)2D  causes decreased Bcl-2 
expression which leads to increased apoptosis in breast cancer, though more 
studies are needed to confirm this relationship. 
 
 
1.4. Cancer Metastasis 
  In order to advance, a tumor must activate changes leading to invasion 
and metastasis into new sites.  Metastasis has no strict definition, but includes 
successful colonization of a new site as a result of specific interactions between 
cancer cells and their microenvironment, allowing these cells to override their 
innate behavior and eventually become a clinically detectable tumor (Chiang and 
Massagué, 2008; Hanahan and Weinberg, 2011; Hunter et al., 2008; Ooi et al., 
2011).  Metastasis can be grouped into three general steps: initiation, 
progression, and perturbation/virulence but theories of mechanism differ. 
 
1.4.1. Theories of Cancer Metastasis 
 Throughout the years of cancer research, several hypotheses have 
developed to explain the exact mechanism of metastasis.  While no one theory 
encapsulates all that is observed during cancer metastasis, six models have 
emerged that attempt to explain primary tumor cell disassociation, secondary site 




include the progression, transient compartment, fusion, gene transfer, early 
oncogenesis, and genetic predisposition, models.    
 
1.4.1.1. Progression Model 
 For over 30 years, the progression model of metastasis has been the most 
well accepted.  The model was first proposed in 1976 by Nowell and promotes 
the idea of primary tumor cell subpopulations, some of which acquire the ability 
to metastasize (Nowell, 1976).  Since not all cells in the primary tumor 
disseminate and migrate to a secondary site, the higher aggression 
subpopulations explain why the primary tumor stays intact and grows while 
additional tumors arise elsewhere.  While a long history of experiments back this 
theory (Fidler and Kripke, 1977; Kang et al., 2003; Minn et al., 2005), two issues 
arise.  In a small subgroup (~5%) of tumor cases, a primary tumor is not 
detectable despite a metastasized disease state (Hunter et al., 2008).  Second, 
the progression model predicts that the aggressive genotype in the metastatic 
subpopulation would exist the lifetime of the secondary tumor but studies have 
shown some of these subpopulations degrade to a lower level metastatic 
capability after multiple regenerations (Harris et al., 1982).  Thus, given these 
discrepancies, alternative models have been proposed. 
 
1.4.1.2. Transient Compartment Model 
 The transient compartment model, also known as the dynamic 




difference in metastatic aggressiveness between the primary and secondary 
tumors (Weiss, 1990).  This model suggests that instead of only primary tumor 
subpopulations acquiring metastatic potential, all the primary tumor cells acquire 
metastatic properties and either position or random events (e.g. epigenetics) 
allow for specific cells to fully metastasize (Weiss, 1990).  While some studies 
support this model (Kerbel et al., 1984; Stopper et al., 1992) the transient 
compartment model fails to explain the clonal nature of metastases since random 
epigenetic events dictate the portions of primary tumor that are capable of 
metastasizing, thus not appearing clonal (Hunter et al., 2008).   
 
1.4.1.3. Fusion Model 
 While more of a theory than a model, the fusion model attempts to explain 
why tumor-derived epithelial cells are able to metastasize (Hunter et al., 2008).  
The fusion model converges on a hypothesis that metastatic tumor cells gain 
lymphoid features via nuclear transduction with myeloid cell fusion or uptake of 
circulating tumor DNA by myeloid cells (García-Olmo and García-Olmo, 2001).  
Cellular fusion is a normal human function (i.e. fertilization, myocytes in muscle 
fibers, osteoclasts, etc) and while there are studies supporting this model, they 
are riddled with cofounders (Busund et al., 2003; Pratt et al., 1989).  Additionally, 
there are no studies supporting this model in human tumors thus, this model has 
lower support within the cancer community than most other models mentioned 





1.4.1.4. Gene Transfer Model 
 Similar to the fusion model, the gene transfer model is based on horizontal 
gene transfer.  In short, this model suggests that circulating tumor cell DNA is 
taken up by stem cells at the secondary sites, not circulating cells (García-Olmo 
et al., 2004) thus, metastasis results from de novo tumor synthesis rather than 
from primary tumors.  Organ specific affinities of metastases is not explained by 
this model nor is it possible that a significant amount of the proposed circulating 
DNA would be taken up in the same organ in order to form a solid tumor (Hunter 
et al., 2008).  For these reasons and more, the gene transfer model is the least 
popular at this time.  
 
1.4.1.5. Early Oncogenesis Model 
 The early oncogenesis model resembles parts of the transient 
compartment model.  Microarray studies within the last decade or so have 
identified protein expression profiles that can predict which tumors can or cannot 
metastasize (Nuyten et al., 2006; Ramaswamy et al., 2003; van ’t Veer et al., 
2002; Wang et al., 2005a).  These profiles generally include the bulk of the tumor, 
thus suggesting the whole tumor has potential to metastasize (transient 
compartment model) but may be dominated by a highly metastatic subpopulation 
within the tumor that is masked by the bulk of the tumors' expression (Hunter et 
al., 2008).  Therefore, it has been proposed that metastatic ability is decided 
early in oncogenic progression, thus giving a similar protein expression profile to 




transient compartment model.  This model suggests the majority of the tumor is 
capable of metastasis, but secondary tumor site invasion is lower in clinical 
observations than what is suggested by this model.  Additionally, the microarray 
data neither confirms nor denies metastatically aggressive subpopulations within 
the primary tumor (Hunter et al., 2008). 
 
1.4.1.6. Genetic Predisposition Model 
 The Hunter laboratory of cancer biology and genetics at the National 
Cancer Institute has piloted the genetic predisposition model, which is based on 
how the genetic background of the primary tumor affects its ability to metastasize 
(Lifsted et al., 1998).  This model suggests that inherited polymorphisms 
influence gene expression not only in normal tissue but in tumors as well, 
possibly allowing for a predisposition toward metastatic capabilities.  The Hunter 
laboratory also suggests possible prediction of tumor development and 
metastatic capability once a metastatic predictive gene expression signature is 
established, as the inherited polymorphisms would be present in all tissues, not 
just cancerous ones, therefore making it possible to predict and possible prevent 
cancer occurrence (Hunter et al., 2008).   The Hunter laboratory is currently 
exploring this proposal in vivo (Yang et al., 2005).  While none of the metastasis 
theories completely explain the phenomenon, it is possible that parts of each 






1.4.2. Metastatic Initiation 
  Metastasis initiation is characterized by the cancer cells undergoing 
epithelial-to-mesenchymal transition (EMT), invasion through the primary tumor 
environment toward the blood, and the bone microenvironment (for those 
cancers prone to metastasize in the bone, such as breast cancer). Epithelial 
carcinomas that metastasize typically develop physiological alterations, have 
changes in cell-to-cell adhesion, and alter how they attach to the extracellular 
matrix (ECM), among other changes (Hanahan and Weinberg, 2011).   
 
1.4.2.1. Epithelial to Mesenchymal Transition 
 EMT is the process where epithelial cells become mesenchymal-like by 
losing their epithelial characteristics.  This mesenchymal-like profile increases 
cancer cell invasiveness (Kallergi et al., 2011).  Induction of EMT is associated 
with activation of the Wnt/β-catenin signaling pathway (Prasad et al., 2009).  
Glycogen synthase kinase 3 inhibition and nuclear β-catenin are markers of the 
Wnt/β-catenin pathway activation and are often correlated with poor prognosis of 
breast cancer patients (Kim et al., 2002; Logullo et al., 2010).  Several markers 
are established in the EMT pathway with some of the most established markers 
being epithelial-cadherin (E-cadherin), Twist (E-cadherin's repressor), neuronal-








 The CDH1 gene on chromosome 16q22.1 encodes the E-cadherin protein, 
a calcium-dependent, transmembrane adhesion, glycoprotein (McVeigh et al., 
2013).  E-cadherin, as its name indicates, is found mainly in epithelial cells and 
interacts with cytoskeleton actin and thus has a role in regulating cellular 
differentiation, growth, migration, and adhesion (Buda and Pignatelli, 2011).  
Specific to its' cell adhesion function, E-cadherin typically interacts with an 
assortment of catenins within the cytoplasm, thus maintaining its' interaction with 
actin filaments (Pötter et al., 1999).  The catenin-binding domain is highly 
conserved and consists of 72 amino acids on E-cadherins carboxyl terminus 
(Pötter et al., 1999).  Within the catenin-binding domain are eight serine residues 
and when phosphorylated, allow for catenin-binding therefore inducing the 
expected cell-adhesion properties (Stappert and Kemler, 1994).  The 
juxtamembrane domain, located past the transmembrane domain but within the 
intracellular part of E-cadherin is said to function independently to suppress cell 
motility (Chen et al., 1997).  Therefore, the intracellular tail of E-cadherin not only 
dictates cytoplasmic protein interactions but also mediates cadherin functions 
(Pötter et al., 1999).  A variety of additional factors influence expression and 
function of the E-cadherin-catenin system in humans such as, epidermal growth 
factor (EGF), tumor growth factor-β (TGF-β), cyclic AMP (cAMP), and androgens 
among other factors (Pötter et al., 1999).   
 Loss of E-cadherin causes loss of epithelial cells apical-basal polarity and 




necessary for proper embryonic development, wound healing, and fibrosis, it also 
initiates tumor progression to metastasis (Lee et al., 2006; Thiery et al., 2009).  
E-cadherin loss is well documented in breast cancer and loss of the CDH1 gene 
function is considered a high-risk mutation for breast cancer susceptibility (Berx 
and Van Roy, 2001; Deng et al., 2012; McVeigh et al., 2013; Rakha et al., 2005; 
Sarrió et al., 2004; Singhai et al., 2011; Vincent-Salomon and Thiery, 2003).  In 
fact, carriers of CDH1 mutations have a 40-50% breast cancer risk compared to 
non-carriers and E-cadherin down regulation predicts poor patient prognosis 
(Schrader et al., 2008).  E-cadherin down regulation leads to decreased cell 
adhesion, which decreases the integrity of breast epithelial cell morphology to a 
more mesenchymal-like morphology (Taylor et al., 2011; Wendt et al., 2011).  
This mesenchymal-like phenotype allows for continued breast cancer 
progression and furthers metastatic initiation. 
 
1.4.2.1.2. Vitamin D Induced Expression of E-cadherin in Breast Cancer 
 E-cadherin has been shown to be increased by 1,25(OH)2D (van Roy and 
Berx, 2008).  In breast cancer EMT, E-cadherin expression is suppressed, thus 
contributing to the mesenchymal-like phenotype (Taylor et al., 2011; Wendt et al., 
2011).  1,25(OH)2D treatment caused a time (12-72 hours of 100 nM) and dose 
dependent (1-100 nM for 72 hours) increase of E-cadherin expression,  which 
decreased metastatic potential in MDA-MB-231 breast cancer cells (Lopes et al., 








 The VIM gene on chromosome 10p13 codes for the vimentin protein, a 
type III intermediate filament.  Type III intermediate filaments are found in a 
variety of human tissues and cells such as endothelium, muscle, glia, fibroblasts, 
astrocytes, and leukocytes (Chung et al., 2013).  The intermediate filament 
proteins are regulated post-translationally via acetylation, ubiquitination, 
sumolyation, O-glycosylation, and phosphorylation, most of which are reversible 
(Chung et al., 2013).  Specifically, vimentin plays an important role in maintaining 
cell shape, cytoskeleton communication, organization, and migration and is 
predominately expressed during embryogenesis (Dave and Bayless, 2014).  Slug, 
H-RAS, Akt, adenomatous polyposis coli (APC), and linker of nucleoskeleton and 
cytoskeleton activate vimentin to promote cell migration, while specific miRNAs  
(i.e. mir-138,mir-30a) and methylenetetrahydrofolate dehydrogenase 2 inhibit this 
function (Chung et al., 2013).  Therefore, vimentin plays a crucial role in cancer 
cell communication and migratory ability leading to metastasis. 
  In breast cancer EMT, the cancerous epithelial cells switch from a keratin-
dominated IF system to a vimentin-dominated intermediate filament system 
(Chung et al., 2013).  Vimentin works as a mesenchymal intermediate filament to 




(Caruso and Stemmer, 2011; Kallergi et al., 2011).  It is also one of the most 
highly expressed EMT markers in a study using MCF10CA1a metastatic breast 
cancer cells (Battula et al., 2012; Caruso and Stemmer, 2011).  Moreover, 
studies show increased vimentin expression is associated with increased cancer 
cell motility (Chu et al., 1993, 1996; Hendrix et al., 1997) and is a poor prognostic 
factor in breast carcinomas (Battula et al., 2012; Caruso and Stemmer, 2011; 
Kallergi et al., 2011).  Further supporting this observation are multiple studies 
with vimentin alterations in human breast cancer cell lines, which showed a 
decreased migration effect upon siRNA/shRNA treatments (McInroy and Määttä, 
2007; Rogel et al., 2011; Vuoriluoto et al., 2011), suggesting vimentin is indeed a, 
if not the, major player in cancer cell motility.  This increased expression may be 
exacerbated by down regulation of mir-30a and mir-138 in tumors, which 
generally functions to inhibit vitmentin motility functions (Cheng et al., 2012; 
Yamasaki et al., 2012).   
 
1.4.2.1.4. Vitamin D Induced-Decrease of Vimentin in Breast Cancer 
 There is some evidence that vitamin D may regulate vimentin expression.  
Vitamin D-binding protein-derived macrophage activating factor treatments on 
MCF-7 breast cancer cells showed significantly lower vimentin expression (Pacini 
et al., 2012).  This suggests that vitamin D may have a role in down regulation of 
vimentin and therefore EMT inhibition.   Several gaps in knowledge remain 




 While there is only one study examining vitamin D-related proteins 
regulation of vimentin in breast cancer, several studies support vitamin D 
regulation of vimentin in prostate and colorectal cancer.  A significant decrease in 
vimentin mRNA abundance was seen in DLD-1 and HCT116 colorectal cancer 
cell lines treated with 1 µM of 1,25(OH)2D for 24 and 48 hours (Findlay et al., 
2014).  Similarly, RWPE-W99 prostate cancer cells had a dose dependent 
decrease in vimentin protein expression shown by Western blot and with 
immunohistochemistry when treated with increasing doses of 1,25(OH)2D (10-9 to 
10-6) (Tokar and Webber, 2005).  Further, as the dose of 1,25(OH)2D increased, 
the percentage of invasive cancer cells decreased (Tokar and Webber, 2005).  
Together, these studies provide evidence to support further exploration of the 
role of 1,25(OH)2D regulated vimentin expression in breast cancer progression.  
 
1.4.2.1.5. N-cadherin 
 The CDH2 gene on chromosome 18q11.2 codes for the N-cadherin 
protein, a calcium-dependent, transmembrane adhesion, glycoprotein.  N-
cadherin is found in a variety of tissues such as muscle, neurons, endothelial 
cells, cardiomyocytes, and mesenchymals.  Main functions of N-cadherin 
includes establishment of left-right asymmetry, early embryo development, 
nervous system synapse function, and cell-cell adhesion.  Similar to E-cadherin, 
N-cadherin is part of the type 1 classical cadherin family (Sun et al., 2014).  It has 
a small cytoplasmic domain, a membrane anchoring domain, and a large 




calcium ions are required to stabilize the links between the extracellular repeats, 
with the first repeat allowing for interaction between N-cadherins on separate 
cells thus facilitating its' classical cell-cell adhesion function (Sun et al., 2014).  
Similar to E-cadherin, the cytoplasmic tail of N-cadherin binds to proteins of the 
catenin family (Sun et al., 2014).  Binding of the catenins allows for N-cadherin to 
interact with other cell membrane proteins to form proper cell-cell junctions.  N-
cadherin-catenin interaction is altered by tyrosine phosphorylation (Lilien and 
Balsamo, 2005).  Cyclin dependent kinase 5, non-receptor tyrosine kinases, and 
receptor tyrosine kinases all associate with N-cadherin adhesion as 
phosphorylators, causing dissociation of the catenin-cadherin complex (Castaño 
et al., 2007; Lilien and Balsamo, 2005; Schuman and Murase, 2003).  
Conversely, dephosphorylation stabilizes the N-cadherin-catenin complex 
through receptor tyrosine phosphatase, and non-receptor phosphatase (Balsamo 
et al., 1998; Müller et al., 1999). 
 In breast cancer EMT, N-cadherin expression is increased concurrently 
with decreased E-cadherin expression (Hazan et al., 1997; Sigurdsson et al., 
2011).  It is thought that N-cadherin and the cell surface receptor fibroblast 
growth factor (FGF), interact and cause invasiveness by increasing matrix 
metallopeptidase-9 (MMP-9) through sustained MAPK-ERK activation (Kim et al., 
2000; Suyama et al., 2002).   Tumor aggressiveness and metastatic potential 
was associated with N-cadherin expression in invasive breast cancer biopsies 
(Nagi et al., 2005).  High N-cadherin expression was significantly associated with 




those that did not (Nakagawa et al., 2011).  Additional evidence comes from a 
clinical cohort of 574 breast cancer patients where those with above the median 
N-cadherin expression had a statistically significant shorter relapse-free period 
compared to those below it (Saadatmand et al., 2013).  Therefore, it is possible 
that higher N-cadherin expression in breast cancer may contribute to tumor 
progression and metastasis. 
 
1.4.2.1.6. Vitamin D Induced-Decrease of N-cadherin in Breast Cancer 
 Currently, only one study investigates the role of 1,25(OH)2D regulation of 
N-cadherin.  Treatment of 100 nM of 1,25(OH)2D for 24, 48, 72, and 96 hours 
resulted in a significant decrease in N-cadherin protein expression in MDA-MB-
453, MDA-MB-361, and BT-474 metastatic breast cancer cell lines (Pendás-
Franco et al., 2007).  While these results are promising, the results need to be 
replicated to establish a correlation between 1,25(OH)2D treatments and 
decreased N-cadherin expression in breast cancer.  
 
1.4.2.1.7. Fibronectin 
 The FN1 gene on chromosome 2q34 encodes for the ECM glycoprotein.  
Fibronectin is involved in a host of functions such as wound healing, blood 
coagulation, immunity, embryo development, cell adhesion, and metastasis 
(Pankov and Yamada, 2002).  Within the extracellular matrix and at the cell 
surface, fibronectin is either dimeric or multimeric and has the potential to 




splicing (Pankov and Yamada, 2002; Sabatier et al., 2013).  In the last few years, 
studies have suggested that fibronectin is the most pivotal extracellular matrix 
organizer (Sabatier et al., 2013).  For example, collagen type 1, TSP-1, and 
latent TGF-beta-binding protein-1 require fibronectin for their proper assembly 
and without such, may lead to developmental abnormalities among other issues 
(Dallas et al., 2005; Liu et al., 1995; Sottile and Hocking, 2002).  Additionally, 
fibronectin is a ligand for many integrin receptors, which are heterodimeric cell-
surface receptors that link the intracellular cytoskeleton and extracellular matrix, 
thus acting as signaling mediators between the extracellular space and the cell 
interior (Pankov and Yamada, 2002).  Integrins regulate these signals through 
secondary molecules such as focal adhesion kinase (FAK), integrin-linked kinase 
(ILK) and more (Hehlgans et al., 2007).  Consequently, cell shape, adhesion, 
polarity, survival, migration, differentiation and proliferation are indirectly 
regulated by fibronectin (Hehlgans et al., 2007). 
 In breast cancer EMT, fibronectin expression is significantly increased.  
Fibronectin has long been known as a marker for EMT (Ignotz and Massagué, 
1986) and is also associated with tumor aggressiveness (Bae et al., 2013).  
Breast cancer cells undergoing EMT had an increased fibronectin expression 
coupled with decreased E-cadherin (as expected) compared to breast cancer 
cells that were inhibited from proceeding to EMT (Trimboli et al., 2008).  
Additionally, increased tumor expression of fibronectin is linked to poor patient 




(Bae et al., 2013; Gorczyca et al., 1993; Ioachim et al., 2002).  Currently, no 
literature exists examining the role of 1,25(OH)2D regulation of fibronectin 
expression in breast cancer. 
 
1.4.2.2. Metastatic Invasion Into the Blood 
 Thus, the combination of these EMT associated protein expressions; 
decreased E-cadherin, and increased N-cadherin, fibronectin, and vimentin, lead 
to increased breast cancer metastasis.  EMT is one of the steps of metastatic 
initiation, but several additional changes must occur in order for the cancer cells 
to acquire full metastatic ability.  Once the cancer cells have acquired their 
mesenchymal phenotype they must also be able to invade the surrounding tissue 
and eventually make it to the blood stream.  MMP-9, and bone morphogenic 
proteins-2 and -7 (BMP-2, BMP-7) are factors with emerging evidence that they 
are involved in cancer invasion to a new cancer site; in this case, breast to bone. 
 MMP's are known to be capable of degradating extracellular matrix and 
basement membrane during normal cell and tissue processes.  Over expression 
of MMP-9 in metastatic breast cancer cells correlates with invasiveness in the 
new site, bone (Cox et al., 2012).  Reinforcing this hypothesis, another study 
showed MMP-9 was highly expressed and associated with increased 
degradation of extracellularmatrix and collagen in both the MCF-7 breast cancer 
line and U937 lymphoma cell line (Chimal-Ramírez et al., 2013).   
 Additionally, CD44, a key regulator of epithelial cell environment, is 




by So et al. (2013) tested how the vitamin D analog, Gemini, affected 
MCF10DCIS basal-like human breast cancer cells and decreased expression of 
CD44.  This knock down of CD44 lead to decreased MMP-9 mRNA abundance 
in the MCF10DCIS line suggesting that vitamin D analogs, thus perhaps 
1,25(OH)2D, play a role in preventing extracellular matrix degradation which may 
inhibit invasion to the bone (So et al., 2013).  Studies in the bone are needed to 
clarify 1,25(OH)2D's precise role on MMP-9. 
 BMP-7 has known roles in locomotion, chemotaxis, and cell proliferation in 
early bone development (Glait-Santar et al., 2012) and assists in cartilage and 
bone formation.  BMP-7 is up regulated and promoted cancer cell growth, 
migration, and metastasis to bone in the highly bone marrow metastatic breast 
cancer cell line, 4T1E/M3 (Sakai et al., 2012).  In the same study, BMP-7 knock 
down in 4T1E/M3 cells caused decreased proliferation, invasion, and migration of 
the breast cells to the bone marrow (Sakai et al., 2012).  Micro-calcifications, 
which occur in early breast cancer and in the breast cells metastasized to bone, 
are used as a detection method for early stage breast cancer.  Increased 
mineralization and calcification of the breast cancer cells occurred in murine 
mammary adenocarcinoma cell line, 4T1, when cultured with an osteogenic 
cocktail media containing a BMP-2 supplement, suggesting BMP-2 may assist in 
tumor development beyond the bone (Cox et al., 2012).  Despite substantial 
research of BMP-7 in relation to breast cancer, there are no studies concerning 




1,25(OH)2D's prominent roles in bone formation, it is important for future studies 
to research their interaction in breast cancer metastasis. 
 
1.4.2.3. Metastatic Marrow Mobilization 
 Bone is the most common site of breast cancer metastasis (Hess et al., 
2006). The bone microenvironment, which is a milieu of growth factors, 
osteoclasts, and osteoblasts, plays a pivotal role in survival of metastatic breast 
cancer cells (Chiang and Massagué, 2008). Chemokine (C-C motif) ligand 2 (Ccl-
2) is one of the best documented controllers involved in the bone 
microenvironment (Chiang and Massagué, 2008).  Ccl-2, a chemokine with 
immunoregulatory, inflammatory, and chemotaxis roles, is also regulated by 
1,25(OH)2D.  Foundational studies show Ccl-2 promotes angiogenesis and acts 
on tumor cells to create an attractive microenvironment rich in growth factors 
(Salcedo et al., 2000).  Co-culturing of pre-osteoblastic and breast 
adenocarcinoma cells, to mimic metastatic breast cancer, resulted in increased 
Ccl-2 expression in the pre-osteoblastic cells (Glait-Santar et al., 2012). This 
suggests that Ccl-2 creates an attractive microenvironment in bone for breast 
cancer cells undergoing metastatic initiation to adhere (Glait-Santar et al., 2012).  
MCF-7 breast cancer cells transfected with the Fokl polymorphism (VDRff) vector 
confirmed the expected increase in Ccl-2 expression (Alimirah et al., 2011).  
Treatment with 1,25(OH)2D resulted in a significant decrease of Ccl-2 , indicating 




investigating the impact of 1,25(OH)2D regulation in the bone microenvironment 
are needed, including the role of breast cancer cell Ccl-2 expression. 
 
1.4.3. Metastatic Progression 
 Metastatic progression is marked by breast cancer cell extravasation from 
the blood into the new cancer site, angiogenesis at the new site, and immune 
evasion of the forming micro-tumors. 
 
1.4.3.1. Extravasation 
 Extravasation is the process of tumor cells traveling through the 
bloodstream, exiting the blood vessels, and heading to the new tumor site in the 
bone (Chiang and Massagué, 2008).  TGF-β and cyclooxygenase-2 (COX-2) are 
two established factors involved in extravasation with new results emerging 
rapidly.  TGF-β suppresses tumorigenesis and promotes cell and tissue 
differentiation.  In breast cancer, the TGF-β tumor suppressor function is reduced, 
thus increasing tumorigenesis. Loss of this TGF-β tumor suppressor function has 
been noted to assist in the movement of breast cancer cells to the bone (Chiang 
and Massagué, 2008).  Once the breast cancer cells are established, the 
mutated TGF-β controls several factors, including E-cadherin, that further 
promote breast cancer metastasis (Proietti et al., 2011; Taylor et al., 2011).  A 
10-fold increase in TGF-β expression inhibited further cancer cell growth in MCF-
7 breast cancer cells when treated for 72 hours with 1,25(OH)2D (Proietti et al., 




is through TGF-β's control of Smads, downstream factors which influence cancer 
cell proliferation and hormonal responses (Proietti et al., 2011).  Additional 
studies detailing 1,25(OH)2D's mechanism of action in enhancing the TGF-β 
tumor suppressor function are needed. 
 COX-2 plays an intimate role in tissue inflammatory responses and can be 
regulated by 1,25(OH)2D.  In breast cancer, COX-2 has an emerging role in 
enhancing cancer cell movement from breast to bone.  One study demonstrated 
that eliminating COX-2 action decreased or prevented movement of breast tumor 
cells to bone (Valcárcel et al., 2011).  A significant decrease in COX-2 
expression was observed when nude mice with MCF-7 breast cancer cell 
xenograft were treated with 1,25(OH)2D compared to those treated with vehicle 
(Swami et al., 2011).  Another study employed similar MCF-7 xenografts but 
included male nude mice as well (Swami et al., 2012).  Consistent with the 
previous study, the results showed a significant decrease in COX-2 mRNA when 
both 1,25(OH)2D intravenous injections and diet supplements were given (Kim et 
al., 2003; Swami et al., 2012).  1,25(OH)2D induced COX-2 down regulation, 
which may lead to decreased inflammatory signals and reduced directional 
signaling that breast cancer cells follow in order to extravasate.  Future studies 
should focus on up and down-stream factors of COX-2 in order to identify the 







1.4.3.2. Vascular Remodeling and Secondary Site Angiogenesis 
 Vascular endothelial growth factor (VEGF) promotes angiogenesis at the 
new tumor site and may be regulated by 1,25(OH)2D.  Angiogenesis is the 
growth of blood vessels to the cells implanted in the bone site to provide nutrients.  
VEGF is a glycosylated protein that stimulates endothelial cell growth, causing 
new blood vessel formation and mediating vascular permeability.  In breast 
cancer, VEGF is increased and causes increased angiogenesis to the tumor site, 
allowing blood to bring the necessary nutrients for its growth (Folkman, 1971; 
Syed Khaja et al., 2013).  Distant metastases over express VEGF, which is 
linked to patient prognosis as shown by microarray analysis of original breast 
tumors, nearby metastases (i.e. rib), and distant metastases (i.e. liver, brain) of 
human biopsy samples (Hu et al., 2009).  The authors hypothesized it was the 
increased VEGF that promoted de novo blood vessel formation to new tumors in 
the patients analyzed (Hu et al., 2009).  Although there are studies exploring the 
role of 1,25(OH)2D in regulating VEGF in the original breast tumor, none exist for 
in the metastases (Mantell et al., 2000; Ben-Shoshan et al., 2007).  It is possible 
that 1,25(OH)2D has an effect on VEGF-stimulated angiogenesis based on 
original breast tumor studies but this is an area needing greater research, 
particularly using 3D in vitro and animal, models. 
 
1.4.3.3. Immune Evasion 
 Chemokine (C-C motif) ligand 5 (Ccl-5) and an array of inflammatory 




immune evasion but few studies involving 1,25(OH)2D are available.  Immune 
evasion is required to protect the tumor from being recognized and attacked by 
the body's immune system.  Ccl-5 and related inflammatory factors generally act 
as chemoattractants for eosinophils and helper-T cells as part of 
immunoregulatory processes.  High levels of Ccl-5 as well as increased TNF-α, 
Ccl-2, and interlukein-1β (IL-1β) were found in breast cancer patient tumor 
samples (Soria et al., 2011).  The same study further proposes that the combined 
expression of Ccl-2 and Ccl-5 and/or TNF-α and IL-1β, promotes breast cancer 
formation and relapse (Soria et al., 2011).  No literature was found directly 
investigating the role of vitamin D on Ccl-5 in breast cancer.  Although one recent 
study examined the role of vitamin D on Ccl-5 and showed that vitamin D 
increased Ccl-5 expression and optimized innate immune function in non-
diseased cattle (Nelson et al., 2010).  Another study looked at vitamin D 
treatment on EAE mice and found it caused increased Ccl-5 as well as a variety 
of other inflammatory factors (Subramanian et al., 2012).  Although these two 
studies showed vitamin D to increase Ccl-5, this vitamin D-induced Ccl-5 
increase appeared to normalize immunofunctionality in both (Nelson et al., 2010; 
Subramanian et al., 2012).  Therefore, vitamin D may act on Ccl-5 in breast 
cancer and have an immunoregulatory role that inhibits the tumor cells from 







1.4.4. Metastatic Perturbation in Bone 
 Metastatic perturbation, or continued growth and disruption of normal 
tissue, begins after the new tumor has formed and encompasses new site 
proliferation as well as immunofunction.  Secondary tumor site cancer cell 
proliferation requires angiogenesis for nutrient and energy delivery.  In normal 
tissues, interluken-11 (IL-11) provides proliferation assistance of megakaryocyte 
progenitor cells and hematopoietic stem cells as well as stimulation of T-cell 
development.  In bone metastases, bone is resorbed to create space for the 
growing tumor.  As osteoclasts break down the bone, osteocytes release immune 
mediator signals, which may play a role in tumor metastasis immunofunction.  A 
foundational study by Hunt et al. (2001) established IL-11 as a mediator of 
osteoclastogenesis and osteolytic bone metastasis, allowing for further bone 
resorption, therefore promoting bone tumor growth and proliferation (Hunt et al., 
2001).  IL-11 can lead to stimulation of RANKL, therefore perturbing osteoclast 
synthesis and promoting continued bone degradation for tumor growth (Ren et al., 
2013).  A recent study showed that high IL-11 levels were associated with 
number of metastases, increased tumor size, age, and pain score in breast 
cancer patients (Ren et al., 2013).  Additionally, patient survival rates were 
significantly lower in patients with increased IL-11 levels (Ren et al., 2013).  
While IL-11 has long been identified as an assistant in new tumor site 
proliferation, no literature exists on its interaction with 1,25(OH)2D.  1,25(OH)2D 




synthesizers/degraders, RANKL, and IL-11, need to be investigated in the 
context of breast cancer metastasis to bone. 
 Endothelin-1 (EDN-1) plays a dual role as a vasoconstrictor and an 
affecter of the central nervous system and is additionally one of the only 
identified factors that may be involved in local immune function within breast to 
bone metastasis.  Immunofunction occurs as the new bone metastases progress 
and begin to secrete their own immune responses and/or modulate those of the 
hosts immune system.  Specifically in breast cancer, EDN-1 has a role in 
macrophage and lymphocyte infiltration therefore supporting the 
immunofunctional actions of the new tumors (Jewell et al., 2010).  EDN-1 is also 
involved in earlier stages of metastatic growth but in the inflammatory processes 
of those tumors.  Tumor mass, bone metastases, immune cell infiltration, and 
tumor mass leukocytes were significantly decreased when EDN-1 inhibitors were 
given to mice with stage 4 (advanced/metastatic) breast cancer (Jewell et al., 
2010).  This finding suggests there is communication between the hosts immune 
system and tumor cell microenvironment which dictates tumor growth in bone 
(Jewell et al., 2010).  Currently, there is no data on 1,25(OH)2D regulation of 
EDN-1 in breast cancer metastasis.   
 
1.4.5. Chemoresistance to Vitamin D in Breast Cancer 
 VDR is expressed in normal mammary epithelium both in cells and in 
tissues (Lopes et al., 2010).  A paradox occurs when considering breast cancer 




conversely, as breast cancer aggressiveness increases, 1,25(OH)2D signaling 
decreases.  This paradox is characterized by three main players: varied VDR 
expression, loss of CYP27B1 expression (codes for 1α-hydroxylase), and over-
expression of CYP24A1 (codes for 24-hydroxylase). 
 
1.4.5.1. Variation of VDR 
 Multiple studies have shown that as cancer progression continues, 
1,25(OH)2D signaling is attenuated (Lopes et al., 2010, 2012; Matilainen et al., 
2010; Yagmurdur et al., 2009).  This may be due to the trend of decreasing VDR 
in breast tumors compared to normal tissue.  In vitro, ex vivo, and in vivo studies 
have all shown a decrease in VDR expression in breast cancer compared to their 
normal counter parts (Banwell et al., 2006; Escaleira and Brentani, 1999; Lopes 
et al., 2010). Similarly, our own laboratory showed that C3H10T1/2 mouse 
fibroblast cells transfected with H-ras had reduced VDRE transcriptional activity 
compared to the untransfected cells, suggesting 1,25(OH)2D signaling through 
the VDR is disrupted in some cancers (Stedman et al., 2003). 
 Furthermore, over 470 single-nucleotide polymorphisms (SNPs) of VDR 
exist (McCullough et al., 2009).  Prior studies suggest a link between breast 
cancer incidence and VDR polymorphisms but results are mixed (Huang, 2014).  
A recent meta-analysis examining the Fok1, Bsm1, Taq1, Apa1, Cdx2, and 
PolyA VDR polymorphisms concluded their link to breast cancer risk, if any, is 
small (Huang et al., 2014).  Specifically, the Fok1, Apa1, Cdx2, and Poly-A 




Taq1 may play a role but many additional studies are needed before that link is 
confirmed (Huang et al., 2014).   
 
1.4.5.2. Loss of CYP27B1 Activation 
 The CYP27B1 gene codes for 1α-hydroxylase, the enzyme which 
produces 1,25(OH)2D.  As mentioned in sections 1.1.1.1. and 1.1.1.3., 1α-
hydroylase is commonly found in the kidney as well as multiple extra-renal 
tissues including the breast (Friedrich et al., 2006; Townsend et al., 2005).  A 
study by Kemmis and Welsh showed a greater than 70% reduction in CYP27B1 
mRNA and protein abundance upon SV40 T-antigens and H-rasV12 oncogene 
transfection in human mammary epithelial cell lines (Kemmis and Welsh, 2008).  
Further, a study comparing MCF-10 breast epithelial cells to MCF-7 breast 
cancer cells showed the MCF-7 cells produced CYP27B1 splice variants which 
create non-functional 1α-hydroxylases (Fischer et al., 2007).  While there is 
evidence for reduced activation of CYP27B1 in breast cancer tissues, these 
studies remain controversial as other studies show opposing results (de Lyra et 
al., 2006; Townsend et al., 2005).  
 
1.4.5.3. Overexpression of CYP24A1 Activation 
 The CYP24A1 gene codes for 24-hydroxylase, the enzyme that gives rise 
to 1,24,25-trihydroxvitamin D and leads to its degradation.  Multiple studies show 
this enzyme is significantly increased in breast cancer tissues compared to 




(Albertson et al., 2000; Fischer et al., 2009; Lopes et al., 2010; Matilainen et al., 
2010; Townsend et al., 2005).  Therefore, even if VDR and 1α-hydroxylase are 
present and active, the predominate role of 24-hydroxlyase will target 
1,25(OH)2D for degradation, indicating a dysregulation in signaling in breast 
cancer even if only one of the three proteins are under-/over-expressed.  
However, together with the potential decrease in VDR and CYP27B1, these 
findings give even further evidence for attenuated 1,25(OH)2D signaling in some 
breast cancers. Thus, alternative treatments, such as vitamin D analogs, may 
preferably help control breast cancer progression (Chiang et al., 2014; El 
Abdaimi et al., 2000; Filip et al., 2010; O’Kelly et al., 2006; So et al., 2013; 
Valrance and Welsh, 2004). 
 
1.4.6. Vitamin D Analogs for Breast Cancer 
 Vitamin D analogs are proposed to have similar anti-cancer effects to 
1,25(OH)2D without the side effects of disturbing calcium metabolism at high 
doses.  Another issue occurs if patients are not given bisphosphonates, a 
common treatment for patients with metastatic breast cancer, but are given high 
1,25(OH)2D doses, which can cause toxic hyper- or hypo-calcemia (Amir et al., 
2010; Simmons et al., 2009).  Thus, vitamin D analogs attempt to combat the 
negative side effects of both long term bisphosphonate use as well as 
1,25(OH)2D-induced calcium metabolism imbalance. 
 One vitamin D analog that has been of interest for many years, EB1089, 




EB1089 study showed several positive effects when injected in nude mice 
xenografted with MDA-MD-231 breast cancer (El Abdaimi et al., 2000).  Injected 
mice had decreased osteolytic bone metastases and bone tumor burden, as 
seen by histomorphometric exams, as well as increased survival rates, showing 
that the vitamin D analog can exert anti-cancer effects (El Abdaimi et al., 2000).  
Interestingly, the EB1089 injections did not induce the classic vitamin D response 
of increased apoptosis in cancer but this did not alter survival rate of the mice (El 
Abdaimi et al., 2000).  Normo-calcemia remained for injected mice, giving hope 
for EB1089 as an anti-cancer agent with little or no side effects (El Abdaimi et al., 
2000). 
 PRI-2208 and PRI-2209, two well researched vitamin D analogs, have 
been tested in both in vitro and in vivo breast cancer models.  Inhibition of cell 
proliferation and decreased tumor growth occurred with both PRI-2208 and PRI-
2209 separately in treated MCF-7 breast cancer cells (Filip et al., 2010).  Tumor 
growth inhibition occurred only with the PRI-2208 analog but both analogs 
caused a decrease in lung metastases number when tested in female C57B1/6 
mice injected with mouse Lewis Lung Carcinoma (LLC) (Filip et al., 2010).  
Additionally, both PRI-2208 and PRI-2209 treatment did not alter serum calcium 
levels (Filip et al., 2010).  Both PRI-2208 and PRI-2209 analogs show promise to 
slow or treat cancer with few calcemic side effects but will require more studies to 
determine their impact.  The future for vitamin D analogs is bright but much 




1.5. Lipid Metabolism 
 Lipids are one of three macronutrients along with proteins and 
carbohydrates.  Lipids include glycerides, phospholipids, sterols, waxes, and fat-
soluble vitamins.  While each class has individual functions, the common 
biological function is to provide cell structure, signaling, and store and synthesize 
energy (Subramaniam et al., 2011).  Additionally, lipids play a role in multiple 
human disease states such as obesity, cardiovascular diseases, diabetes, and 
cancer.  Humans use various anabolic and catabolic pathways to synthesize and 
break down lipids as the bodies needs alter but how this is accomplished varies 
on the chemical structure of each lipid. 
 
1.5.1. Functions of Specific Lipid Classes 
 The commonalities between all classes includes their hydrophobicity and 
are generally mostly hydrocarbons.  However, each lipid class has a different 
structure and thus performs varying functions within the realm of energy 
metabolism.   
 
1.5.1.1. Fatty Acids 
  Fatty acids contain long hydrocarbon chains with a carboxylic acid 




In order to make a lipid, these fatty acid chains link with a backbone structure 
such as glycerol, creating a mono-, di-, or tri-acylglyercol.  The amount of 
hydrogens connected to the long carbon tails determines if each fatty acid is 
saturated or unsaturated.  Saturated fatty acids maintain a relatively linear 
structure, and contain all single bonds where as unsaturated fatty acids are bent 
due to the cis- or trans- double bond at the sight of unsaturation.  
 The balance between synthesis and degradation of triacylglycerols and 
fatty acids is determined by a number of factors.  In a normal healthy human 
being, this balance is predominately determined by energy need; where 
degradation occurs when energy is needed, most often during starvation or 
exercise; and synthesis typically occurs in excess energy states or altered tissue 
status such as cancer, diabetes, or genetic disorders of lipid metabolizing 
proteins(Campbell and Reece, 2008). Lipogenic pathways include fatty acid 
synthesis, cholesterogenesis, sphingomyelin and phospholipid synthesis, among 
others.   
 Fatty acid synthesis and degradation are similar processes in reverse.  
Fatty acid synthesis begins with an activated acyl group and an activated malonyl 
group, which undergo a condensation reaction to form a four-carbon fragment.  
This four-carbon fragment is then reduced, dehydrated, and reduced again to 
produce a hydrocarbon chain with the final product being butyryl CoA.  
Elongation continues by adding (through condensation reactions) activated 
malonyl coA groups until palmitate (a 16-carbon fatty acid) is synthesized (Berg 




can occur through special enzymes located on the cytoplasmic face of the 
endoplasmic reticulum.  Conversely, fatty acid degradation is the reverse of the 
synthetic process.  An activated fatty acid (with an activated acyl group) is 
oxidized to form a double bond which is next hydrated to become a hydroxyl.  
The hydroxyl is once again oxidized but into a ketone, which is cleaved by 
coenzyme A to produce acetyl coA and a fatty acid with two less carbons (Berg 
et al., 2007).  Degradation continues until the original fatty acid is completely 
converted to all acetyl CoA units. 
 The process of β-oxidation leads to the degradation of the activated fatty 
acids for energy in a stepwise fashion.  Before fatty acids can be oxidized for 
energy, they must be linked to coenzyme A via thioester bonding.  This bonding 
occurs on the outer mitochondrial membrane, activating the fatty acid.  Upon 
activation, the fatty acids translocate across the inner mitochondrial membrane 
by conjugating with carnitine.  The acyl group from coenzyme A transfers to the 
hydroxyl group on carnitine to form acyl-carnitine, which is catalyzed by carnitine 
palmitoyl transferase 1 (CPT1) on the outer membrane.  Once conjugated, the 
acyl-carnitine carries the fatty acid across the inner mitochondrial membrane into 
the mitochondrial matrix via translocase (Berg et al., 2007).  On the matrix side, 
the acyl group is transferred back to coenzyme A by CPT2.  The fatty acid can 
next begin degradation in the mitochondrial matrix through a serious of four 
repeating reactions: oxidation of the β-carbon, hydration, oxidation, and thiolysis.  
As a result, the fatty acid is shortened by two carbons and flavin adenine 




(NADH), and acetyl CoA are synthesized. This sequence of reactions repeats 
until the fatty acid is completely broken down into acetyl CoA and energy 
metabolites (Campbell and Reece, 2008).  For example, complete β-oxidation of 
16-carbon palmitoyl CoA becomes eight acetyl CoA molecules, seven FADH2, 
seven NADH, and 7 hydrogen ions.  The NADH molecules enter complex 1 of 
the electron transport chain, known as NADH dehydrogenase, which oxidizes 
NADH to NAD and pumps the hydrogen molecule into the intermembrane space 
of the mitochondria.  Similarly, FADH2 molecules enter complex 2, known as 
succinate dehydrogenase, and is oxidized to FAD.  The two removed hydrogen's 
are shuttled to complex 3, cytochrome b, where one is pumped into the 
intermembrane space.  The last hydrogen is pumped through the fourth and final 
complex, creating a proton gradient.  This gradient causes the hydrogen's to 
translocate through the ATP-synthase protein, which powers the synthase to 
convert ADP + inorganic phosphate to ATP. In the palmitate example, complete 
oxidation of this molecule would result in 106 ATP molecules (Campbell and 
Reece, 2008).  Unsaturated and odd-chain fatty acids require additional steps 
beyond typical β-oxidation to complete degradation.   
 Unsaturated odd-numbered carbon fatty acids are degraded using just the 
isomerase enzymes, converting the double bonds again to the trans-Δ2-double 
bond (Berg et al., 2007).  Additionally, saturated odd-number carbon fatty acids 
have a altered degredation.  Rather than the two acetyl CoA molecules being 
produced in typical β-oxidation, odd-number fatty acids produce one acetyl CoA 




conversion into succinyl CoA via a carboxylase enzyme (Berg et al., 2007).  Odd-
chain and unsaturated fatty acids require additional steps to the traditional β-
oxidation pathway but ultimately produce ATP as well. 
 As with proteins, lipid structure determines their function.  Fatty acids and 
the fats they create (triglycerides, etc) are mainly for energy storage in the form 
of lipid droplets in adipose tissue.  Fat storage is not just for energy but it also 
allows for insulation, cushioning of organs, and protection.  Non-stored fatty acids 
are used as building blocks for glycolipids and phospholipids, which are vital 
components to cell membrane structure (Campbell and Reece, 2008).   
 Cells other than just adipocytes contain lipid droplets that often serve as 
an individual energy reserve.  Cells can utilize their lipid droplet for energy 
production, signaling, or membrane alterations and synthesis (Zechner et al., 
2009).  The ability to mobilize tri-, di-, and mono-glycerides from the lipid droplet 
depends on lipases and lipid droplet surface proteins such as perilipin 2 (PLIN2), 
adipose triglyceride lipase (ATGL), and hormone sensitive lipase (HSL), which 
will be discussed in detail in a later section 1.5.2.3..   
 
1.5.1.2. Cholesterol  
 Cholesterol is part of a larger lipid family known as the sterols.  
Cholesterol has a tetra-cyclic ring structure with an iso-octyl side chain attached 
at carbon 17 (Ikonen, 2008).  Cholesterol has a multitude of functions including 
cell membrane structure, hormone and bile acid precursor, signal transduction, 




In humans, the brain has the highest cholesterol content over any other organ 
(Ikonen, 2008).  The main function of cholesterol is to alter cell membrane fluidity 
by interacting with membrane phospholipids (Ohvo-Rekilä et al., 2002).  Similarly, 
it assists in membrane organization by regulating membrane proteins and lipid 
rafts (Maxfield and van Meer, 2010).   
 De novo cholesterol synthesis is a 26 step process but can be broken 
down into three main steps.  Step one, in the cytoplasm, is formation of 
isopentenyl pyrophosphate from acetyl CoA, this molecule is an active isoprene 
unit and is the core building block of cholesterol. Within the first step, acetoacetyl 
CoA is reduced to mevalonate via HMG-CoA reductase, synthesis of mevalonate 
is the rate-limiting step in cholesterol synthesis.  Step two condenses six 
isopentenyl pyrophosphate molecules into squalene in the endoplasmic reticulum.  
The last step, three, is cycling squalene until its tetracylic product is converted 
into cholesterol, which also takes place in the endoplasmic reticulum.  
Cholesterol can either stay in its natural form or go on to become a steroid 
hormone, bile acid, or fat soluble vitamins (A, D, E, and K) (Berg et al., 2007).  
Cholesterols are stored in an esterified form which is synthesized via acyl-CoA 
cholesterol acyltransferase 1 (ACAT1), the cholesterol ester is stored within the 
intracellular lipid droplet where it can be released and utilized if needed.  
Cholesterol esters are not part of cell membranes, rather they are packed into 
intracellular lipid droplets which are released when needed for membranes, 




Cholesterol is not degraded for energy but can be excreted in the feces through 
bile acid (Campbell and Reece, 2008). 
 Regulation of cholesterol synthesis occurs via four main pathways, all of 
which involve controlling HMG CoA reductase (Berg et al., 2007).  First, 
phosphorylation of the enzyme decreases its activity which occurs when there 
are low levels of ATP.  Second, translation of the enzyme mRNA can be inhibited 
by non-sterol metabolites derived from mevalonate or high dietary cholesterol.  
Third, the enzyme can be degraded through ubiquitination or proteolysis.  Fourth, 
the rate of the enzymes mRNA transcription can be altered.  This alteration is 
controlled by the sterol regulatory element binding protein (SREBP), which 
associates on the endoplasmic reticulum when inactive and is associated with 
SREBP-cleavage activating protein (SCAP), a cholesterol sensor molecule (Berg 
et al., 2007).  Additionally, insulin inducing gene 2 (Insig2) associates with 
SREBP and binds to SCAP and anchors the complex onto the endoplasmic 
reticulum (Stipanuk, 2006).  When cholesterol levels are low, SCAP guides 
SREBP to the Golgi apparatus utilizing the help of Cop-II proteins.  Within the 
Golgi, SREBP is cleaved by a MMP and serine protease.  The released DNA-
binding domain (N-terminus) translocates into the nucleus and binds to the sterol 
regulator element (SRE) of the HMG-CoA reductase gene and several other 
cholesterol synthetic genes, and enhances their transcription.  Conversely, when 
cholesterol levels are high, the release of SREBP from the endoplasmic 
reticulum is inhibited and the cleaved DNA-binding domain of SREBP in the 





 Another abundant lipid class is phospholipids.  Their structure resembles 
fatty acids in that two long fatty acid tails connected to a glycerol backbone.  A 
negatively charged phosphate group attaches to the third glycerol hydroxyl group.  
Alterations in the types of phospholipids come from differing chain length of the 
fatty acids attached, saturation of the fatty acid, and the molecules that may be 
linked to the phosphate group (such as choline or serine) (Campbell and Reece, 
2008).   
 Synthesis of phospholipids begins with production of phosphatidate, also 
known as diacylglycerol 3-phosphate (Figure 2).  Synthesis of phosphatidate 
occurs in the endoplasmic reticulum and the outer mictochondrial membrane and 
is formed mainly by reduction of dihydroxyacetone phosphate or through glycerol 
phosphorylation.  Adding two fatty acids to the reduced dihydroxyacetone 
phosphate/phosphorylated glycerol next creates phosphatidate.  However, 
addition of only one chain yields a lysophosphatidate (Berg et al., 2007).  Next, 
either an activated diacylglycerol or an activated alcohol combine to form their 
characteristic lipid. For example, ethanolamine can be phosphorylated to create 
active phosphorylethanolamine which is further altered into 
phosphatidylethanolamine (PE).  Additionally, the phospholipids can interchange 
their functional groups to become phosphatidylcholines (PCs), 
phosphatidylserines (PSs), and phosphatidylinositols(PIs).   
 Phospholipids are known for their amphipathic character via their 




for cell membranes.  In water, phospholipids self-assemble into bilayers to shield 
their hydrophobic tails, thus creating a boundary between the cellular cytosol and 
the external environment.  This lipid bilayer is necessary for the structure of all 
cells as it as it is a barrier with selective permeability (Campbell and Reece, 
2008).  Cell membrane permeability can be altered a number of ways, one being 
the phospholipid composition.  If all the fatty acids in the phospholipid bilayer are 
saturated, no kinks or gaps in the bilayer will occur.  If there are unsaturated fatty 
acids, the bilayer will have altered fluidity, permeability, and morphology.  
Therefore, phospholipid content in the cell membrane lipid bilayer may determine 
cell fate as it can alter the ability for foreign substances to enter, signaling 
capacity, as well as morphology of the cell (Campbell and Reece, 2008). 
 Functions of phospholipids span beyond lipid bilayers and into signal 
transduction, typically as intracellular second messengers.  The most common 
example is that of the G-protein coupled receptor response by phophatidylinositol 
(4,5)-bisphosphonate, which is split into two intra-cellular messengers: inositol-
1,4,5-triphophosphate and diacylglycerol by phospholipase C (Campbell and 
Reece, 2008).  These second messengers act on multiple physiological 
pathways such as calcium release for muscle contraction and activation of 
protein kinase C which leads to changes in chemotaxis, opioid sensitivity, cell 
proliferation, and cell survival  
(Jiang et al., 1997; Lyon and Tesmer, 2013; Mathews et al., 2008; Newton, 2010; 
Penniston et al., 2014; Woodcock et al., 2009).  PI's, are most often signaling 




Additionally, PI's can alter cell motility, invasiveness, proliferation, and actin 
cytoskeleton (Corda et al., 2012).  PS's are mostly found in brain tissue myelin 
and parts of the cell membrane.  PS's are also involved in blood coagulation, 
apoptosis regulation, bone formation, and neuron survival (Lentz, 2003; Leventis 
and Grinstein, 2010).  PC's are the most abundant phospholipids in plants and 
animals and are the largest constituent of the cell lipid bilayer.  Furthermore, PC's 
are a component of lipoproteins, thus they are the most abundant phospholipid in 
the circulating plasma (Cole et al., 2012).  PC is also thought to be involved in 
minor signaling pathways in the nucleus and comprises part of human lung 
surfactant (Goss et al., 2013).  Lastly, PE's are the third most abundant 
phospholipid in plants and animals, accumulating particularly in the liver, brain, 
and mitochondria, thus playing a large role in cell membrane composition (Vance 
and Tasseva, 2013).  Specifically, PE is thought to have a major role in inhibiting 
negative amino acids from entering the cytoplasm, thus maintaining the positively 
charged intracellular space.   
 
1.5.1.4. Sphingolipids and Ceramides 
 A second subclass of phospholipids are sphingolipids, which are 
structurally similar to phospholipids but in lieu of a glycerol backbone, 
sphingosine is used.  Additionally, the sphingosine molecule itself contains a long 
hydrocarbon chain with a terminal amino group.  A fatty acid is next linked to the 




and Reece, 2008).  The sphingolipid group includes ceramides and 
sphingomyelins among other highly complex lipid moitites. 
 Sphingolipids are formed through the condensation of palmitoyl CoA and 
serine to form 3-ketosphinganine.  This product is then further reduced to 
dihydrosphingosine, followed by conversion into ceramide (Berg et al., 2007).  
Ceramides consist of a sphingosine backbone with its' amino group attached to a 
fatty acid.  The terminal hydroxyl group of the sphingosine is also adjustable 
depending on its location and function.  An example of this is in nerve fibers 
where the sphingosine has a PC attached to comprise part of the myelin sheath 
around the nerve axon (Stipanuk, 2006). 
 Ceramides often have a sphingoid base linked to a fatty acid and are only 
found in trace levels, as they are mainly an intermediate of complex sphingolipid 
metabolism.  As the central molecule in sphingolipid metabolism, ceramides can 
be synthesized through multiple pathways but is most often synthesized from 
palmitoyl CoA and serine de novo (Saddoughi et al., 2008).  Ceramides are 
frequently found as part of lipid rafts in the cell membrane but their highest 
accumulation occurs in the outer-most epidermis layer (skin) and function in 
conjunction with cholesterol and free fatty acids to form a protective barrier 
(Bouwstra and Ponec, 2006).  Additionally, ceramides are second messengers in 
signal transduction during stressful situations (Stancevic and Kolesnick, 2010).  
Ceramides are particularly important in apoptosis initiation but the exact 




 Sphingomyelins are compromised of a ceramide with a PC side chain.  
Sphingomyelins are the second most abundant phospholipid, just below the 
abundance of PC's, with the greatest amount found in the cell membrane (Slotte, 
2013).  Furthermore, they serve as a part of the sphingomyelin cycle which 
serves to synthesize a multitude of ceramide and sphingolipid derivatives, some 
of which function as intracellular messengers as well as cell membrane 
constructs (Merrill, 2011).  Lastly, sphingomyelins may have a role in iron 








































1.5.2. Lipid Pathways in Breast Cancer 
 It is well established that cancer cells undergo a switch to a greater rate of 
glycolysis, labeled the Warburg effect, thus it is possible that alterations in lipid 
metabolism occur as well.  In fact, a lipogenic phenotype is associated with 
cancer progression and is thought to provide survival and growth advantages 
(Louie et al., 2013; Swinnen et al., 2006).  Changes in several lipid classes and 
moitites such as cholesterol (Moon et al., 2014), ceramides (Saddoughi et al., 
2008), PIs (Altomare et al., 2004; Yan et al., 2009), and sphingosin-1-phosphate 
(Van Brocklyn et al., 2002) have been linked to various cancers. These lipid 
alterations, particularly that of the cell membrane, can lead to changes in 
membrane fluidity, ligand-receptor interactions, endocytosis, antigen presentation, 
lipid-lipid/lipid-protein interactions, and micro-domain formation (Escribá et al., 
2008).  Lastly, lipids also act as second messengers which control cell 
proliferation, apoptosis, division, and inflammation among other roles (Emoto and 
Umeda, 2000).  Therefore, the lipogenic phenotype of cancer suggests these 
pathways are altered, possibly promoting cancer progression. 
 
1.5.2.1. Fatty Acids in Breast Cancer 
 Several studies have shown that malignant cells utilize free fatty acids at a 
greater rate than non-malignant cells, which are usually esterified to glycerol 
backbones in lipid droplets (Prentki and Madiraju, 2008).  It is hypothesized that 
these fatty acids are employed as energy sources via β-oxidation, or as 




well established that breast cancers have increased fatty acid levels, a debate 
remains whether that increase is due to increased exogenous uptake or 
endogenous synthesis.  While there is evidence to support both sides of the 
argument, the fact remains that increased fatty acids in breast cancer are 
associated with a variety of pro-breast cancer effects such as decreased survival 
(Liu et al., 2011), increased proliferation (Louie et al., 2013; Rysman et al., 2010), 
increased migration (Antalis et al., 2010), metastasis (Vazquez-Martin et al., 
2008) and more.  Additionally, β-oxidation may be altered as studies show an 
increase in carnitine palmitoyltransferase 1a (CPT1a) in breast cancer, 
suggesting an increase in mitrochondrial fatty acid update for β-oxidation, thus 
energy production (Sanchez-Alvarez et al., 2013; Shen et al., 2013). 
 
1.5.2.1.1. Fatty Acid Synthase 
 Fatty acid synthase (FAS) is the second and final committed step in fatty 
acid synthesis.  The FAS enzyme catalyzes nearly 40 reactions within separate 
domains of its active homodimer structure.  Thus, it is an efficient process rather 
than having different enzymes for each intermediate and also allows for greater 
control of fatty acid synthesis via regulating the FAS enzyme (Stipanuk, 2006).  
FAS activity is high in the fed state and low in the fasted state with transcriptional 
regulation as well as protein expression levels (Stipanuk, 2006).  It is the only 
human protein that can perform intracellular reductive de novo synthesis of long 
chain fatty acids, thus it is major target for control of lipid synthesis (Notarnicola 




 It is well established that FAS is up regulated in many cancers, including 
breast cancer (Antalis et al., 2011; Currie et al., 2013; Menendez and Lupu, 2007; 
Menendez et al., 2004; Qiao et al., 2003; Vazquez-Martin et al., 2008; Wang et 
al., 2012; Yang et al., 2003).  Further, an association between up regulated FAS 
and increased fatty acid levels in breast cancer has been established (Menendez 
and Lupu, 2007).  Breast tumor associated FAS up regulation possibly follows 
two paths: Ras activation and/or PI3K activation.  MCF10A human breast cells 
transformed with H-ras oncogene had increased FAS due to up regulation of 
MAPK and PI3K signaling as determined through inhibitor studies (Yang et al., 
2003).  MAPK/PI3K up regulation is induced by multiple cell surface receptors 
such as receptor tyrosine kinase, epidermal growth factor receptor, and HER2, 
which eventually causes increased FAS transcription.  It has been further 
suggested that the increased FAS may act on cell surface HER2 as positive 
feedback, therefore maintaining the high levels of FAS and thus fatty acids in the 
cancer cells (Vazquez-Martin et al., 2008).  Since increased FAS in breast 
cancer is associated with poor prognosis, it is an appealing target for therapeutic 
intervention (Puig et al., 2009).  Inhibition of FAS has been shown to cause 
multiple cell-death inducing effects such as inhibition of pro-apoptotic proteins 
(Menendez et al., 2005a, 2005b), inhibition of DNA replication (Liu et al., 2002; 
Pizer et al., 1998), disturbance of membrane function (Menendez et al., 2005b; 
Nagy et al., 2002), end-product starvation, malonyl-CoA toxicity (Pizer et al., 
2000; Thupari et al., 2001), and p53 regulated metabolic stress (Menendez and 




target for breast cancer treatment, animal models treated with FAS inhibitors had 
adverse side effects, therefore more research is needed prior to clinical 
application (Loftus, 2000)(Loftus et al., 2000).  
 
1.5.2.1.2. Vitamin D and FAS 
 While there are no studies exploring 1,25(OH)2D's regulation of FAS 
expression in breast cancer, there are a few studies in prostate cancer.  FAS was 
significantly decreased in a cDNA microarray in LNCaP prostate cancer cells 
when treated with 10 nM of 1,25(OH)2D for 24 hours (Qiao et al., 2003).  This 
observation was as there was a significant decrease in FAS mRNA abundance at 
6, 24, and 48 hours of 1,25(OH)2D treatment (Qiao et al., 2003).  Further 
investigation by this laboratory group determined a potential mechanism of action 
of 1,25(OH)2D regulation of FAS.  They propose 1,25(OH)2D increases the 
expression of fatty-acid-CoA ligase 3 (FACL3), leading to an increase in long 
chain fatty acyl-coAs, which are natural inhibitors of FAS, thus decreasing the 
enzymes' expression (Qiao and Tuohimaa, 2004).  A similar mechanism may 
occur in breast cancer cells, but this remains to be elucidated. 
   
1.5.2.1.3. Stearoyl-CoA Desaturase 1 
 Stearyol-CoA Desaturase 1 (SCD1) converts saturated fatty acids into 
unsaturated fatty acids and is anchored to the endoplasmic reticulum (Enoch et 
al., 1976).  SCD1 is up regulated by the PI3K/mTOR pathway, insulin, and 




SCD1 plays a role in balancing the ratio of unsaturated verse saturated fatty 
acids that are attached to phospholipids.  Thus, modification of SCD1 may lead 
to alterations in membrane fluidity and therefore cell survival and proliferation 
(Mauvoisin et al., 2013). 
 Increased SCD1 activity is associated with increased breast cancer risk as 
well as multiple other cancers (Holder et al., 2013).  Additionally, the balance 
between unsaturated and saturated fatty acids, often controlled by SCD1, was 
said to predict breast cancer incidence in preliminary epidemiological studies 
(Chajès et al., 1999, 2008).  Specific mono-unsaturated and saturated fatty acid 
chains on PCs were found to be significantly higher in breast tumor biopsy 
samples compared to normal tissue and correlated with increased SCD1 
expression, suggesting high SCD1 may be the culprit for synthesizing the 
tumorigenic lipid classes (Ide et al., 2013).  Further, inhibition of SCD1 caused a 
decrease in proliferation and survival of breast cancer cells (Morgan-Lappe et al., 
2007; Scaglia et al., 2009).  In relation to EMT, decreased SCD1 expression is 
thought to be involved in maintaining the epithelial phenotype of primary breast 
cancer cells, thus inhibiting EMT (Mauvoisin et al., 2013).  Lastly, patients with 
ER+ and/or PR+ and/or HER2+ breast cancer have the highest SCD1 expression 
compared to triple negative tumors, and also have a significantly shorter relapse-
free time and overall survival, though the exact mechanism is currently under 
investigation (Holder et al., 2013). There no studies examining the role of 





1.5.2.1.4. Carnitine Palmitoyl Transferase 1a 
 As referenced in the lipid metabolism section, CPT1a controls the 
entrance of long-chain fatty acids into the mitochondrial inner membrane space 
where they undergo β-oxidation.  CPT1a is indirectly regulated by the adenosine 
monophosphate-activated protein kinase (AMPK).  AMPK phosphorylation 
inhibits upstream lipogenic enzymes such as acetyl-coA carboxylase (ACC), 
which causes a decrease in malonyl CoA levels, thus decreasing fatty acid 
synthesis.  Malonyl CoA is an inhibitor of CPT1a, thus when it is decreased, 
CPT1a is activated and begins transferring fatty acids for β-oxidation.   
 CPT1a mRNA abundance is increased in MCF-7 and MDA-MB-231 breast 
cancer cells compared to 184B5 normal breast cells (Linher-Melville et al., 2011).  
Immunohistochemistry of breast invasive ductal carcinomas (IDCs) showed 
specific nuclear localization of the CPT1a protein compared to normal breast 
tissue (Mazzarelli et al., 2007).  Additionally, histone deacetylase (HDAC) activity 
was significantly higher in the MCF-7 cells compared to the MCF-12F.  Therefore, 
the authors tested HDAC and CPT1a with their results suggesting CPT1a could 
function as a recruiter for HDAC proteins in order to silence regulatory genes in 
cancer (Mazzarelli et al., 2007).   There no studies examining the role of 








1.5.2.2. Cholesterol in Breast Cancer 
 Further, the cholesterol pathway is altered in breast cancer.  Statin 
treatment, which inhibits endogenous cholesterol synthesis, in breast cancer 
cells caused cell cycle arrest, suggesting cholesterol is a required component of 
cancer cell replication (Gray-Bablin et al., 1997; Rao et al., 1998).  There is a 
trend of altered lipoprotein profiles in breast cancer patients, with those in 
advanced stages showing low cholesterol levels, a documented phenomenon in 
these patients (Furberg et al., 2004; Kritchevsky and Kritchevsky, 1992; 
Potischman et al., 1991).  It is hypothesized that cancer cells have an increased 
demand for cholesterol as it is necessary for membrane formation, signaling, and 
lipid rafts, thus the low cholesterol levels seen in advanced patients are due to 
the cancer, not a cause of cancer (Danilo et al., 2013).  Cholesterol accumulation 
may be associated with an estrogen receptor status as in vitro models have 
shown increased proliferation in ER- breast cancer cell lines compared to the 
ER+ lines (Antalis et al., 2010).   
 An increased estrogen status is associated with increased breast cancer 
risk, it is possible that cholesterol exerts some of its effects indirectly through its' 
precursor, estrogen, which is an activator of pathways such as ERK1/2 (Yager 
and Davidson, 2006).  Additionally, cholesterol can travel through the blood 
within lipoproteins, which have been shown to induce proliferation, migration, and 
signaling pathways that promote breast cancer such as Ras (Grewal et al., 2003) 




major part of lipid rafts which are known to assist in regulating cell apoptosis, 
invasion, and migration (Danilo et al., 2013; George and Wu, 2012; Murai, 2012). 
 
1.5.2.2.1. Insulin Inducing Gene 2 
 Insig2, discovered in 2002, is associated with the endoplasmic reticulum 
membrane and assists in controlling cholesterogenesis from a transcriptional 
level (Yabe et al., 2002).  Insig2 associates with SREBP and binds to SCAP and 
anchors the complex onto the endoplasmic reticulum (Stipanuk, 2006).  When 
cholesterol levels are low, SCAP guides SREBP to the Golgi apparatus utilizing 
the help of Cop-II proteins.  Within the Golgi, SREBP is cleaved by an MMP and 
serine protease.  The released DNA-binding domain (N-terminus) translocates to 
the nucleus and binds to the SRE of the HMG-CoA reductase gene and several 
other cholesterol synthetic genes, and enhances their transcription.  Conversely, 
when cholesterol levels are high, the release of SREBP from the endoplasmic 
reticulum is inhibited by Insig2 and the cleaved DNA-binding domain of SREBP 
in the nucleus degrades, thus inhibiting further synthesis.  Expression of Insig2 is 
at a low but constant level and does not depend on SREBPs, but does require 
the presence of sterols (Goldstein et al., 2006; Yabe et al., 2002).  
 While no studies currently exist examining the expression or role of Insig2 
in breast cancer, there are some studies in pancreatic and colon cancer.   Insig2 
has been identified as a negative prognostic marker for colon cancer based on  
in vitro studies (Li et al., 2008).  The results of the suggest found that increased 




growth, and apoptosis inhibition (Li et al., 2008).  Similarly, Insig2 expression is 
also increased in pancreatic cancer cell lines, especially in hypoxic states 
(Kayashima et al., 2011).  Pancreatic cancer cells with Insig2 knockdown 
resulted in a significant decrease of proliferation and invasion, suggesting Insig2 
has a role in these processes (Kayashima et al., 2011).  While the trend appears 
to be increased Insig2 expression is linked to cancer progression, its role within 
breast cancer remains to be determined.  The only known link between 
1,25(OH)2D and Insig2 is the discovery of a VDRE in the promoter region of the 
Insig2 gene in pre-adipocyte cells (Lee et al., 2005).  No other studies were 
found linking 1,25(OH)2D and Insig2 in any cancer. 
 
 1.5.2.2.2. Acyl-CoA Cholesterol Acyltransferase 1 
 As mentioned before, ACAT1 esterifies free cholesterol to a cholesterol 
ester for neutral storage within a cell.  When cholesterol concentrations increase, 
a negative feedback loop causes inhibition of HMG CoA reductase, therefore 
reducing cholesterol production.  This HMG CoA reductase decrease causes 
increased ACAT1 activity, shuttling the remaining free cholesterol into storage.   
 Few studies have examined the role of ACAT1 in breast cancer despite 
the known lipogenic phenotype in progressing cancer.  A study comparing the 
ER+ breast cancer cell line, MCF-7 to the ER- lines, MDA-MB-231 and MDA-MB-
436 showed a significantly greater number of cytoplasmic lipid droplets in the ER 
negative cell lines compared to the ER+ line (Antalis et al., 2010).  From this, it 




protein expression, and activity of ACAT1 as well as increased low density 
lipoprotein (LDL) update, which stimulated proliferation.  When ACAT was 
inhibited in these cell lines, proliferation was significantly reduced in the ER- lines 
(Antalis et al., 2010).  Similarly, MDA-MB-231 breast cancer line grown in a 
lipoprotein depleted media, resulted in decreased lipid droplet formation and a 
significant decrease in cell migration (Antalis et al., 2010).  When LDL was 
restored to the media, the cancer cell was able to migrate, suggesting a 
differential but important role for LDL and ACAT1 in ER+/- breast cancer 
progression (Antalis et al., 2011).  There no studies examining the role of 
1,25(OH)2D  on ACAT1 expression or activity in any cancer lines. 
 
1.5.2.3. Intracellular Lipid Storage in Breast Cancer 
 Accumulation of lipid droplets in breast cancer comes as no surprise with 
their lipogenic phenotype.  Lipid droplets consists of more than just lipids but also 
protein kinases, enzymes, and regulatory membrane proteins, and are regulated 
through cell signaling.  Lipid droplets can be 'activated', leading to influences on 
intracellular lipid metabolism, inflammatory mediation, and membrane synthesis, 
therefore suggesting that lipid droplets are more organelle-like than a benign 
structure (Bozza and Viola, 2010). 
 Free fatty acids in the cell cytoplasm are toxic, thus hydrolyzing them into 
triglycerides and packing them into lipid droplets for storage is optimal.  In breast 
cancer, it is hypothesized that the lipid droplets not only serve as an energy 




activated receptor-gamma (PPARγ) activation stimulates conversion of free fatty 
acids to triglycerides for storage, thus protecting the cell from lipotoxicity and 
death (Kourtidis et al., 2009).  Specifically, PPARγ-binding protein (PBP) co-
activates with PPARγ activation leading to increased transcription of lipogenic 
genes.  Particularly, this co-activation increases nuclear receptor family 1, group 
D, member 1 (NR1D1), a recently identified cancer survival promoter, ATP-citrate 
lyase (ACLY), FAS, and up to 30 additional lipogenic genes (Kourtidis et al., 
2010; Wang et al., 2012). 
 Eicosanoids, a type of signaling lipids, are found in high concentration 
within lipid droplets of normal epithelial and cancerous cells (Plotkowski et al., 
2008).  Further, multiple studies have linked increased lipid droplet formation to 
increased eicosanoid synthesis (Accioly et al., 2008; Bozza et al., 1997; Pacheco 
et al., 2002).  Human group X secreted phospholipase A2 (hGX sPLA2), releases 
fatty acids from membranes and lipoproteins.  In invasive breast cancer cells 
(MDA-MB-231), hGX sPLA2 induces lipid droplet formation, proliferation, and 
survival, even during serum depletion (Pucer et al., 2013).  From this, it is clear 
that intracellular lipid droplets in breast cancer play a pivotal role in cancer cell 
survival, proliferation, inflammation, and more. 
 
1.5.2.3.1. Perilipin 2 
 PLIN2, which is also known as adipose differentiation-related protein 
(ADRP/ADFP), is found on the surface of lipid droplets in nearly all cell types and 




(Matsubara et al., 2011; McIntosh et al., 2012).  Many studies suggest this 
protein is expressed early within adipocyte differentiation and has a role in 
cellular lipid exchange, lipid accumulation, droplet structure, and ultimately cell 
proliferation in majority of normal cell types (McIntosh et al., 2012).  Further, 
PLIN2 promoted accumulation of droplet core lipids, cholesterol esters and 
triglycerides, as well as droplet surface lipids, PCs, PSs, and sphingomyelins 
(McIntosh et al., 2012).  Together, this data suggests that PLIN2 can regulate 
lipid droplet composition and lipid exchange through direct protein-lipid 
interactions on the surface of the droplet. 
 It has been suggested that lipid droplets in cancer may function as 
specialized sites of signaling to induce inflammatory responses intracellularly 
(Bozza and Viola, 2010).  One study suggests there is a direct association 
between the amount of lipid droplets and PLIN2 mRNA abundance in MDA-MB-
231 breast cancer cells (Pucer et al., 2013).  Additionally, PLIN2 is one of the 
only diagnostic markers for the rare secretory carcinoma breast cancer (Osako et 
al., 2013).  There no studies examining the role of 1,25(OH)2D in regulating 
PLIN2 expression or activity in any cancer lines. 
 
1.5.2.3.2. Adipose Triglyceride Lipase 
 ATGL, also called Desnutrin or iPLA2, is coded from the Patatin-like 
phospholipase domain containing 2 (PNPLA2) gene.  ATGL is most often found 
in adipose tissue and on intracellular lipid droplets where it preferentially 




systemic lipid accumulation, severe fat deposition, myopathy, increased cold 
sensitivity, and leukocyte malformation (Jordans anomaly), suggesting a 
pertinent role for ATGL in normal systemic function (Zechner et al., 2009).  The 
mechanisms of ATGL regulation are not yet elucidated, but it is hypothesized that 
they interact with perilipins and other lipid droplet proteins (Listenberger et al., 
2007).  In fact, the only known ATGL up-regulator is comparative gene 
identification-58, which increases activation of ATGL five-fold, but the mechanism 
of this effect has not been elucidated (Zimmermann et al., 2009).   
 The only data on ATGL expression in breast cancer is by Gnerlich et al. 
(2013) who showed that ATGL expression is not altered based on breast tumor 
size or node size (Gnerlich et al., 2013).  ATGL is involved in the majority of 
cancers through its role in cancer-associated cachexia, the uncontrolled loss of 
adipose and muscle tissue.  To test ATGLs role in cachexia, researchers 
implanted xenografts of LLC cells or B16 melanoma cells in C57BL/6 wild type 
and AGTL knock-out (Das et al., 2011).  The knockout of ATGL lead to 
decreased fatty acid mobilization, retention of muscle and adipose tissues, thus 
preventing cancer-associated cachexia in these mice (Das et al., 2011).  There 
no studies examining the role of 1,25(OH)2D regulation of ATGL expression or 
activity in any cancer lines. 
 
1.5.2.3.3. Hormone Sensitive Lipase 
 HSL is the next step of lipolysis after ATGL hydrolysis of a triacylglyceride 




diacylglyceridess to monoacylglycerides in adipose and other tissues.  The long-
form HSL, found mainly in steroidogenic tissues, converts cholesterol esters to 
free cholesterol for steroid hormone production, particularly on the intracellular 
lipid droplets.  HSL is activated by protein kinase A, ERK, Glycogen Synthase 
Kinase-4, and AMPK and is regulated both pre- and post-transcriptionally via 
phosphorylation (Lampidonis et al., 2011).  The phosphorylated HSL then 
translocates from the cell cytoplasm to the lipid droplet surface where it 
preferentially degrades diacylglycerides to monoacylglycerides or cholesterol 
ester to free cholesterol (Egan et al., 1992).   
 Similar to Insig2, literature supporting or negating a role of HSL in breast 
cancer does not currently exist.  However, similar to ATGL, HSL is suggested to 
play a role in cancer-associated cachexia.  HSL mRNA abundance is increased 
two fold in the adipose tissue of cancer patients compared to non-diseased and 
also directly correlated with the serum free fatty acid level (Thompson et al., 
1993).  Further, gastrointestinal cancer patients with cachexia had a 50% 
increase in gene expression and two times the protein expression of HSL in their 
adipocytes compared to gastrointestinal cancer patients without cachexia 
(Agustsson et al., 2007).  Therefore, it is possible that cancer-associated 
cachexia in this group is due to the significant increase in HSL and that perhaps 
cachexia can be prevented with HSL inhibitors. There are no studies examining 






1.5.2.4. Phospholipids and Complex Glycerolipids in Breast Cancer 
 Shifts in phospholipids have also been noted in breast cancer. The 
synthesizing enzyme and precursors to phosphatidic acid, a precursor for de 
novo phospholipid synthesis, are increased in breast cancer compared to normal 
tumors (Brockmöller et al., 2012).  Other studies show that phosphatidic acid, 
upon Ras- or PI3K-activated cleavage by phospholipase D2, is a major activator 
of the MAPK and Akt signaling pathways, which increase cancer cell survival 
(Yalcin et al., 2010).  Increased phospholipids may be the cause of increased 
PI3K signaling seen in breast cancer which ultimately leads to changes in cell 
growth and transformation.  Increased choline flux into PC's and other lipids is 
also noted in breast cancer tumor cells (Ridgway, 2013).  Breast cancer cells 
under metabolic stress respond by significantly increasing PE production, 
suggesting it as a survival mechanism (Zhu and Bakovic, 2012).  Additionally, 
several PI moities, which indirectly regulate GTPases, are dysregulated in breast 
cancer, suggesting their aberrant signaling may contribute to cancer progression 
(Wang et al., 2005b).  Lastly, in human biopsy samples, specific long chain PC's 
(PC(30:0), PC(32:1), etc) are up regulated in patients with below median 
prognosis (Hilvo et al., 2011). 
 Sphingolipids have an emerging role in breast cancer progression.  Their 
core, ceramide, is a pro-apoptotic sphingolipid which can go on to form 
sphingosine-1-phosphate (S1P), a pro-survival sphingolipid (Saddoughi et al., 
2008).  This suggests sphingolipids play a major role in determining cancer cell 




progression by regulating cancer cell survival and growth (Nava et al., 2002; 
Sarkar et al., 2005).  Furthermore, sphingomyelin synthesis activates the 
cleavage of diacylglycerol, an intracellular second messenger, from PC, which 
activates protein kinase C, a pro-proliferative kinase (Saddoughi et al., 2008).  
Perhaps most importantly, increased levels of glucosylceramide, a product of 
ceramide, is associated with development of breast cancer drug resistance, 
further inducing cancer survival (Ogretmen and Hannun, 2004).  
 While there is literature on lipid metabolism in cancer, how 1,25(OH)2D 
may regulate lipid metabolism in any cancer, particularly the breast, has few 
studies.  A lipogenic phenotype is associated with an increase in cancer 
aggressiveness, thus lipid metabolism is an appealing therapeutic target for 
breast cancer.  Additionally, 1,25(OH)2D down-regulated FAS mRNA abundance 
in prostate cancer cells, which may lead to decreased aggressiveness.  FAS, 
SCD1, CPT1a, Insig2, ACAT1, PLIN2, ATGL, and HSL are among the many lipid 
metabolism enzyme of interest for therapeutic targets but few studies exam their 
function within breast cancer, and even fewer, if any, studies look at 1,25(OH)2D 
regulation of these enzymes.  The understanding of lipid metabolism in breast 
cancer and the potential regulatory role of 1,25(OH)2D in breast cancer lipid 
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 It has been established that 1,25-dihydroxyvitamin D (1,25(OH)2D) can 
alter glycolysis and the Krebs cycle of breast cancer cells (Jiang et al., 2010; 
Zheng et al., 2013) but little information is available on 1,25(OH)2D's alterations 
of lipid metabolism in breast cancer cells.  The purpose of this study was to 
determine if there was an effect of 1,25(OH)2D on proteins that regulate lipid 
metabolism in MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a epithelial 
breast cancer cells.  While no significant effects were seen at 24 hours of 
treatment with 10 nM of 1,25(OH)2D, several changes were see at 48 hours with 
the most significant effects in the MCF10CA1a line.  With 48 hour treatment of 
1,25(OH)2D there was a significant increase of fatty acid synthase (FAS), acetyl-
CoA acetyltransferase 1 (ACAT1), insulin-inducing gene 2 (Insig2), perilipin 2 
(PLIN2), and a non-significant trend towards an increase in stearoyl-CoA 
desaturase 1 (SCD1) in the MCF10CA1a line.  Additionally, there was a non-
significant trend towards a decrease in carnitine palmitoyl transferase 1a 
(CPT1a), adipose triglyceride lipase (ATGL), and hormone sensitive lipase (HSL).  
Lipid accumulation was greater in the MCF10CA1a compared to the other 
MCF10A cell lines as shown by oil red O staining.  1,25(OH)2D treatment caused 
a non-significant trend towards a decrease in total triglyceride concentration in 




upon 1,25(OH)2D treatment were noted in specific phospholipids, 
sphingomyelins, and ceramides using MS-MS. Together, these results suggest 
that 1,25(OH)2D alters lipid metabolism by increasing lipid storage and 
decreasing lipid degradation in epithelial breast cancer cells.  
 
2.2. Introduction 
          In 2013, it is estimated that 232,340 people will be diagnosed and 39,620 
will die of breast cancer in the United States alone (PDQ Screening and 
Prevention Editorial Board, 2014). It is well established that cancer cells undergo 
a switch to increased glycolysis, termed the Warburg effect, thus it is probable 
that alterations in lipid metabolism occur as well.  In fact, a lipogenic phenotype is 
associated with cancer progression and is thought to provide survival and growth 
advantages (Louie et al., 2013; Swinnen et al., 2006).  Changes in several lipid 
classes and moieties such as cholesterol (Moon et al., 2014), ceramides 
(Saddoughi et al., 2008), phophotidylinositols (Altomare et al., 2004; Yan et al., 
2009), and sphingosine-1-phosphate (S1P) (Van Brocklyn et al., 2002) have 
been linked to various cancers. These lipid alterations, particularly that of the cell 
membrane, can lead to changes in membrane fluidity, ligand-receptor 
interactions, endocytosis, antigen presentation, lipid-lipid/lipid-protein interactions, 
and microdomain formation (Escribá et al., 2008).  Lipids also act as second 
messengers which control cell proliferation, apoptosis, division, and inflammation 
among other roles (Emoto and Umeda, 2000).  Therefore, the lipogenic 




metabolism are altered, possibly promoting cancer progression. Specifically in 
breast cancer, increased fatty acids are associated with a variety of pro-breast 
cancer effects such as decreased survival (Liu et al., 2011), increased 
proliferation (Louie et al., 2013; Rysman et al., 2010), increased migration 
(Antalis et al., 2011), metastasis (Vazquez-Martin et al., 2008). 
 1,25(OH)2D is proposed to be a chemopreventive agent for breast cancer.  
Epidemiological studies link increased UV exposure, thus vitamin D levels, 
and/or adequate oral vitamin D intake, to a decreased prevalence of breast 
cancer (Garland et al., 2007).  Additionally, there is an association between 
decreased breast cancer prognosis and low serum 25-hydroxyvitamin D 
(25(OH)D), the vitamin D status marker (Kermani et al., 2011; Peterlik et al., 
2009).  Many studies have shown that the active form of vitamin D, 1,25(OH)2D, 
exerts inhibitory effects on primary breast tumors through reducing angiogenesis 
and proliferation and increasing apoptosis of the cancer cells (Hanahan and 
Weinberg, 2011).  Our own laboratory has shown that 1,25(OH)2D can attenuate 
the Warburg effect in breast cancer cells (Jiang et al., 2010; Zheng et al., 2013), 
therefore it is possible that 1,25(OH)2D may also attenuate lipid metabolism that 
promotes breast cancer progression. 
 A multitude of enzymes regulate lipid metabolism and are shown to be 
altered in a cancerous state.  FAS is the second and final committed step in fatty 
acid synthesis.  Additionally, it is the only human protein that can perform 
intracellular reductive de novo synthesis of long chain fatty acids, thus it is major 




that FAS is up-regulated in many cancers, including breast cancer (Menendez 
and Lupu, 2007).  Since increased FAS in breast cancer is associated with poor 
prognosis, it is an appealing target for therapeutic intervention (Puig et al., 2009).  
While there are no studies examining if 1,25(OH)2D can affect expression of FAS 
in breast cancer, there are limited studies in prostate cancer.  FAS was 
significantly decreased in LNCaP prostate cancer cells when treated with 10 nM 
of 1,25(OH)2D for 24 hours, as shown with microarray and RT-PCR (Qiao et al., 
2003).  A similar effect may occur in breast cancer cells but this remains to be 
elucidated. 
 SCD1 plays a role in balancing the ratio of unsaturated versus saturated 
fatty acids which are utilized as components of the cell membrane attached to 
phospholipids.  Thus, modification of SCD1 may lead to alterations in membrane 
fluidity and therefore cell survival and proliferation (Mauvoisin et al., 2013).  
Increased SCD1 activity is associated with increased breast cancer risk as well 
as multiple other cancers (Holder et al., 2013).  Inhibition of SCD1 caused a 
decrease in proliferation and survival of breast cancer cells (Morgan-Lappe et al., 
2007; Scaglia et al., 2009).  In relation to the epithelial-to-mesenchymal transition 
(EMT) stage of metastasis, decreased SCD1 expression is projected to be 
involved in maintaining the epithelial phenotype of primary breast cancer cells, 
thus inhibiting EMT (Mauvoisin et al., 2013).  Currently, there are no studies 





 CPT1a controls the entrance of long-chain fatty acids into the 
mitochondrial inner membrane space where they undergo β-oxidation.  CPT1a 
mRNA abundance is increased in MCF-7 and MDA-MB-231 breast cancer cells 
compared to 184B5 normal breast cells (Linher-Melville et al., 2011).  However, 
there are no studies examining the role of 1,25(OH)2D regulation of CPT1a 
expression in any cancer types. 
 Insig2 is associated with the endoplasmic reticulum membrane with sterol-
regulatory element binding protein (SREBP) and SREBP-cleavage activating 
protein (SCAP), which together control cholesterogenesis at a transcriptional 
level (Yabe et al., 2002).  Expression of Insig2 is at a low but constant level and 
does not depend on SREBPs but does require the presence of sterols in a 
normal healthy individual (Goldstein et al., 2006; Yabe et al., 2002).  While no 
studies currently exist examining the expression or role of Insig2 in breast cancer, 
there are some studies in pancreatic and colon cancer.   Increased Insig2 
expression lead to increased colon cancer cell invasion, proliferation, growth, and 
apoptosis inhibition (Li et al., 2008).  Similarly, pancreatic cancer cells with Insig2 
knockdown resulted in a significant decrease of proliferation and invasion 
(Kayashima et al., 2011).  The only known link between 1,25(OH)2D and Insig2 is 
the discovery of a VDRE in the promoter region of the Insig2 gene in 
preadipocyte cells (Lee et al., 2005).  No other studies were found linking 
1,25(OH)2D and Insig2 in any cancer types. 
 ACAT1 ubiquitously esterifies free cholesterol to a cholesterol ester for 




negative feedback loop causes inhibition of HMG CoA reductase, therefore 
ceasing cholesterol production.  This HMG CoA reductase decreased causes 
increased ACAT1 activity, shuttling the remaining free cholesterol into storage.  
Few studies examined the role of ACAT1 in breast cancer despite the known 
lipogenic phenotype in progressing cancer.  Despite this, one study showed that 
ACAT1 inhibition resulted in decreased breast cancer cell proliferation.  Currently, 
there are no studies examining the role of 1,25(OH)2D in regulation of ACAT1 
expression or activity in any cancer types.  
 PLIN2, also known as adipose differentiation-related protein 
(ADRP/ADFP), is located on the surface of lipid droplets in nearly all cell types.  
Current research suggests that PLIN2 can regulate lipid droplet composition and 
lipid exchange through direct protein-lipid interactions on the surface of the 
droplet.  It is well established that cancerous cells express a lipogenic phenotype, 
thus it is probable that lipid droplet size and number are subsequently increased, 
and therefore possible that PLIN2 is also regulated.  Despite this, few studies 
have examined PLIN2 regulation in cancerous states although one study 
suggests there is a direct association between the amount of lipid droplets and 
PLIN2 mRNA levels in MDA-MB-231 breast cancer cells (Pucer et al., 2013).  
Additionally, PLIN2 is one of the only diagnostic markers for the rare secretory 
carcinoma breast cancer (Osako et al., 2013).  Currently, no studies examining 





 ATGL is located in adipose tissue and on intracellular lipid droplets where 
it preferentially hydrolyzes triacylglycerides to diacylglycerides.  In ATGL 
knockout mice there is whole-body lipid accumulation, severe fat deposition, 
myopathy, increased cold sensitivity, and leukocyte malformation (Jordans 
anomaly), suggesting a pertinent role for ATGL in normal systemic function 
(Zechner et al., 2009).  The only data on ATGL expression in breast cancer is by 
Gnerlich et al. (2013) who showed that ATGL expression is not altered based on 
breast tumor size or node size (Gnerlich et al., 2013).  Knockout of ATGL led to 
decreased fatty acid mobilization and retention of muscle and adipose tissues, 
thus preventing cancer-associated cachexia in mice (Das et al., 2011).  Again, 
there are no current studies examining the role of 1,25(OH)2D in regulating ATGL 
expression or activity in any cancer type.  
 HSL controls the next step of lipolysis after ATGL which is the hydrolysis 
of a triacylglyceride to a diacylglyceride.  The short-form HSL preferentially 
hydrolyzes diacylglycerides to monoacylglycerides in adipose and other tissues.  
The long-form HSL, located mainly in steroidogenic tissues, converts cholesterol 
esters to free cholesterol for steroid hormone production, particularly on the 
intracellular lipid droplets.  Similar to Insig2, literature on HSL in breast cancer 
does not currently exist.  However, similarly to ATGL, HSL is suggested to play a 
role in cancer-associated cachexia.  HSL mRNA level is increased two-fold in the 
adipose tissue of cancer patients compared to non-diseased and also directly 




Additionally, there are no studies examining the role of 1,25(OH)2D regulation of 
HSL expression or activity in any cancer type. 
 Clearly there is little research on the effects of 1,25(OH)2D regulation of 
lipid metabolism in models of breast carcinogenesis and metastasis.  In this 
study, a range of normal to metastatic epithelial breast cells were utilized as a 
model of progressive carcinogenesis and metastasis to examine the function of 
1,25(OH)2D in regulation of specific lipid metabolism enzymes (FAS, CPT1a, 
PLIN2, HSL, ATGL, ACAT1, SCD1, Insig2) and lipid moieties.  The hypothesis of 
this study is that 1,25(OH)2D decreases lipid metabolism and sequesters the 
lipids.  The results of these studies will provide information that will help the 
development of breast cancer prevention strategies. 
 
 
2.3. Materials and Methods 
2.3.1. Chemicals and Reagents 
 1,25(OH)2D was purchased from Biomol (Plymouth Meeting, PA).  
Dulbecco's modified Eagle medium (DMEM/F-12), horse serum, trypsin-EDTA, 
oil red O, para-formaldehyde, and penicillin/streptomycin were purchased from 
Life Technologies, Gibco-BRL (Grand Island, NY).  Cholera toxin was from 
Calbiochem (Darmstadt, Germany). Trypan blue, insulin, epidermal growth factor, 
hydrocortisone, and 3-(4,5-dimythylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide 
(MTT) were purchased from Sigma-Aldrich (St. Louis, MO).  Bovine serum 




chromatography (TLC) plates Reagent A and B for BCA were purchased from 
Thermo Scientific (Rockford, IL).  The Non-polar lipid mix B for TLC standards 
was purchased from Matreya LLC (Pleasant Gap, PA).  Triglyceride assay 
reagents and lipid mix standard were purchased from Wako Diagnostics 
(Richmond, VA).  Tri-Reagent was purchased from Molecular Research Center, 
Inc. (Cincinnati, OH).  Dimethyl sulfoxide (DMSO) was purchased from Avanto 
Performance Materials (Center Valley, PA).  ROX dye and SYBR Green Brilliant 
II and III were purchased from Agilent Technologies (Santa Clara, CA).  Rnasin, 
Random Primers, Oligo DT, XTP Random Nucleotide Mix, MMLVRT, and M-
MLVRT 5x Buffer were purchased from Promega (Madison, WI). 
 
2.3.2. Cell Culture 
 MCF10A and MCF10A cells stably transfected with the Harvey ras 
oncogene (MCF10A-ras) were cultured in DMEM/F12(1:1) supplemented with 5% 
horse serum, 1% penicillin-streptomycin, 50 μg/L cholera toxin, 50 mg/L 
hydrocortisone, 10 mg/L insulin, and 20 μg/L epidermal growth factor in a 
humidified environment at 37C with 5% carbon dioxide.  Cells were maintained in 
linear (2D) growth, and frozen back in 85% supplemented media, 5% DMSO, 
and 10% heat-inactivated fetal bovine serum (HI-FBS).  1,25(OH)2D was given to 
cells in 100% sterile ethanol with a final concentration of less than 1%. 
  The MCF10CA1h and MCF10CA1a cells were gifts from Dr. Julia 
Kirshner, Purdue University.  Both cell lines were cultured in DMEM/F12 (1:1) 




humidified environment at 37oC with 5% carbon dioxide.  Cells were maintained 
in linear (2D) growth and frozen in 85% supplemented media, 5% DMSO and 10% 
HI-FBS for storage.  1,25(OH)2D was given to cells in 100% ethanol with a final 
concentration less than 1%. 
 
2.3.3. Real Time-Polymerase Chain Reaction 
 MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells were treated 
with either vehicle (100% ethanol) or 10 nM of 1,25(OH)2D for 48 hours prior to 
harvest.  RNA was harvested and isolated using TriReagent following the 
manufacturer's instructions.  The total isolated RNA was reverse transcribed 
using a reverse transcription mixture: Rnasin, Random Primers, Oligo DT, XTP 
Random Nucleotide Mix, MMLVRT, and M-MLVRT 5x Buffer.  After this, the 
cDNA was quantified and real-time PCR was completed with Brilliant II or Brilliant 
III SYBR Green QPCR Master Mix.  The abundance of the mRNA of interest was 
determined via the threshold cycle (Ct) value and normalized to 18S mRNA 
abundance.  Results were expressed as arbitrary units and were considered 
significant if P<0.05. Primers utilized were purchased from Integrated DNA 
Technologies (Coralville, IA) :  
-18S 
 Forward: 5'-TTAGAGTGTTCAAAGCAGGCCCGA-3' 
 Reverse: 5'-TCTTGGCAAATGCTTTCGCTCTGG-3' 
-ACAT1:  
 Forward: 5'-TGGGCAATGGAGTCTTACTCTGCT-3' 
 Reverse: 5'-AAACAGCTGGCTCCAAATCAGGGA-3' 
-ATGL: 
 Forward: 5'-CAGACAACCTGCCACTCTATG-3' 





 Forward: 5'-GGATCCTGGACAATACC-3' 
 Reverse: 5'-CAGGGAGTCTCTATAAC-3' 
-FAS: 
 Forward: 5'-AGTTCACGGACATGGAGCACAACA-3' 
 Reverse: 5'-ATGGTACTTGGCCTTGGGTGTGTA-3' 
-HSL: 
 Forward: 5'-CTCTCCAAGTGTGTCAG-3' 
 Reverse: 5'-GGGTTCTTGACTATGGG-3' 
-Insig2: 
 Forward: 5'-TGGTCCAGTGTAATGCGGTGTGTA-3' 
 Reverse: 5'-GACCACAGTTGCCAAGAAGCCAAT-3' 
-PLIN2: 
 Forward: 5'-AGCCAACAGACCATTTCTCAGCTC-3' 
 Reverse: 5'-TTAAAGGAGGCAGCATTGCGGAAC-3' 
-SCD1: 
 Forward: 5'-CCCACCTACAAGGATAAG-3' 
 Reverse: 5'-CTGGCAGAGTAGTCATAG-3' 
 
2.3.4. Lipid Extraction for Lipid Analysis 
 MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells were 
cultured in DMEM/F:12(1:1) as described above in triplicate 60mm dishes and 
treated with either vehicle or 10 nM 1,25(OH)2D for 48 hours.  Twenty-four hours 
after the last treatment, cells were washed with 1x Tris-buffered Saline (TBS) 
containing 0.2% Bovine Serum Albumin (BSA) and then again with only 1x TBS.  
A 3:2 ratio of hexane to isopropanol was added to each dish and placed on a 
shaker for 30 minutes at room temperature.  After incubation, the solution was 
transferred to glass test tubes.  The organic solution wash and extraction were 
repeated a second time.  Test tubes with lipid extractions were capped, 
parafilmed, and stored at 4oC until analysis by TLC, gas chromatography (GC), 
or colorimetric analysis.  Remaining dishes were allowed to dry and 3 mL of 0.1 




in order to solubilize the proteins.  The protein solution was transferred into 
polystyrene tubes and stored at -20oC until BCA assay. 
 
2.3.5. Triglyceride Colorimetric Analysis 
 Following lipid extraction, the organic fraction was dried with nitrogen, 
washed with 1% Triton-X, vortexed to dissolve the lipids, and dried again with 
nitrogen.  Cells were washed with 2% Triton-X and vortexed to dissolved the 
lipids, followed by incubation for 15 minutes in 37oC.  After incubation, an 
equivalent ratio of water was added to the tubes and incubated for 15 minutes in 
37oC.  Samples were aliquoted in 2 µl triplicates into a 96-well plate.  A serial 
dilution of the Lipid Mix Standard was employed.  Reagent Color A (180 µl) was 
added to all wells and the plate was incubated for 5 minutes at 37oC.  Reagent 
Color B (60 µl) was added to all wells and the plate was incubated for 15 minutes 
at 37C.  Absorbance was measured at 600 nm wavelength by spectrophotometer 
and corrected to protein concentration determined by BCA.  Results were 
expressed as mg of triglycerides per µg of protein, averaged for each treatment 
group and cell line. 
 
2.3.6. Thin Layer Chromatography 
 Following the lipid extraction, the samples were dried with nitrogen.  A 
glass chromatography chamber was equilibrated with a 80:20:1 
hexane:ether:acetic acid solution and a sheet of filter paper.  After drying, 




small amount of chloroform, per manufacturer's instructions.  Standards and 
samples were spotted and completely dried in 5 µl intervals on a Whatman TLC 
plate until 20 µl was reached for each sample.  Once complete, the plate was 
placed into the equilibrated glass chamber until the solvent line was one inch 
from the top of the plate.  The plate was removed and allowed to dry and placed 
inside a solid phase iodine chamber until band staining was strong.  The TLC 
plate was removed, photographed, and allowed to evaporate until no color 
remained.  The plate was stored in a dark, cool, room temperature area for re-
visualization as needed. 
 
2.3.7. Oil Red O Staining 
 MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells were 
cultured in DMEM/F:12(1:1) as described above in triplicate 60 mm dishes with 
and without cover slips on the bottom, and treated with either vehicle or 10 nM 
1,25(OH)2D for 48 hours.  Twenty-four hours after the last treatment, the media 
was aspirated and cells were washed once with PBS and fixed using 4% para-
formaldehyde for 15 minutes at room temperature.  Cells were washed three 
times with phosphate buffered saline (PBS) and once with 60% isopropanol.  A 
3:2 ratio of 1% Oil Red O in isopropanol to water was then added to the cells and 
incubated at room temperature for 20 minutes.  Cells were washed once with 60% 
isopropanol, three times with PBS, and once with water.  The 60 mm dishes were 
sealed with parafilm; cells grown on cover slips were inverted onto slides and 




2.3.8. Lipid Extraction for MS-MS Analysis 
 MCF10CA1a cells were cultured in DMEM:F12(1:1) as described above in 
triplicate 60 mm dishes and treated with either vehicle or 10 nm 1,25(OH)2D for 
48 hours, harvested and replated, and treated for an additional 96-hours.  
Twenty-four hours after the last treatment, cells were washed with 1x TBS with 
0.2% BSA, followed by washing with 1x TBS.  A lysis buffer cocktail was added 
to each plate and incubated at room temperature for 5 minutes.  Plates were 
scraped and aliquoted into glass tubes.  A methanol-chloroform (3:5) mixture was 
added to each tube and incubated for 30 minutes at room temperature on a 
shaker.  After incubation, the tubes were centrifuged to separate polar and non-
polar fractions, being careful to not aspirate the cell pellet.  Fractions were 
harvested and aliquoted into separate corresponding glass tubes, dried with 
nitrogen, and stored in -80oC until analysis.   
 
2.3.9. Mass Spectrometry 
 Positive and negative node mass spectrometry was performed on each 
polar sample via the LTQ-Orbitrap XL-Nano LC-high resolution hybrid ion trap 
(Thermo Orbitrap) machine at Purdue Discovery Park, Bindley Bioscience (West 
Lafayette, IN).  Parameters for analysis were as follows: 
 Molecular weight difference: 0; maximum number of modifications: 0; 
 centralization: yes; LC peak width: 10; minimum effective retention time: 
 0.5; maximum effective retention time: 38.0; minimum noise-to-signal 




 frequency cut off: 60; minimum fraction of sample in which a peak must be 
 detected in control sample: 0.66; minimum fraction of samples in which a 
 peak must be detected in treatment sample: 0.3; mass tolerance: 0.2; T-
 test threshold: 0.05. 
 
2.3.10. Bicinchoninic Acid Assay (BCA) 
 BCA assay was utilized for the colorimetric detection of the total protein 
concentration of a sample.  A standard curve was created utilizing increasing 
concentrations of BSA .  Samples were placed in triplicate on the plate, a mixture 
of Reagent A to Reagent B (50:1) was put in each well and the plate was 
incubated in the dark for 30 minutes at 37oC.  Colorimetric detection was 
quantified by spectrophotometer at 592 nm wavelength (Powerwave, Biotek 
Instruments Inc, Winooski, VT).   
 
2.3.11. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] Assay 
 MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells were 
cultured in DMEM/F:12(1:1) as described above in a 24-well plate and were 
treated with either vehicle or 10nM 1,25(OH)2D for 48 hours.  Twenty-four hours 
after the last treatment, the media was aspirated and a 0.5 mg/mL of MTT 
working mix was added to each well and incubated in the dark for 2 hours at 
37oC.  After incubation, DMSO was added and thoroughly mixed in each well and 
the plate was incubated in the dark for 5 minutes at 37oC.  Afterwards, the plate 




duplicate into a 96-well plate and quantified at 570 nm with a 700 nm reference 
wavelength via spectrophotometer (Powerwave, Biotek Instruments Inc., 
Winooski, VT).   
 
2.3.12. Statistical Analysis 
 Values presented are means ± SEM.  Student T-tests and ANOVA were 
performed using SAS 9.2 or 9.3.  Data was considered statistically significant 
with a p-value of P<0.05.  MS-MS samples were processed through the Purdue 




 To determine if 1,25(OH)2D alters lipid metabolism, MCF10A, MCF10A-
ras, MCF10CA1h, and MCF10CA1a cells were treated with vehicle or 10 nM of 
1,25(OH)2D for 24 or 48 hours and mRNA abundance determined.  Twenty-four 
hour treatment of all four cell lines resulted in no significant differences among 
ACAT1, FAS, Insig2, or PLIN2 in any of the cell lines.  Following 1,25(OH)2D 
treatment for 48 hours, ACAT1 levels were significantly increased (p=0.007) in 
MCF10CA1a cells with a non-significant trend towards an increase (p=0.06) in 
the MCF10A cells (Figure 2A).  Similarly, FAS (p=0.004) (Figure 2B), Insig2 
(p=0.03) (Figure 2C), and PLIN2 (p=0.01) (Figure 2D) were all significantly 
increased in the MCF10CA1a cells with no significant differences or trends in the 




decreases in HSL (p=0.08) (Figure 2E), ATGL (p=0.08) (Figure 2F), and CPT1a 
(Figure 2G) in the MCF10CA1a cells.  No change was seen in SCD1 mRNA 











































































































































































































































































































Figure 2. mRNA abundance of vehicle and 1,25(OH)2D treated MCF10A, 
MCF10A-ras, MCF10CA1h, and MCF10CA1a cells.  All cells were treated for 48 
hours with either vehicle or 1,25(OH)2D (10 nM).  A representative quantification 
of the mRNA abundance is shown for each lipid metabolism enzyme, indicated 
with vehicle (open bars) and 1,25(OH)2D treatment (black bars).  Values are 
expressed as lipid enzyme mRNA relative to 18S mRNA for each sample relative 
to vehicle control.  Results are expressed as mean ± SEM. (n ≥ 3). Bars with 
common letter subscripts are not significantly different (p<0.05).  2A. ACAT1; 2B. 






















Due to these alterations in lipid metabolism enzymes, oil red O staining 
and TLC were performed to visually assess the differences between cytoplasmic 
lipid droplet accumulation and lipid classes, respectively, with 48 hours of 
1,25(OH)2D treatment.  Upon oil red O staining, it was apparent that lipid 
accumulation was increased in the metastatic cell line (Figure 3), specifically, 
visual assessment determined that the size and number of lipid droplets 
increased, thus agreeing with the conjecture that aggressive cancer is 
characterized with a lipogenic phenotype.  Differences in oil red O staining were 
difficult to visually assess between vehicle and 1,25(OH)2D treatment therefore, 
TLC was performed to better identify differences.  Visual assessment of the 
iodinated plates showed a slight increase in cholesterol with 1,25(OH)2D 
treatment in the MCF10A cells, but a decrease in cholesterol with 1,25(OH)2D 
treatment in the MCF10A-ras and MCF10CA1a cells lines (Figure 4).  
Additionally, visual assessment showed that 1,25(OH)2D treatment increased 
free fatty acids, as represented by the oleic acid standard, in both the MCF10A-
ras and MCF10CA1a cell lines while no changes were seen with the 









Figure 3. Oil red O staining of vehicle and 1,25(OH)2D treated MCF10A, 
MCF10A-ras, MCF10CA1h, and MCF10CA1a cells.  All cells were treated for 48 
hours with either vehicle or 1,25(OH)2D (10 nM).  A representative image of the 

































    
  
 
Figure 3. TLC of vehicle and 1,25(OH)2D treated MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells.  All 
cells were treated for 48 hours with either vehicle or 1,25(OH)2D (10 nM).  Standards are listed along the far left 
column and are designated by the "S" on the x-axis.  A test spot was done on the far left and is labeled "T".  A 























 The same samples used to perform the TLC were tested for total 
triacylglyceride content relative to their protein concentration.  While the only 
significant difference between treatment groups was in the MCF10A-ras cells 
(P=0.03), there were no significant differences between the treatment groups in 
the other three cell lines upon 48 hours of vehicle or 1,25(OH)2D.  Despite this, it 
was again observed that there was a significant increase in triglycerides as the 













































Figure 5. Triglyceride colorimetric analysis of vehicle and 1,25(OH)2D treated 
MCF10A, MCF10A-ras, MCF10CA1h, and MCF10CA1a cells.  All cells were 
treated for 48 hours with either vehicle or 1,25(OH)2D (10 nM).  A representative 
quantification of the triglyceride colorimetric analysis is shown, indicated with 
vehicle (open bars) and 1,25(OH)2D treatment (black bars).  Values are 
expressed as average milligrams of triglycerides per treatment group relative to 
the average milligrams of protein per the same treatment group for each sample 
relative to vehicle control.  Results are expressed as mean ± SEM. (n ≥ 3). Bars 














































To identify the specific lipids that were altered with 48 hour 1,25(OH)2D 
pretreatment, replating, and subsequent 96 hour 1,25(OH)2D treatment, MS-MS 
was performed on MCF10CA1a cells.  The negative and positive spray together 
produced over 400 significant changes (P ≤  0.01) in individual lipid moieties.  
Significant increases in some phosphotidylinositols (PIs), phosphotidylchoines 
(PCs), phosphotidylethanolamines (PEs), and sphingomyelins with long chain 
fatty acids attached (data not shown) were seen in the 1,25(OH)2D treated group.   
Additionally, there were significant decreases in some glucosylceramides, also 
with long chain fatty acids attached.  Overall, majority of the significantly altered 
lipids upon 1,25(OH)2D treatment were those with long chain fatty acids attached.  
The analysis of these changes is ongoing in our laboratory.  
 To assure our differences were not a result of changes in cell viability, an 
MTT assay was performed on all four cells lines with vehicle or 10 nM of 
1,25(OH)2D for 48 hours prior to harvest.  While there was a trend towards a 
decrease in number of live cells with 1,25(OH)2D treatment in all the lines, only 





































Figure 6. MTT assay of vehicle and 1,25(OH)2D treated MCF10CA1a cells.  All 
cells were treated for 48 hours, harvested and replated, and treated for an 
additional 96 hours with either vehicle or 1,25(OH)2D (10 nM).  A representative 
quantification of the MTT assay is shown, indicated with vehicle (open bars) and 
1,25(OH)2D treatment (black bars).  Values are expressed as cell number of 
each sample relative to vehicle control.  Results are expressed as mean ± SEM. 














 In the current study, the effect of 1,25(OH)2D treatment on lipid 
metabolism enzyme mRNA abundance was explored in epithelial breast cancer 
cell lines including untransformed MCF10A, H-ras oncogene transfected 
MCF10A-ras, to aggressive MCF10CA1h, and metastatic MCF10CA1a cells.  
Together these cell lines represent a model for breast cancer progression.  This 
study is the first to examine how 1,25(OH)2D may regulate FAS, SCD1, CPT1a, 
Insig2, ACAT1, PLIN2, ATGL, and HSL in metastatic breast cancer.  The results 
show that 10 nM of 1,25(OH)2D did not have significant effects at 24 hours but 
upon 48 hours of treatment, several alterations were noted.  Specifically, in the 
metastatic MCF10CA1a line, there were significant increases in FAS, ACAT1, 
Insig2, and PLIN2, which suggests there is an increase in cholesterol storage 
(ACAT1) and lipid storage (PLIN2) as well as a decrease in synthesis of new 
cholesterol (Insig2).  Increased FAS may indicate increased triglyceride synthesis 
as well.  Additionally, a trend towards a decrease in CPT1a, HSL, and ATGL, 
was observed. These results suggest that lipolysis of the stored lipids is 
decreased (HSL, ATGL) and that β-oxidation may also be decreased (CPT1a).  
No effects were seen in SCD1 expression, suggesting that the balance of 
saturated and unsaturated fatty acids within a cell may not be significantly altered 




may shift lipid metabolism toward storage and decrease lipolysis and β-oxidation 
in metastatic MCF10CA1a cells.  Therefore, 1,25(OH)2D may inhibit cancer cell 
growth and/or metastasis by shifting lipids usually needed for signaling, energy, 
or proliferation, into storage.  While these endpoints remain to be tested, it is 
clear 1,25(OH)2D has a consistent effect on several enzymes involved with lipid 
metabolism. 
 Visual increases in lipid droplets and fatty acids were seen as cell line 
aggressiveness increases.  While visual alterations of cells treated with 
1,25(OH)2D were not detectable, trends between cell lines were seen in levels of 
cytoplasmic lipid droplet accumulation by oil red O, and in levels of lipids 
separated by TLC.  The visual trend of increased lipid droplets confirms the 
notion that increasing cancer aggressiveness is associated with increased 
cytoplasmic lipid accumulation (Louie et al., 2013; Swinnen et al., 2006).  
Additionally, the visual increase in oleic acid in the MCF10CA1a cells suggests 
specific lipid moieties are altered within cancer progression.  Interestingly, total 
triglycerides were significantly increased only in the MCF10A-ras line upon 
1,25(OH)2D treatment while MCF10CA1a cells had a trend towards a decrease.   
Although this decrease does not agree with the significant increase in FAS 
mRNA abundance, it may suggest that FAS is synthesizing fatty acids for 
alternative lipid synthesis such as phospholipids, sphingomyelins, cholesterols, 
etc.   
 Therefore, lipidomics of the MCF10CA1a cells was performed on samples 




performed by laboratory member, Tomasz Wilmanski, identified potential 
differences in several lipid moieties.  There were significant decreases in 
glucosylceramides concurrently with significant increases in PCs, PEs, PIs, PSs, 
and sphingomyelins containing long-chain fatty acids in the 1,25(OH)2D treated 
cells compared to vehicle.  This suggests that lipid metabolism is shifted toward 
phospholipid and SM synthesis upon 1,25(OH)2D treatments and may explain 
the trend towards a decrease of TAG but increased FAS.  To our knowledge, this 
is the first study examining the effects of 1,25(OH)2D regulation of the 
abundance of advanced lipid moieties.  Increased phospholipids may lead to a 
multitude of changes within a cancer cell such as altered cell membrane 
permeability and fluidity.  It is also probable that there are changes in signaling 
transduction pathways as both phospholipids and sphingomyelins have both 
been identified as intracellular messengers.  While the results of recent studies 
have shown that increased PCs (Hilvo et al., 2011; Ridgway, 2013), PEs (Zhu 
and Bakovic, 2012), and PIs (Wang et al., 2006) may be linked to cancer cell 
survival signaling, it is known that treatment with 1,25(OH)2D induces apoptosis 
(Pileczki et al., 2012; Simboli-Campbell et al., 1996) and growth inhibition 
(García-Quiroz et al., 2013; Suetani et al., 2012).  Thus, since lipidomics 
revealed an increase in phospholipid abundance, MTT was performed to identify 
if MCF10CA1a did indeed have decreased viability.  The normal MCF10A cells 
had a significant decrease in viability but there was only a trend towards a 
decrease in the metastatic MCF10CA1a cells.   Together these results suggest 




perhaps this is driven more by alterations in neutral lipid availability and not 
phospholipid abundance.  Alternatively, the increase in phospholipids may shift 
intracellular signaling for decreasing the invasive potential of the cancer cell (see 




 To our knowledge, this is the first study to examine how 1,25(OH)2D 
regulates FAS, SCD1, CPT1a, Insig2, ACAT1, PLIN2, ATGL, and HSL as well as 
the abundance of lipid moieties in metastatic breast cancer.  Overall, our results 
suggest that 1,25(OH)2D may shift lipid metabolism toward storage and decrease 
lipolysis as indicated by decreased lipases and CPT1a concurrently with 
increased FAS, Insig2, ACAT1, and PLIN2.  Furthermore, the results show that 
1,25(OH)2D further increases phospholipids and sphingomyelins while causing a 
slight decrease in cell viability suggesting the altered lipids may alternatively 
used for signaling and not proliferation.  Together, these results suggest 
1,25(OH)2D alters the lipid metabolism within metastatic epithelial breast cancer 










 2.7. References 
Altomare, D.A., Wang, H.Q., Skele, K.L., De Rienzo, A., Klein-Szanto, A.J., 
Godwin, A.K., and Testa, J.R. (2004). AKT and mTOR phosphorylation is 
frequently detected in ovarian cancer and can be targeted to disrupt ovarian 
tumor cell growth. Oncogene 23, 5853–5857. 
 
Antalis, C.J., Uchida, A., Buhman, K.K., and Siddiqui, R.A. (2011). Migration of 
MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids 
and cholesterol esterification. Clin. Exp. Metastasis 28, 733–741. 
 
Van Brocklyn, J., Letterle, C., Snyder, P., and Prior, T. (2002). Sphingosine-1-
phosphate stimulates human glioma cell proliferation through Gi-coupled 
receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta. 
Cancer Lett. 181, 195–204. 
 
Das, S.K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., Gorkiewicz, 
G., Tamilarasan, K.P., Kumari, P., Trauner, M., et al. (2011). Adipose triglyceride 
lipase contributes to cancer-associated cachexia. Science 333, 233–238. 
 
Emoto, K., and Umeda, M. (2000). An essential role for a membrane lipid in 
cytokinesis. Regulation of contractile ring disassembly by redistribution of 
phosphatidylethanolamine. J. Cell Biol. 149, 1215–1224. 
 
Escribá, P.V., González-Ros, J.M., Goñi, F.M., Kinnunen, P.K.J., Vigh, L., 
Sánchez-Magraner, L., Fernández, A.M., Busquets, X., Horváth, I., and Barceló-
Coblijn, G. (2008). Membranes: a meeting point for lipids, proteins and therapies. 
J. Cell. Mol. Med. 12, 829–875. 
 
García-Quiroz, J., Rivas-Suárez, M., García-Becerra, R., Barrera, D., Martínez-
Reza, I., Ordaz-Rosado, D., Santos, N., Villanueva, O., Santos-Cuevas, C.L., 
Avila, E., et al. (2013). Calcitriol reduces thrombospondin-1 and increases 
vascular endothelial growth factor in breast cancer cells: Implications for tumor 
angiogenesis. J. Steroid Biochem. Mol. Biol. 
 
Garland, C.F., Gorham, E.D., Mohr, S.B., Grant, W.B., Giovannucci, E.L., Lipkin, 
M., Newmark, H., Holick, M.F., and Garland, F.C. (2007). Vitamin D and 
prevention of breast cancer: pooled analysis. J. Steroid Biochem. Mol. Biol. 103, 
708–711. 
 
Gnerlich, J.L., Yao, K.A., Fitchev, P.S., Goldschmidt, R.A., Bond, M.C., Cornwell, 
M., and Crawford, S.E. (2013). Peritumoral expression of adipokines and fatty 





Goldstein, J.L., DeBose-Boyd, R.A., and Brown, M.S. (2006). Protein sensors for 
membrane sterols. Cell 124, 35–46. 
 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of Cancer: The Next 
Generation. Cell 144, 646–674. 
 
Hilvo, M., Denkert, C., Lehtinen, L., Müller, B., Brockmöller, S., Seppänen-
Laakso, T., Budczies, J., Bucher, E., Yetukuri, L., Castillo, S., et al. (2011). Novel 
theranostic opportunities offered by characterization of altered membrane lipid 
metabolism in breast cancer progression. Cancer Res. 71, 3236–3245. 
 
Holder, A.M., Gonzalez-Angulo, A.M., Chen, H., Akcakanat, A., Do, K.-A., Fraser 
Symmans, W., Pusztai, L., Hortobagyi, G.N., Mills, G.B., and Meric-Bernstam, F. 
(2013). High stearoyl-CoA desaturase 1 expression is associated with shorter 
survival in breast cancer patients. Breast Cancer Res. Treat. 137, 319–327. 
 
Jiang, Y., Zheng, W., and Teegarden, D. (2010). 1α, 25-Dihydroxyvitamin D 
regulates hypoxia-inducible factor-1α in untransformed and Harvey-ras 
transfected breast epithelial cells. Cancer Lett. 298, 159–166. 
 
Kayashima, T., Nakata, K., Ohuchida, K., Ueda, J., Shirahane, K., Fujita, H., Cui, 
L., Mizumoto, K., and Tanaka, M. (2011). Insig2 is overexpressed in pancreatic 
cancer and its expression is induced by hypoxia. Cancer Sci. 102, 1137–1143. 
 
Kermani, I.A., Kojidi, H.T., Gharamaleki, J.V., Sanaat, Z., Ziaei, J.E., Esfahani, A., 
Seifi, S., Ghojazadeh, M., Dolatkhah, R., Kermani, A.A., et al. (2011). Association 
of serum level of 25 hydroxy-vitamin D with prognostic factors for breast cancer. 
Asian Pac. J. Cancer Prev. APJCP 12, 1381–1384. 
 
Lee, S., Lee, D.-K., Choi, E., and Lee, J.W. (2005). Identification of a functional 
vitamin D response element in the murine Insig-2 promoter and its potential role 
in the differentiation of 3T3-L1 preadipocytes. Mol. Endocrinol. Baltim. Md 19, 
399–408. 
 
Li, J., Byrne, M.E., Chang, E., Jiang, Y., Donkin, S.S., Buhman, K.K., Burgess, 
J.R., and Teegarden, D. (2008). 1alpha,25-Dihydroxyvitamin D hydroxylase in 
adipocytes. J. Steroid Biochem. Mol. Biol. 112, 122–126. 
 
Linher-Melville, K., Zantinge, S., Sanli, T., Gerstein, H., Tsakiridis, T., and Singh, 
G. (2011). Establishing a relationship between prolactin and altered fatty acid β-







Liu, R.-Z., Graham, K., Glubrecht, D.D., Germain, D.R., Mackey, J.R., and 
Godbout, R. (2011). Association of FABP5 expression with poor survival in triple-
negative breast cancer: implication for retinoic acid therapy. Am. J. Pathol. 178, 
997–1008. 
 
Louie, S.M., Roberts, L.S., Mulvihill, M.M., Luo, K., and Nomura, D.K. (2013). 
Cancer cells incorporate and remodel exogenous palmitate into structural and 
oncogenic signaling lipids. Biochim. Biophys. Acta 1831, 1566–1572. 
 
Mauvoisin, D., Charfi, C., Lounis, A.M., Rassart, E., and Mounier, C. (2013). 
Decreasing stearoyl-CoA desaturase-1 expression inhibits β-catenin signaling in 
breast cancer cells. Cancer Sci. 104, 36–42. 
 
Menendez, J.A., and Lupu, R. (2007). Fatty acid synthase and the lipogenic 
phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763–777. 
 
Moon, H., Hill, M.M., Roberts, M.J., Gardiner, R.A., and Brown, A.J. (2014). 
Statins: protectors or pretenders in prostate cancer? Trends Endocrinol. Metab. 
TEM. 
 
Morgan-Lappe, S.E., Tucker, L.A., Huang, X., Zhang, Q., Sarthy, A.V., Zakula, D., 
Vernetti, L., Schurdak, M., Wang, J., and Fesik, S.W. (2007). Identification of 
Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, 
and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based 
screen. Cancer Res. 67, 4390–4398. 
 
Notarnicola, M., Messa, C., and Caruso, M.G. (2012). A significant role of 
lipogenic enzymes in colorectal cancer. Anticancer Res. 32, 2585–2590. 
 
Osako, T., Takeuchi, K., Horii, R., Iwase, T., and Akiyama, F. (2013). Secretory 
carcinoma of the breast and its histopathological mimics: value of markers for 
differential diagnosis. Histopathology 63, 509–519. 
 
PDQ Screening and Prevention Editorial Board (2014). Breast Cancer Prevention 
(PDQ®). 
 
Peterlik, M., Boonen, S., Cross, H.S., and Lamberg-Allardt, C. (2009). Vitamin D 
and calcium insufficiency-related chronic diseases: an emerging world-wide 
public health problem. Int. J. Environ. Res. Public. Health 6, 2585–2607. 
 
Pileczki, V., Braicu, C., Gherman, C.D., and Berindan-Neagoe, I. (2012). TNF-α 
gene knockout in triple negative breast cancer cell line induces apoptosis. Int. J. 





Pucer, A., Brglez, V., Payré, C., Pungerčar, J., Lambeau, G., and Petan, T. 
(2013). Group X secreted phospholipase A(2) induces lipid droplet formation and 
prolongs breast cancer cell survival. Mol. Cancer 12, 111. 
 
Puig, T., Porta, R., and Colomer, R. (2009). [Fatty acid synthase: a new anti-
tumor target]. Med. Clínica 132, 359–363. 
 
Qiao, S., Pennanen, P., Nazarova, N., Lou, Y.-R., and Tuohimaa, P. (2003). 
Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in 
prostate cancer cells. J. Steroid Biochem. Mol. Biol. 85, 1–8. 
 
Ridgway, N.D. (2013). The role of phosphatidylcholine and choline metabolites to 
cell proliferation and survival. Crit. Rev. Biochem. Mol. Biol. 48, 20–38. 
 
Rysman, E., Brusselmans, K., Scheys, K., Timmermans, L., Derua, R., Munck, S., 
Van Veldhoven, P.P., Waltregny, D., Daniëls, V.W., Machiels, J., et al. (2010). 
De novo lipogenesis protects cancer cells from free radicals and 
chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70, 
8117–8126. 
 
Saddoughi, S.A., Song, P., and Ogretmen, B. (2008). Roles of bioactive 
sphingolipids in cancer biology and therapeutics. Subcell. Biochem. 49, 413–440. 
 
Scaglia, N., Chisholm, J.W., and Igal, R.A. (2009). Inhibition of stearoylCoA 
desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in 
cancer cells: role of AMPK. PloS One 4, e6812. 
 
Simboli-Campbell, M., Narvaez, C.J., Tenniswood, M., and Welsh, J. (1996). 
1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of 
apoptosis in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 58, 367–
376. 
 
Suetani, R.J., Ho, K., Jindal, S., Manavis, J., Neilsen, P.M., Pishas, K.I., Rippy, 
E., Bochner, M., Kollias, J., Gill, P.G., et al. (2012). A comparison of vitamin D 
activity in paired non-malignant and malignant human breast tissues. Mol. Cell. 
Endocrinol. 362, 202–210. 
 
Swinnen, J.V., Brusselmans, K., and Verhoeven, G. (2006). Increased 
lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. 
Metab. Care 9, 358–365. 
 
Thompson, M.P., Cooper, S.T., Parry, B.R., and Tuckey, J.A. (1993). Increased 
expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer 





Vazquez-Martin, A., Colomer, R., Brunet, J., Lupu, R., and Menendez, J.A. 
(2008). Overexpression of fatty acid synthase gene activates HER1/HER2 
tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 41, 59–85. 
 
Wang, S.E., Shin, I., Wu, F.Y., Friedman, D.B., and Arteaga, C.L. (2006). 
HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated 
by transforming growth factor beta. Cancer Res. 66, 9591–9600. 
 
Yabe, D., Brown, M.S., and Goldstein, J.L. (2002). Insig-2, a second 
endoplasmic reticulum protein that binds SCAP and blocks export of sterol 
regulatory element-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 99, 12753–
12758. 
 
Yan, W., Fu, Y., Tian, D., Liao, J., Liu, M., Wang, B., Xia, L., Zhu, Q., and Luo, M. 
(2009). PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in 
hypoxic hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 382, 
631–636. 
 
Zechner, R., Kienesberger, P.C., Haemmerle, G., Zimmermann, R., and Lass, A. 
(2009). Adipose triglyceride lipase and the lipolytic catabolism of cellular fat 
stores. J. Lipid Res. 50, 3–21. 
 
Zheng, W., Tayyari, F., Gowda, G.A.N., Raftery, D., McLamore, E.S., Porterfield, 
D.M., Donkin, S.S., Bequette, B., and Teegarden, D. (2013). Altered glucose 
metabolism in Harvey-ras transformed MCF10A cells. Mol. Carcinog. 
 
Zhu, L., and Bakovic, M. (2012). Breast cancer cells adapt to metabolic stress by 
increasing ethanolamine phospholipid synthesis and 
CTP:ethanolaminephosphate cytidylyltransferase-Pcyt2 activity. Biochem. Cell 










CHAPTER 3 1,25-DIHYDROXYVITAMIN D ALTERS THE EPITHELIAL-TO-
MESENCHYMAL TRANSITION OF  BREAST CANCER METASTASIS TO 
BONE IN MCF10CA1A CELLS 
 
 
Barnard, Alle; Wilmanski, Tomasz; and Teegarden, Dorothy 
Department of Nutrition Science, Purdue University, West Lafayette, IN 47906 
 
700 West State Street 




Key Words: 1,25-dihydroxyvitamin D, Epithelial-to-Mesenchymal transition, E-





 It is known that 1,25-dihydroxyvitamin D (1,25(OH)2D) exerts anti-cancer 
effects on primary breast tumors (Welsh, 2004) but the role of 1,25(OH)2D in 
metastasis has yet to be determined.  The purpose of this study was to 
determine if there was an effect of 1,25(OH)2D on epithelial-to-mesenchymal 
transition (EMT) protein markers and cell viability in MCF10CA1a metastatic 
epithelial breast cancer cells.  To identify the impact of 1,25(OH)2D regulation of 
EMT and metastasis of breast epithelial cells to bone we employed a 
reconstructed metastasis (rMET) model.  Upon 1,25(OH)2D treatment in the 
upper well of the rMET model, which recapitulates the mammary environment, 
mammospheres were visually smaller but not statistically significant upon 
quantification, compared to vehicle treated cells.  Similarly, 3-(4,5-
dimythylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) assays had a non-
significant trend towards a decrease in the amount of viable cells between 
treatments in 3D.  Additionally, the total number of cells to metastasize and 
survive in the bone marrow conditioned media (BMCM) and reconstructed bone 
matrix (rBM) were significantly reduced in the 1,25(OH)2D group versus vehicle.  
To determine the impact of 1,25(OH)2D regulation of  EMT, the mRNA 
abundance of markers of EMT in the upper well was determined.  A significant 




was seen following 48 hours of 10 nM of 1,25(OH)2D treatment compared to 
vehicle in 2D cell culture.  Additionally, mRNA abundance of epithelial-cadherin 
(E-cadherin), which is decreased during EMT, had a trend towards an increase 
while neuronal-cadherin (N-cadherin) was unchanged.  Immunofluorescent 
staining of the upper well mammospheres for E-cadherin, vimentin, perilipin 2 
(PLIN2) proteins, co-stained with neutral lipid stain, Bodipy, and the nuclear stain, 
4',6-diamidino-2-phenylindole (DAPI), were completed.  Although a visual 
difference employing the Zeiss microscope showed little difference between 
treatments, confocal images are being obtained and analyzed by our laboratory 
to more carefully assess the differences in protein expression.  Together, these 
results suggest that 1,25(OH)2D decreases breast to bone metastasis by altering 
viability in the BMCM and rBM as well as alterations in mRNA abundance of 
characteristic EMT protein proteins in metastatic epithelial breast cancer cells, 




          In 2013, it is estimated that 232,340 people will be diagnosed and 39,620 
will die of breast cancer in the United States alone (PDQ Screening and 
Prevention Editorial Board, 2014).  Of those diagnosed with breast cancer, 32% 
will have spread to lymph nodes and another 5% to distant sites with 84.4% and 
24.3% survival rates at five years, respectively.  Compared to a 98.6% survival 




metastasis of the tumor is correlated with increased mortality (Centers for 
Disease Control and Prevention).  While there are several non-modifiable breast 
cancer risk factors such as age, gender, and genetics, it may be possible to 
prevent breast cancer progression and/or metastasis by altering other factors.  
Thus, additional research is needed to determine alternative propositions for 
breast cancer progression and/or metastasis prevention. 
 1,25(OH)2D has support as a chemopreventive agent for breast cancer.  
Epidemiological studies link increased UV exposure, thus vitamin D levels, 
and/or adequate oral vitamin D intake, to a decreased prevalence of breast 
cancer (Garland et al., 2007).  Additionally, there is an association between 
decreased breast cancer prognosis and low serum 25-hydroxyvitamin D 
(25(OH)D), the vitamin D status marker (Kermani et al., 2011; Peterlik et al., 
2009).  Many studies have shown 1,25(OH)2D's inhibitory effects on primary 
breast tumors through reduced angiogenesis and proliferation with increased 
apoptosis of the cancer cells (Hanahan and Weinberg, 2011).  New literature has 
begun to explore the role of 1,25(OH)2D in prevention of breast cancer 
metastasis to the bone. 
 Metastasis initiation is affected by the cells undergoing EMT, invasion 
through the primary tumor environment toward the blood, and the bone 
microenvironment (for those cancers prone to metastasize in the bone, such as 
breast cancer). Epithelial carcinomas that metastasize typically develop 
physiological alterations, a process where epithelial cells become mesenchymal-




profile increases cancer cell invasiveness (Kallergi et al., 2011).  Several proteins 
are associated with EMT with some of the most established being decreased E-
cadherin, and increased vimentin, N-cadherin, and fibronectin. 
 E-cadherin, a transmembrane adhesion glycoprotein has roles in cellular 
migration and adhesion (Buda and Pignatelli, 2011).  E-cadherin loss is well 
documented in breast cancer and causes loss of epithelial cells apical-basal 
polarity and cellular adhesion, characteristics of the EMT transition.  Specifically, 
its' down regulation leads to decreased cell adhesion which decreases the 
integrity of breast epithelial cell morphology to become more mesenchymal-like 
morphology (Taylor et al., 2011; Wendt et al., 2011).  E-cadherin has been 
shown to be increased by 1,25(OH)2D (van Roy and Berx, 2008).  Treatment 
with 1,25(OH)2D caused a time (12-72 hours of 100 nM) and dose dependent 1-
100 nM for 72 hours) increase of E-cadherin expression,  which decreased 
metastatic ability in MDA-MB-231 breast cancer cells (Lopes et al., 2012). 
 Vimentin, an intermediate filament protein, plays an important role in 
maintaining cell shape, communication, organization, and migration (Davies and 
Samuels, 2010).  Studies show increased vimentin expression is linked to 
increased cancer cell motility (Chu et al., 1993, 1996; Hendrix et al., 1997) and is 
a poor prognostic factor in breast carcinomas (Battula et al., 2012; Caruso and 
Stemmer, 2011; Kallergi et al., 2011).  Currently there are no studies 





 N-cadherin, a calcium-dependent, transmembrane, adhesion glycoprotein, 
has a role in cell adhesion and neuronal development.  In breast cancer EMT, N-
cadherin expression is increased co-currently with decreased E-cadherin 
expression (Hazan et al., 1997; Sigurdsson et al., 2011).  Tumor aggressiveness 
and metastatic potential was associated with N-cadherin in invasive breast 
cancer biopsies (Nagi et al., 2005).  Additionally, high N-cadherin expression was 
significantly associated with triple negative breast cancer patients who also had 
metastasis compared to those that did not (Nakagawa et al., 2011). Currently, 
only one study investigated the role of 1,25(OH)2D regulation of N-cadherin 
expression.  Treatment with 100 nM of 1,25(OH)2D for 24, 48, 72, and 96 hours 
resulted in a significant decrease in N-cadherin protein expression (Pendás-
Franco et al., 2007).   
 Fibronectin is involved in a host of functions, two of which include cell 
adhesion and metastasis (Pankov and Yamada, 2002).  Fibronectin has long 
been positively associated with EMT in cancer (Ignotz and Massagué, 1986) and 
is also associated with tumor aggressiveness (Bae et al., 2013).  Additionally, 
increased tumor expression of fibronectin is linked to poor patient prognosis and 
a tumor size >10 mm (Bae et al., 2013; Gorczyca et al., 1993; Ioachim et al., 
2002).  Unfortunately, no literature exists examining the role of 1,25(OH)2D in 
regulation of fibronectin expression in breast cancer. 
 Thus, it is likely the combination of decreased E-cadherin, and increased 
N-cadherin, fibronectin, and vimentin, lead to increased breast cancer metastasis.  




cadherin expression, likely decreasing EMT potential, and therefore metastasis 
initiation (Lopes et al., 2012; Pacini et al., 2012).  Weak or no literature exists on 
the role of 1,25(OH)2D in regulation of vimentin and fibronectin expression.   
 The effects of 1,25(OH)2D regulation of E-cadherin, N-cadherin, vimentin, 
and fibronectin has not been well researched in models of breast carcinogenesis 
and metastasis.  In the current study, metastatic breast epithelial cells were 
utilized as a model of carcinogenesis and metastasis to examine the function of 
1,25(OH)2D in regulation of E-cadherin, N-cadherin, vimentin, and fibronectin.  
The hypothesis of this study is that 1,25(OH)2D inhibits metastasis and increases 
E-cadherin, while simultaneously decreasing N-cadherin, vimentin, and 
fibronectin in metastatic epithelial breast cancer cells.  These results will 
contribute to understanding how 1,25(OH)2D acts on the breast tissue throughout 
cancer, specifically during EMT. 
 
 
3.3. Materials and Methods 
3.3.1. Chemicals & Reagents 
 1,25(OH)2D was purchased from Biomol (Plymouth Meeting, PA).  
Penicillin/streptomycin, RPMI 1640, Alexa-488, Alexa-680, DAPI, Triton-X, fetal 
bovine serum, L-glutamine, and the Viability Live/Dead kit for mammalian cells 
were from Life Technologies, Gibco-BRL (Grand Island, NY). Vectashield was 
purchased from Vector Laboratories Incorporated (Burlingame, PA).  HEPES, 




chloride, and Puromycin were from Sigma-Aldrich (St. Louis, MO).  Matrigel, 0.8 
micron transmembrane inserts, Rat tail collagen 1, Cell Recovery Solution,  were 
purchased from BD Biosciences (San Jose, CA).  Bodipy lipid droplet stain was a 
gift from Dr. Kim Buhman, Nutrition Science, Purdue University.  Tri-Reagent was 
purchased from Molecular Research Center, Inc. (Cincinnatti, OH).  Primary anti-
mouse antibodies for E-cadherin and VIM were purchased from Cell Signaling 
Technologies (Beverly, MA).  PLIN2 primary anti-mouse antibody was purchased 
from Abcam (Cambridge, MA). Dimethyl sulfoxide (DMSO) was purchased from 
Avanto Performance Materials (Center Valley, PA).  Saponin, bovine serum 
albumin, and Fibronectin were purchased from EMD Milipore (Billerica, MA).  
Reagent A and B for BCA were purchased from Thermo Scientific (Rockford, IL).  
ROX dye and SYBR Green Brilliant II and III were purchased from Agilent 
Technologies (Santa Clara, CA).  Rnasin, Random Primers, Oligo DT, XTP 
Random Nucleotide Mix, MMLVRT, and M-MLVRT 5x Buffer were purchased 
from Promega (Madison, WI).  10% Neutral Buffered Formalin (NBF) was 
purchased from VWR International (Radnor, PA). Aqua-Hold II Pap Pen was 
purchased from Scientific Device Laboratory (Des Plaines, IL). 
 
3.3.2. Cell Culture 
 MCF10CA1a and MCF10CA1a-GFP were gifts from Dr. Julia Kirshner, 
Biological Sciences, Purdue University.  Both cell lines were cultured in 
DMEM/F12 (1:1) supplemented with 5% horse serum and 1% penicillin-




maintained in linear (2D) growth and frozen back in 85% supplemented media, 5% 
DMSO and 10% heat-inactivated fetal bovine serum (HI-FBS).  When using the 
MCF10CA1a-GFP cells, two to three Puromycin treatments (2-5 µg/mL) were 
given prior to plating in order to eliminate cells without the GFP present.  
1,25(OH)2D was given to cells in 100% sterile ethanol with a final concentration 
less than 1%. 
 Fetal mesenchymal stem cells (FnMSC), were a gift from Dr. Julia 
Kirshner, Purdue University, who received them originally from Dr. Caroletta 
Glackin, Beckman Research Institute and City of Hope National Medical Center 
(Gutova et al., 2008).  FnMSC cells were cultured in alpha-MEM supplemented 
with 10% FBS, 1% penicillin-streptomycin, and 1% L-glutamine.  Cells were 
maintained in linear (2D) growth and frozen back in a 9:1 ratio of FBS:DMSO. 
 
3.3.3. Real Time-Polymerase Chain Reaction (RT-PCR) 
 MCF10CA1a cells were treated with either vehicle (100% ethanol) or 10 
nM of 1,25(OH)2D for 48 hours replated and treated for an additional 96 hours, 
prior to harvest.  RNA was harvested and isolated using TriReagent following the 
manufacturer's instructions.  The total isolated RNA was reverse transcribed 
using a reverse transcription mixture: Rnasin, Random Primers, Oligo DT, XTP 
Random Nucleotide Mix, MMLVRT, and M-MLVRT 5x Buffer.  After this, the 
cDNA was quantified and real-time PCR was completed with Brilliant III SYBR 
Green QPCR Master Mix.  The abundance of the mRNA of interest was 




abundance.  Results were expressed as arbitrary units and were considered 
significant if P<0.05. Primers utilized were purchased from Integrated DNA 
Technologies (Coralville, IA) :  
-18S 
 Forward: 5'-TTAGAGTGTTCAAAGCAGGCCCGA-3' 
 Reverse: 5'-TCTTGGCAAATGCTTTCGCTCTGG-3' 
-E-Cadherin: 
 Forward: 5'-GAAGAGAGACTGGGTTATTC-3' 
 Reverse: 5'-GTGAGAGAAGAGAGTGTATG-3' 
-Fibronectin: 
 Forward: 5'-GGAGATTCATGGGAGAAGTATG-3' 
 Reverse: 5'-GACCACTTGAGCTTGGATAG-3' 
-N-Cadherin: 
 Forward: 5'- CATCATCATCCTGCTTATCC-3' 
 Reverse: 5'-ATAGTCCTGGTCTTCTTCTC-3' 
-Vimentin: 
 Forward: 5'-CTCGTCACCTTCGTGAATAC-3' 
 Reverse: 5'-CGTTGATAACCTGTCCATCTC-3' 
 
 
3.3.4. 3D Reconstructed Metastatic Model (Figure 7) 
 MCF10CA1a or MCF10CA1a-GFP cells were cultured in media described 
above in triplicate 60mm dishes and were treated with either vehicle or 10 nM 
1,25(OH)2D for 48 hours.  MCF10CA1a-GFP cells were not used during any 
experiments containing fluorescent staining.  Twenty-four hours after the last 
treatment, cells were harvested and plating density was calculated by trypan blue 
for culture in 24-well plate 8µm transmembrane inserts.  rMET set up begins with 
the reconstructed bone, which consist of two solid layers: reconstructed 
endosteum (rEND) and rBM without hyaluronic acid.  rEND components include 
5.32 parts of fibronectin (1 mg/mL), 1 part rat tail collagen type I (2 mg/mL, 




rEND was coated on the bottom of each 24-well plate and incubated at 37oC with 
5% CO2 and humidity for one hour.  rBM components include 3.72 parts of 
Matrigel, 2.43 parts of Fibronectin (1 mg/mL), and 1 part rat tail collagen I (2 
mg/mL diluted via 100 mM HEPES in sterile 1x PBS).  rBM was evenly layered 
on top of the rEND and again incubated at 37oC with 5% CO2 and humidity for 
one hour.  Cells were plated at 50,000 cells/insert within Matrigel in the 8 µm 
transmembrane inserts and incubated at 37oC in 5% CO2 and humidity for 30-45 
minutes.  Transwells were placed into wells containing the reconstructed bone 
and the bottom well was filled with 1 mL/well of 80% bone marrow growth media 
(BMGM) and 20% bone marrow conditioned media (BMCM).  BMGM has a base 
of RPMI 1640 and contains 20% FBS, 1% penicillin-streptomycin, 10-6 M dilution 
of sodium succinate and hydrocortisone, and a 6.2 x 10-4 M dilution of calcium 
chloride.  The BMCM was acquired by seeding the FnMSC cells at a 1.8 x 106 
density in a T-75 flask with 10 mL of BMGM.  On day two, the cells were 80-90% 
confluent and the media was aspirated, cells were rinsed once with sterile 
calcium magnesium free-PBS (CMF-PBS), and 15 mL of fresh BMGM was 
added to the flask.  On day four, the media was collected into conical tubes, 
centrifuged to remove cells and debris, and sterile filtered through a 0.2 µm filter, 
thus creating BMCM.  If not immediately used, BMCM was frozen in -80oC.  
FnMSC cells used for BMCM creation are then discarded.  The transwell 
containing the MCF10CA1a/MCF10CA1a-GFP cells received 500 µl/insert of 
mammary epithelial growth media (MEGM).  MEGM consists of RPMI 1640 with 




37oC in humidity and 5% CO2 and treatments of either vehicle (100% ethanol) or 
10 nM of 1,25(OH)2D were given every 24 hours for seven days, if treatment was 
longer, 50:50 BMCM media change occurred on day eight.  Cells were imaged 
every two to three days using Axiovision 4.8.2 SP software for the Zeiss 
microscope.   
 Twenty-four hours after the last treatment, the MEGM media on the 
transmembrane inserts was aspirated and cells were washed once with PBS.  
Cell Recovery Solution (62 µl,CRS) was added to each transmembrane and 
incubated for 10 minutes at room temperature.  The solution was transferred into 
tubes and an additional 93 µl of CRS was added to each tube and the mix was 
incubated for another hour and 45 minutes in 4oC.  After incubation, the cell 
samples were centrifuged, supernatant was aspirated, and cells were 
resuspended in a low volume of sterile PBS.  Cells were immunofluorescently 
stained on slides.  
 BMGM/BMCM media that was in the wells containing reconstructed bone 
was aspirated, centrifuged, and live versus dead cells were manually counted 
with trypan blue.  Cells that had migrated from the Matrigel layer in the 
transmembrane insert into the layers of the reconstructed bone were either 
photographed or stained for viability or immunoflluorescence.   
 
3.3.5. Mammosphere Diameter Measurements 
 On the day of harvest, the upper well was imaged at 20x magnification in 




software on the Zeiss microscope provided a scale of 100 μm which was used to 
manually measure the center-most mammosphere of each image to the closest 
whole number.  Mammosphere sizes were averaged per treatment group and 










































3.3.6. Live/Dead Viability Assay for Mammalian Cells 
 Cells stained for viability were those that had migrated from the upper well  
(reconstructed breast) and had burrowed into the rBM in the wells of the 24-well 
plates.  After the BMCM media was removed, cells were quickly washed once 
with 1x PBS.  Live stain, Calceinin AM (CAM), and dead stain, Ethidium 
homodimer-1 (EthD-1), were diluted to 2 µM and 4 µM in 1x PBS, respectively 
and added to each well.  The plate was covered and incubated for 35 minutes in 
the dark at 37oC.  Immediately after the incubation, the stains were quantified 
using a microplate reader (Synergy H1 Hybrid Reader, Biotek Instruments Inc, 
Winooski, VT) and the cells were immediately imaged using Axiovision 4.8.2 SP 
on the Zeiss microscope. 
 
3.3.7. Immunofluorescent Staining 
 Immunofluorescent staining was completed in both the harvested 
transwell breast mammospheres, spotted on slides, and the intact reconstructed 
bone in the well.  Protocol for intact staining was completed within the well, and 
the protocol for harvested cells was in tubes or on glass slides as indicated.   
 For cells harvested from upper well (reconstructed breast), cells were 
rinsed twice with PBS and if in tubes; centrifuged between each wash.  Cells 
were fixed using 10% neutral buffered formalin for 15 minutes at room 
temperature, and if in tubes, they were centrifuged after incubation.  Neutral 
buffered formalin was removed and cells were washed twice with PBS in the 




plates that were outlined with a Aqua-Hold II Pap pen to prevent spills over the 
sides of the slide.  All samples were permeabilized; E-cadherin and vimentin 
samples were permeabilized with 0.1% Triton-X in PBS; PLIN2 and Bodipy 
samples were permeabilized with 0.1% Saponin in PBS, for 10 minutes at room 
temperature. Samples were blocked over night using 1% BSA in PBS in the dark 
with humidity at 4oC.  The next day (day two), the blocking solution was removed, 
samples were washed three times with PBS,  and primary antibodies were added 
with only one antibody per sample.  Antibodies used were E-cadherin (1:200), 
vimentin (1:50), and PLIN2 (1:50).  All antibodies were in 1% BSA-PBS solution 
and incubated with the samples overnight in the dark with humidity at 4oC.  
Primary antibodies were removed the following day (day 3) and samples were 
washed three times with PBS.  Secondary antibodies, Alexa-488 (1:500) and 
Alexa-680 (1:500) were added one per sample for one hour at room temperature, 
in the dark.  Simultaneously, samples being tested for PLIN2 were incubated with 
lipid droplet stain, Bodipy (10 µg/mL), along with secondary antibody Alexa-680 
(1:500).  Dependent on the combination of staining  necessary, the combination 
of Alexa dyes altered per experiment.  Typically,  Alexa-488 was utilized for E-
cad and Alexa-680 was utilized for vimentin; but if co-staining with Bodipy, Alexa-
680 had to be utilized for E-cad so they were contrasting colors.  After the 
incubation time, the secondary antibodies and Bodipy were removed, samples 
were washed twice with PBS, and the nuclear stain, DAPI (1:25) was added to 
every sample for 8-10 minutes at room temperature in the dark.  After the 




and one drop of Vectashield was added, and a coverslip was placed on top.  
Samples were imaged immediately after (<24 hours) using Axiovision 4.8.2 SP 
and stored in the dark at 4oC when not in use.  
 
3.3.8. 3-(4,5-dimythylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide Assay (MTT) 
 MCF10CA1a cells were cultured in the rMET model as described above in 
a 24-well plate and were treated with either vehicle or 10 nM 1,25(OH)2D.  
Twenty-four hours after the last treatment, the media was aspirated and a 0.5 
mg/mL MTT working mix was added to each transwell and incubated in the dark 
for 2 hours at 37oC.  After incubation, cells were harvested out the Matrigel using 
CRS as previously described.  DMSO was added and thoroughly mixed in each 
well, the plate was incubated in the dark for 5 minutes at 37oC.  The plate was 
tapped to assist in dissolving the solutes and the solution was aliquoted in 
duplicate into a 96-well plate and quantified at 570 nm with a 700 nm reference 
wavelength via spectrophotometer (Powerwave, Biotek Instruments Inc., 
Winooski, VT).   
 
3.3.9. Statistical Analysis 
 Values presented are means ± SEM.  T-tests and ANOVA were performed 






 In order to determine if 1,25(OH)2D alters E-cadherin, N-cadherin, 
vimentin, and fibronectin mRNA abundance in MCF10CA1a cells, cells were 
treated with vehicle or 10 nM of 1,25(OH)2D and mRNA abundance determined.  
mRNA abundance showed that E-cadherin had an trend towards an increase 
(P=0.09) (Figure 8A), N-cadherin was unchanged (P=0.31) (Figure 8B), and 
vimentin (P=0.001) (Figure 8C) and fibronectin (P=0.0001) (Figure 8D) were 
significantly increased by 1,25(OH)2D compared to vehicle after 48 hour pre-























































































































Figure 2. mRNA abundance of vehicle and 1,25(OH)2D treated MCF10CA1a 
cells.  All cells were treated for 48 hours, harvested, replated and treated for an 
additional 96 hours with either vehicle or 1,25(OH)2D (10 nM).  A representative 
quantification of the mRNA abundance is shown for each protein, indicated with 
vehicle (open bars) and 1,25(OH)2D treatment (black bars).  Values are 
expressed as mRNA of interest, relative to 18S mRNA for each sample, relative 
to vehicle control.  Results are expressed as mean ± SEM. (n ≥ 3). Statistical 
significance was defined as *P < 0.05.  8A. E-cadherin; 8B. N-cadherin; 8C. 










In order to determine the role of 1,25(OH)2D in the metastatic cell invasion 
and viability, the in vitro rMET model was utilized.  No change in mammosphere 
size in the reconstructed breast portion of the 1,25(OH)2D treated cells within the 
transwell was noted compared to vehicle (Figure 9A and 9B).  Similarly, a non-
significant trend towards a decreases was present in the 1,25(OH)2D treated 
samples assessed through by MTT (P=0.001) (Figure 10).   Furthermore, there 
was a significant decrease in the number of live cells and number of dead cells in 
the BMCM of the 1,25(OH)2D treated wells compared to vehicle according to 
trypan blue exclusion counts (P=0.004) (Figure 11).  Microplate reading of the 
rBM live/dead viability stains showed a significant decrease in live cells upon 
1,25(OH)2D treatment (Figure 12).  Additionally, a significant decrease was seen 
in the dead cells compared to the live cells, though there was no difference in the 

































Figure 9. Representative figures of mammosphere sizes in the reconstructed 
breast matrix (upper well) of the 3D model.  All cells were treated for 48 hours in 
2D prior to replating in 3D for 7 days with either vehicle of 1,25(OH)2D (10 nM) 
treatment.  Representative images are shown (9A) and values are expressed as 
average µm diameter of treated mammospheres relative to the average µm 
diameter of vehicle control mammospheres (9B).  Results are expressed as 
mean ± SEM. (n≥3).  Images are 20x magnification with 5ms of exposure with a 
brightfield filter. 
 






























































Figure 10. MTT assay of vehicle and 1,25(OH)2D treated MCF10CA1a cells from 
upper well (reconstructed breast) of the rMET model.  All cells were treated for 
48 hours in 2D prior to plating in 3D for 7 days with either vehicle of 1,25(OH)2D 
(10 nM).  A representative quantification of the MTT assay is shown, indicated 
with vehicle (open bars) and 1,25(OH)2D treatment (black bars).  Values are 
expressed as average cell number of each sample relative to vehicle control.  































Figure 11. Trypan blue exclusion quantifications of live versus dead MCF10CA1a 
cells in the BMCM of the 3D model.  All cells were treated for 48 hours in 2D prior 
to plating in 3D for 7 days with either vehicle of 1,25(OH)2D (10 nM) treatments.  
After harvest, BMCM was centrifuged, supernatant removed, and pellet was 
resuspended in 7-10 µl of PBS.  Quantifications shown are indicated with vehicle 
(open bars) and 1,25(OH)2D treatment (black bars).  Values are expressed as 
absolute average cell counts.  Results are expressed as mean ± SEM. (n≥3). 






























































Figure 12. Quantified fluorescence of live versus dead metastasized 
MCF10CA1a cells in the rBM of the 3D model treated with vehicle or 1,25(OH)2D.  
All cells were treated for 48 hours in 2D prior to plating in 3D for 7 days with 
either vehicle of 1,25(OH)2D (10 nM) treatments.  At day 7 of the 3D model, the 
rBM was washed and stained with 2 µM calcein AM (live) and 4 µM Ethidium 
homodimer-1 (dead). A representative quantification of the microplate values are 
shown, indicated with vehicle (open bars) and 1,25(OH)2D (black bars).  Values 
are expressed as absolute average of treatment groups. Results are expressed 














































In order to determine the role of 1,25(OH)2D regulation on the expression 
of E-cadherin, vimentin, and PLIN2 protein in metastasis, the rMET model was 
again utilized. The upper reconstructed breast portion and the rBM cells were all 
immunostained to show their protein expression as well as DAPI for nuclear 
location and Bodipy for neutral lipid droplet location.  No visual differences in E-
cadherin (Figure 13), vimentin (Figure 14), and lipid droplets or PLIN2 (Figure 15) 





















Figure 1. Immunofluorescent staining of the upper reconstructed breast portion 
and rBM for E-cadherin.  Blue staining is DAPI, representing the nucleus.  E-
cadherin is the green stain (Alexa-488).  The representative images of the 
reconstructed breast portion are 20x magnification, and the rBM images are 10x 














Figure 14. Immunofluorescent staining of the upper reconstructed breast portion 
and rBM for vimentin.  Blue staining is DAPI, representing the nucleus.  Vimentin 
is the pink-red stain (Alexa-680).  The representative images of the reconstructed 
breast portion are 20x magnification, and the rBM images are 10x magnification; 









Figure 15. Immunofluorescent staining of the upper reconstructed breast portion 
and rBM for lipid droplets and PLIN2.  Blue staining is DAPI, representing the 
nucleus.  Lipid droplets are green (Bodipy) and PLIN2 is the pink-red stain 
(Alexa-680).  The representative images of the reconstructed breast portion are 














 In the current study, the effect of 1,25(OH)2D treatment on breast to bone 
cancer metastasis in vitro was explored in MCF10CA1a metastatic breast 
epithelial cells in a rMET model.  The results determined that 1,25(OH)2D had no 
significant impact in regulating the mammosphere diameter (Figures 3A and 3B) 
and 1,25(OH)2D caused a trend towards a decrease in the viability of the cells 
within the reconstructed breast compartment after 48 hours of 10 nM 1,25(OH)2D 
2D pre-treatment and subsequent 3D treatment for seven days.  These results 
do not strongly confirm 1,25(OH)2D's role in inhibiting proliferation and/or 
inducing apoptosis within breast cancer as previously established (García-Quiroz 
et al., 2013; Simboli-Campbell et al., 1996) but may upon replication of the 
experiment.   
 Recent evidence suggests 1,25(OH)2D may play a role in inhibiting 
metastasis of cancer cells.  In the current studies, 1,25(OH)2D not only inhibited 
growth in the reconstructed breast but significantly decreased survival of 
metastatic breast cancer cells in the BMCM and reconstructed bone matrix 
compared to vehicle control after 48 hours of 10 nM 1,25(OH)2D 2D pre-
treatment and subsequent 3D treatments for seven days in the breast matrix 3D 
component only.  It is probable that the 1,25(OH)2D treated cells that do make it 




signaling, thus inhibiting their ability to implant in the reconstructed bone.  
Furthermore, our results show that even the 1,25(OH)2D treated cells that 
implant in the rBM are significantly fewer than the vehicle control cells.  Together, 
these results suggest that 1,25(OH)2D action causes alterations within the 
primary site(breast) but the effects extend far past the primary location of 
exposure and into distant sites, such as the bone.  This further emphasizes the 
importance of 1,25(OH)2D treatment of the primary tumor to inhibit metastasis.   
 More recently, literature suggests 1,25(OH)2D may inhibit EMT (Tan, 2007; 
Lopes, 2012)(Lopes et al., 2012; Tan et al., 2007), therefore decreasing and/or 
inhibiting metastasis.  Specifically, Lopes and colleagues showed that 100 nM of 
1,25(OH)2D treatment for 72 hours caused a significant increase of E-cadherin 
protein expression in aggressive breast cancer cells (Lopes et al., 2012).  Few 
studies have explored the role of 1,25(OH)2D in regulation of N-cadherin, 
vimentin, and fibronectin, the other important characteristic proteins of EMT.  In 
the current study, 10 nM of 1,25(OH)2D lead to a trend toward an increase of E-
cadherin mRNA abundance compared to vehicle control at 48 hours of 2D pre-
treatment and subsequent 96 hour 2D treatment after re-plating (in order to 
mimic the rMET model) in MCF10CA1a cells.  On the other hand, 1,25(OH)2D 
significantly induced vimentin and fibronectin mRNA abundance but had no effect 
on N-cadherin mRNA abundance compared to vehicle control utilizing the same 
cell line and treatment conditions.  While our E-cadherin results agree with those 
of Lopes (Lopes et al., 2012) and Van Roy (van Roy and Berx, 2008) the 




suggest 1,25(OH)2D inhibition of metastasis is not through regulation of EMT 
alone.  To test the expression of the EMT proteins in the reconstructed bone 
matrix, immunofluorescent staining of E-cadherin, vimentin, and DAPI was 
implemented but significant differences between treatment groups were not seen 
based on visual analysis.  This may be explained by the heterogeneous nature of 
cancerous tumors and the immunostained cells maybe those that are 
1,25(OH)2D resistant and therefore would not show differences in expression.  
Even so, 1,25(OH)2D lead to a  trend towards a decrease in the number of live 
cells in the breast and a significant decrease in the number of live cells in the 
bone components, suggesting 1,25(OH)2D treatment for metastasis inhibition is 
an effective intervention.   
 As stated in chapter 2, increased cancer aggression is associated with 
increased cytoplasmic lipid droplet accumulation (Louie et al., 2013; Swinnen et 
al., 2006), which was confirmed in our studies and was altered by 1,25(OH)2D 
treatment.  Preliminary testing of lipid involvement in metastasis was performed 
via immunofluorescent staining in the rBM with Bodipy, for neutral lipids, and 
perilipin 2 (PLIN2), a lipid droplet associated protein that has a role in regulating 
entrance and exit of triacylglycerides and cholesterol esters from cytoplasmic 
lipid droplets.  Visual assessment did not show any differences between 
treatments in lipid droplet accumulation or PLIN2 protein expression in the rBM.  
However, this could be attributed to the heterogeneous nature of cancerous 
tumors and the immunostained cells may be those that are1,25(OH)2D resistant 








 Overall, the results of the current studies support that 1,25(OH)2D 
decreases breast cancer metastasis in metastatic breast cancer cells.  Further, 
our results reveal a vital role in 1,25(OH)2D treatment at the primary location 
(breast) as inhibition was moderately observed at the breast site as well as the 
distal bone even in the absence of direct 1,25(OH)2D treatment in the bone 
compartment.  Additionally, our results suggest the mechanism of 1,25(OH)2D 
inhibition of metastasis may not be strictly through EMT alterations as 
1,25(OH)2D treatment showed the expected increase in E-cadherin but 
unexpected increases in vimentin and fibronectin as well.  Further, alterations 
were not seen between the treatment groups upon immunofluorescent staining of 
the cells implanted in the rBM suggesting the heterogeneous nature of tumor 
cells may include 1,25(OH)2D resistant cells that successfully metastasize.  Our 
experiments exploring the link between increased lipids and metastatic breast 
cancer did not appear to be effected by 1,25(OH)2D treatment according to 
immunofluorescent staining.  This again supports the theory that 1,25(OH)2D 
resistant cells exist within the MCF10CA1a cell line.  Together these results 
support that 1,25(OH)2D inhibits metastasis but the exact mechanism remains to 
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CHAPTER 4 FUTURE DIRECTIONS 
 
4.1. Summary 
 Vitamin D via sunlight or diet is associated with a decreased risk in breast 
cancer in human epidemiological studies (Garland et al., 2007; Mohr et al., 2014).  
It is well known that the active form of vitamin D, 1,25-dihydroxyvitamin D 
(1,25(OH)2D), can reduce proliferation, inhibit angiogenesis, promote 
differentiation, and promote apoptosis in primary breast tumors via regulation of 
gene expression (García-Quiroz et al., 2013; Mantell et al., 2000; Simboli-
Campbell et al., 1996).  In this thesis, we explored the novel regulation of 
1,25(OH)2D in factors that are essential to breast cancer progression and 
metastasis, including mRNA abundance of several lipid metabolism regulating 
enzymes; and employed a novel 3D reconstructed metastasis model to explore 
the role of 1,25(OH)2D in metastasis from breast to bone in vitro.  
 
4.1.1. Lipid Metabolism 
 A lipogenic phenotype is associated with cancer progression and is 
thought to provide survival and growth advantages (Louie et al., 2013; Swinnen 




to changes in membrane fluidity, ligand-receptor interactions, endocytosis, 
antigen presentation, lipid-lipid/lipid-protein interactions, microdomain formation, 
and second messenger signaling (Emoto and Umeda, 2000; Escribá et al., 2008).  
Specifically in breast cancer, increased fatty acids are associated with a variety 
of pro-breast cancer effects such as decreased survival (Liu et al., 2011), 
increased proliferation (Louie et al., 2013; Rysman et al., 2010), increased 
migration (Antalis et al., 2011), metastasis (Vazquez-Martin et al., 2008), and 
more. 
 Many studies have shown 1,25(OH)2D's inhibitory effects on primary 
breast tumors through reduced angiogenesis and proliferation with increased 
apoptosis of the cancer cells (Hanahan and Weinberg, 2011).  Our own 
laboratory has shown that 1,25(OH)2D can attenuate the Warburg effect in breast 
cancer cells (Zheng et al., 2013), therefore it is possible that 1,25(OH)2D may 
also attenuate the pro-breast cancer lipid metabolism.  For our studies, we used 
a model for multistage carcinogenesis of breast cancer which includes 
untransformed MCF10A cells, Harvey-ras transfected MCF10A-ras cells, 
aggressive MCF10CA1h cells, and metastatic MCF10CA1a cells.   
 The MCF10A cell line series originated from a benign breast tissue biopsy 
from a female with fibrocystic disease whose cells were immortalized (Santner et 
al., 2001).  The immortalized cells that grew as attached cells were labeled, 
MCF10A cells, and are used as a normal breast tissue control in many studies, 
including our own.  The transformed MCF10A-ras line, also called MCF10AneoT, 




represents cancer initiation (Imbalzano et al., 2009).  The MCF10A-ras cells were 
then cycled through immuno-compromised mice via repeated selection for 
progressively more aggressive tumor formation in the xenograft tumors 
(Imbalzano et al., 2009).  The most aggressive cells from organoids were 
immortalized and labeled MCF10CA1h and are a recognized malignant cell line 
representative of malignant breast cancer (Santner et al., 2001).  The most 
aggressive cells from trocar transplantation were immortalized and labeled 
MCF10CA1a and are a recognized malignant cell line representative of 
metastatic breast cancer (Santner et al., 2001).  Since the MCF10A cell line is 
derived from the same genetic background, variation between cell lines is 
decreased thus making it easier to identify genetic differences between the lines, 
potentially allowing for identification of crucial genetic changes that may allow 
cancer development (Santner et al., 2001).  Together, the MCF10A cell line 
series provides a complete spectrum of breast cancer cells from the normal, 
MCF10A, to the fully malignant, metastatic, MCF10CA1a cells. 
 Certain lipid metabolism enzymes were significantly altered upon 
1,25(OH)2D treatment in our studies.  Our RT-PCR results show that 1,25(OH)2D 
did not have significant effects at 24 hours but upon 48 hours of treatment 
several alterations were noted in the metastatic MCF10CA1a line.  There were 
no significant differences between treatment groups of any enzyme tested in the 
MCF10A, MCF10A-ras, and MCF10CA1h cell lines.  However, in the 
MCF10CA1a cell line, after 48 hours of 10 nM of 1,25(OH)2D treatment in 2D, we 




concurrently with a trend towards a decrease in CPT1a, ATGL, and HSL mRNA 
abundance but no effect in SCD1 mRNA abundance.  Together these suggest 
that 1,25(OH)2D may shift lipid metabolism toward storage and may also 
decrease lipolysis through inhibition of lipases and decreasing mitochondrial β-
oxidation.  Additionally, since no effect was seen on SCD1 mRNA abundance 
upon 1,25(OH)2D treatment, the balance of saturated and unsaturated fatty acids 
within a cell may not be significantly altered.   
 We also demonstrated that a lipogenic phenotype was associated with an 
increased aggressiveness in the MCF10A cell line.  Oil red O staining, thin layer 
chromatography (TLC), and triglyceride analysis all demonstrated the greatest 
amount of lipids in the most aggressive cell line (MCF10CA1a).  Lipidomics was 
employed to further explore the regulatory effects of 1,25(OH)2D in specific lipid 
classes in MCF10CA1a cells.  We noted significant increases in some 
phosphotidylinositols's (PIs), phosphotidylcholines (PCs), 
phosphotidylethanolamine's (PEs), and sphingomyelin's with longer than usual, 
long chain fatty acids attached as well as significant decreases in some 
glucosylceramides with long chain fatty acids attached.  This suggests that lipid 
metabolism is shifted toward phospholipid and sphingomyelin synthesis upon 
1,25(OH)2D treatments.   
 Together, we believe this data suggests that 1,25(OH)2D may shift lipid 
metabolism toward storage, decrease β-oxidation, and alter phospholipid 




MCF10CA1a cells to decrease proliferation by sequestering lipids in storage and 
altering survival signaling by shifting phospholipid synthesis.  
 
4.1.2. Metastasis 
 Breast cancer metastasis significantly decreases patient survival rate 
compared to non-metastatic breast cancer patients, thus it is important to identify 
measures that prevent metastasis (Centers for Disease Control and Prevention).  
1,25(OH)2D has established inhibitory effects on primary breast tumors and new 
literature suggests 1,25(OH)2D may also have a role in preventing breast cancer 
metastasis to the bone through inhibition of the epithelial-to-mesenchymal 
transition (EMT) (Hanahan and Weinberg, 2011).  Several proteins are 
associated with the EMT pathway with some of the most established markers 
being epithelial-cadherin (E-cadherin), neuronal-cadherin (N-cadherin), 
fibronectin, and vimentin.  E-cadherin is found mainly in epithelial cells and 
interacts with cytoskeleton actin and thus has a role in regulating cellular 
differentiation, growth, migration, and adhesion (Buda and Pignatelli, 2011).  
Loss of E-cadherin causes loss of epithelial cells apical-basal polarity and cellular 
adhesion, characteristics of the EMT transition.  E-cadherin loss is also well 
documented in breast cancer and mutations in its coding gene, CDH1, increase 
breast cancer risk up to 50% (Schrader et al., 2008).  N-cadherin functions 
include establishment of left-right asymmetry, early embryo development, 
nervous system synapse function, and cell-cell adhesion.  In breast cancer EMT, 




tumor aggressiveness and metastatic potential (Hazan et al., 1997; Kim et al., 
2000; Sigurdsson et al., 2011; Suyama et al., 2002).  Fibronectin is involved in a 
host of functions such as wound healing, blood coagulation, immunity, embryo 
development, cell adhesion, and metastasis (Pankov and Yamada, 2002).  
Fibronectin has long been known as a marker for EMT (Ignotz and Massagué, 
1986) and is also associated with tumor aggressiveness (Bae et al., 2013), poor 
patient prognosis, and a tumor size > 10mm (Bae et al., 2013; Gorczyca et al., 
1993; Ioachim et al., 2002).  Vimentin plays an important role in maintaining cell 
shape, cytoskeleton communication, organization, and migration and is 
predominately expressed during embryogenesis (Dave and Bayless, 2014).  In 
breast cancer EMT, vimentin is significantly increased and is associated with 
increased cancer cell motility and poor patient prognosis (Battula et al., 2012; 
Caruso and Stemmer, 2011; Chu et al., 1993, 1996; Hendrix et al., 1997; Kallergi 
et al., 2011).  We hypothesized that 1,25(OH)2D increases E-cadherin, 
decreases N-cadherin, vimentin, fibronectin and decreases the number of cells 
able to successfully metastasize and survive into the reconstructed bone matrix. 
 To test our hypotheses, the effect of 1,25(OH)2D treatment on breast to 
bone cancer metastasis in vitro was explored in MCF10CA1a metastatic breast 
epithelial cells in a 3D reconstructed metastasis model.  After 48-hour 2D pre-
treatment and 7 day 3D treatment of 1,25(OH)2D there was a trend towards a 
decrease in the number of viable cells in the reconstructed breast matrix, and a 
significant decrease in the number of live cells in the bone marrow conditioned 




treated group compared to vehicle.  These results confirm 1,25(OH)2D's role in 
inhibiting proliferation and/or inducing apoptosis within breast cancer as 
previously established (García-Quiroz et al., 2013; Simboli-Campbell et al., 1996).  
Additionally, our results show that 1,25(OH)2D significantly decreases the 
amount of cells that survive metastasis to the bone, suggesting that 1,25(OH)2D 
action causes alterations within the primary site (breast) but the effect extends 
into distant sites such as the bone.  Furthermore, the expected mesenchymal 
phenotype was not seen in the rBM of the 1,25(OH)2D treated cells, suggesting 
the EMT may be altered. 
 Due to the phenotypical alterations seen in the rBM, we examined the 
effect of 1,25(OH)2D regulation of characteristic EMT proteins' (E-cadherin, N-
cadherin, vimentin, fibronectin) mRNA abundance.  Forty-eight hours of 
1,25(OH)2D treatment lead to a trend towards an increase in E-cadherin mRNA 
abundance, a significant increase in vimentin and fibronectin mRNA abundance, 
and no change in N-cadherin mRNA abundance compared to vehicle. While our 
E-cadherin results agree with those by Lopes (Lopes et al., 2012) and Van Roy 
(van Roy and Berx, 2008), the concurrent results of increased vimentin, 
fibronectin and unaltered N-cadherin suggest 1,25(OH)2D inhibition of metastasis 
may not be through regulation of EMT alone.  We additionally completed 
immunofluorescent staining of EMT factors, E-cadherin and vimentin, and to test 
potential alterations in lipid accumulation we also stained for perilipin 2 (PLIN2) 
and cytoplasmic lipid droplets of the successfully metastasized cells in the 




These results are currently being analyzed to determine significant differences 
but visual analysis did not show any alterations.  While this is likely due to the 
heterogeneous nature of cancerous tumors, a significant reduction in cells that 
survived metastasis was seen upon 1,25(OH)2D treatment.  Taken together with 
the altered characteristic EMT associated proteins' mRNA abundance, it is clear 
that 1,25(OH)2D has an inhibitory role of breast to bone cancer metastasis.  
 
 
4.2. Future Directions 
 We expected that 1,25(OH)2D would either decrease lipid metabolism or 
sequesters the lipids, therefore decreasing cell viability and proliferation in 
tumorigenic breast cells.  Our data demonstrated that 48 hours of 1,25(OH)2D 
(10 nM) treatment in 2D culture induced mRNA abundance of enzymes 
associated with lipid storage while decreased mRNA abundance in lipolytic 
enzymes and decreased CPT1a mRNA abundance which may reduce entry into 
the β-oxidation pathway in the metastatic MCF10CA1a cells.  It is possible that 
the reason we did not observe significant differences in the other tumorigenic cell 
lines, MCF10A-ras and MCF10CA1h, was due to needing a longer treatment 
time and/or higher dose to elicit the effect seen in the MCF10CA1a.  Additionally, 
the metabolism and transcriptional control may be less regulated in the 
MCF10CA1a cells compared to less metastatic cells, and the 10 nM treatment for 
48 hours was sufficient to alter the transcriptional regulation of some lipid 




PLIN2, HSL, ATGL, ACAT1, SCD1, and Insig2) with either longer treatment 
times and/or higher doses with 1,25(OH)2D would help address this question.   
 Since our results suggest that 1,25(OH)2D may shift lipid metabolism 
toward storage and decrease lipid availability via decreased lipase transcription 
and entry into the mitochondria for β-oxidation, it would be beneficial to measure 
these endpoints.  Radio-labeling exogenous lipids and following them throughout 
both vehicle and 1,25(OH)2D treated cells may help identify where shifts in lipid 
metabolism occur.  In the case that exogenous lipid uptake is not altered, 
quantification of oil red O staining and/or immunofluorescent 
staining/quantification of cytoplasmic lipid droplets and rate-limiting lipid 
metabolism enzymes should be tested, respectively, to see if other intracellular 
lipid pathways are altered.  Additionally, measuring break down of oleate into 
carbon dioxide, using radioisotopes, could answer the question of the impact of 
decreased CPT1a on β-oxidation upon 1,25(OH)2D treatment.   
 Moreover, our lipidomics results indicate that phospholipids with long 
chain fatty acids were significantly increased while glucosylceramides with long 
chain fatty acids were significantly decreased in 1,25(OH)2D treated 
MCF10CA1a cells.  This indicates that both cell membrane permeability and 
intracellular signaling may be altered in 1,25(OH)2D treated cells.  To test if the 
cell membrane permeability is altered, fluorescein diacetate, which freely enters 
the cells, and ethidium homodimer-1, which is excluded from the cell, could be 
employed with flow cytometry to see if there are shifts between the vehicle and 




greater interest to test the specific enzymes involved in synthesis of PIs, PCs, 
PEs, sphingomyelin's, and glucosylceramide's with long chain fatty acids to 
determine how 1,25(OH)2D may regulate these pathways.  More research is 
necessary to determine the mechanisms by which 1,25(OH)2D alters lipid 
metabolism in breast cancer.  This information will assist in the development of 
targeted strategies for cancer prevention and prevention of metastasis, which will 
lead to an increased patient survival rate and reduce the incidence of breast 
cancer. 
 When exploring the effects of 1,25(OH)2D regulation on metastasis, we 
expected 1,25(OH)2D to increase E-cadherin while simultaneously decreasing N-
cadherin, vimentin, and fibronectin via transcriptional regulation in metastatic 
MCF10CA1a cells.  However, our data demonstrated that 1,25(OH)2D induced a 
significant trend towards an increase in E-cadherin, a significant increase in 
vimentin, and fibronectin, and had no effect on N-cadherin mRNA abundance.  
To our knowledge, no research is published on the effects of 1,25(OH)2D 
regulation of vimentin and fibronectin.  Our results do not agree with Pendas-
Franco et al. as they have showed 1,25(OH)2D to significantly decrease N-
cadherin expression (Pendás-Franco et al., 2007).  It is possible that this is due 
to the high concentration (100 nM) of 1,25(OH)2D compared to ours (10 nM), 
despite their treatment duration being shorter.  Our results show a trend towards 
an increase in E-cadherin upon 1,25(OH)2D treatment which agrees with Van 
Roy et al. and Lopes et al. who show similar effects in other aggressive breast 




determine how 1,25(OH)2D regulates EMT proteins and their impact on inhibiting 
metastasis, western blots with and without transcriptional or translational 
inhibitors should be performed.    
 While exploring the effects of 1,25(OH)2D regulation of metastasis, we 
further expected 1,25(OH)2D to inhibit the amount of cells able to successfully 
metastasize from breast to bone.  We utilized a novel 3D reconstructed 
metastasis model to test our hypothesis and defined successful metastasis as a 
viable cell that has transferred from the reconstructed breast matrix down to the 
rBM, embedded, and has continued to survive there.  Our data agrees with our 
hypothesis as 1,25(OH)2D treatment significantly decreased the number of cells 
in the reconstructed breast matrix, and the number of live cells in the BMCM and 
the rBM.  Quantified characterization of the MCF10CA1a cells in the 
reconstructed breast portion as well as those on the underside of the membrane 
(invasive phase), in the surviving cells in the BMCM, and those surviving in the 
rBM, should be completed and compared between vehicle and 1,25(OH)2D 
treated groups.  It is likely that cells in the reconstructed breast matrix will have 
different protein characterization between groups, with the 1,25(OH)2D cells 
having a less aggressive phenotype.  However, I hypothesize that the cell 
characterization between groups becomes more similar as metastatic steps 
continue; i.e. surviving cells in the rBM of both groups may have more similar 
characteristics due to both of their abilities to successfully metastasize and 




vimentin and/or fibronectin cells with and without 1,25(OH)2D treatment could 
help identify the 1,25(OH)2D mechanism of action in metastasis inhibition. 
 This being said, we did observe significant differences in the phenotype of 
cells surviving in the rBM with an absence of mesenchymal-like phenotype in the 
1,25(OH)2D treated cells.  Therefore, characterization may not be identical 
between groups and thus additional studies in animals should be completed.  
Using a xenograft mouse model with MCF10CA1a cells treated with vehicle or 
1,25(OH)2D from the 3D reconstructed metastasis model we could measure 
bone tumor latency, number, size, histochemical grade, and overall survival.  
Those results may provide insight into 1,25(OH)2D's mechanism of action in 
metastatic inhibition, thus potential clinical implications.    
 Several future studies could lead to a link between 1,25(OH)2D's ability to 
alter lipid metabolism and its' ability to inhibit and alter metastatic ability of 
MCF10CA1a cells in vitro.  A lipid panel of both vehicle and 1,25(OH)2D treated 
MCF10CA1a cells from each stage of the 3D reconstructed metastasis model 
may reveal significant alterations between groups and thus a potential 
mechanism.  If this is true, inhibitors of the specific lipid metabolizing enzymes of 
interest could be introduced into the 3D model and a comparison of metastasis in 
the cells between 1,25(OH)2D and vehicle treated cells.  Eventually, the same 
study could be repeated but with xenografts of the 3D grown and treated 
MCF10CA1a cells into immuno-compromised mice and lipid panels, inhibitors, 




knowledge, no studies have linked 1,25(OH)2D to altering lipid metabolism and 
thus metastasis of breast cancer in any experimental model. 
 Breast cancer is associated with a variety of both non-modifiable and 
modifiable risk factors.  The modifiable risk factors can be altered via a healthy 
diet and exercise regimen.  Research suggests and supports vitamin D as a 
potential breast cancer preventative agent.  However, little or no data is available 
on 1,25(OH)2D's mechanism of action in altering lipid metabolism and inhibition 
of metastasis and/or their interaction.  Our research contributes to filling this gap 
in the literature and our results support that vitamin D acts on metastatic 
mammary epithelial cells.  Specifically, our results support that 1,25(OH)2D may 
shift lipid metabolism toward storage and inhibit lipolysis, which may be part of 
the mechanism of our other observation, which demonstrated a significant 
decrease in the number of live 1,25(OH)2D treated cells able to successfully 
metastasize to the BMCM and ultimately, rBM.  Our studies open the doors for a 
wide range of future studies to further evaluate the role and mechanism of 
1,25(OH)2D regulation of lipid metabolism and breast cancer metastasis, some of 
which were outlined in this chapter.  Overall, our findings contribute to the 
knowledge of vitamin D biology and its function in mammary cancer and 
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